Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Treatment B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
despite I-Claim
the I-Claim
fact I-Claim
that I-Claim
most I-Claim
patients I-Claim
suffered I-Claim
from I-Claim
multiple I-Claim
comorbidities I-Claim
and I-Claim
were I-Claim
heavily I-Claim
pretreated I-Claim
. I-Claim

Erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression-free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
HRQoL I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

Only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim

These B-Claim
results I-Claim
may I-Claim
have I-Claim
implications I-Claim
for I-Claim
the I-Claim
design I-Claim
of I-Claim
combination I-Claim
regimens I-Claim
incorporating I-Claim
IFN I-Claim
with I-Claim
targeted I-Claim
agents I-Claim
. I-Claim

This B-Claim
intervention I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
unmet I-Claim
needs I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
it I-Claim
is I-Claim
likely I-Claim
that I-Claim
it I-Claim
is I-Claim
cost-effective I-Claim
. I-Claim

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

Therapy B-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
should I-Claim
provide I-Claim
symptom I-Claim
relief I-Claim
and I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
because I-Claim
most I-Claim
patients I-Claim
are I-Claim
symptomatic I-Claim
at I-Claim
baseline I-Claim
. I-Claim

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

ADAPt-C B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low-income I-Claim
, I-Claim
predominantly I-Claim
Hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim

Unless B-Claim
additional I-Claim
follow-up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160-mg/d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ALA-PDT I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
AKs I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
indicate I-Claim
that I-Claim
patients I-Claim
with I-Claim
gastrointestinal I-Claim
cancer I-Claim
, I-Claim
who I-Claim
undergo I-Claim
surgery I-Claim
for I-Claim
stomach I-Claim
, I-Claim
pancreatic I-Claim
, I-Claim
primary I-Claim
liver I-Claim
, I-Claim
or I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
benefit I-Claim
from I-Claim
a I-Claim
formal I-Claim
program I-Claim
of I-Claim
psychotherapeutic I-Claim
support I-Claim
during I-Claim
the I-Claim
inpatient I-Claim
hospital I-Claim
stay I-Claim
in I-Claim
terms I-Claim
of I-Claim
long-term I-Claim
survival I-Claim
. I-Claim

Group B-Claim
CBT I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
women I-Claim
who I-Claim
have I-Claim
problematic I-Claim
HFNS I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
with I-Claim
additional I-Claim
benefits I-Claim
to I-Claim
mood I-Claim
, I-Claim
sleep I-Claim
, I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1-8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

High-dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5-year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
reduced I-Claim
skeletal-related I-Claim
events I-Claim
in I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

Using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim

Results B-Claim
suggest I-Claim
that I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
fat I-Claim
restriction I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
fat I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
-0.28 I-Claim
) I-Claim
, I-Claim
and I-Claim
change I-Claim
in I-Claim
self-efficacy I-Claim
for I-Claim
F I-Claim
& I-Claim
V I-Claim
consumption I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
's I-Claim
effect I-Claim
on I-Claim
daily I-Claim
F I-Claim
& I-Claim
V I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
.11 I-Claim
) I-Claim
. I-Claim

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

Low-dose B-Claim
radioiodine I-Claim
plus I-Claim
thyrotropin I-Claim
alfa I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
high-dose I-Claim
radioiodine I-Claim
, I-Claim
with I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
adverse I-Claim
events I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

A B-Claim
significant I-Claim
immediate I-Claim
and I-Claim
insignificant I-Claim
long-term I-Claim
effect I-Claim
on I-Claim
limb I-Claim
volume I-Claim
was I-Claim
noted I-Claim
. I-Claim

EGFR-mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
EGFR I-Claim
wild-type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim

Nevertheless B-Claim
, I-Claim
both I-Claim
community I-Claim
settings I-Claim
were I-Claim
acceptable I-Claim
to I-Claim
and I-Claim
preferred I-Claim
by I-Claim
patients I-Claim
compared I-Claim
with I-Claim
hospital I-Claim
, I-Claim
were I-Claim
safe I-Claim
, I-Claim
with I-Claim
no I-Claim
detrimental I-Claim
impact I-Claim
on I-Claim
overall I-Claim
health-care I-Claim
costs I-Claim
. I-Claim

Targeted B-Claim
therapies I-Claim
may I-Claim
improve I-Claim
chemotherapy I-Claim
effectiveness I-Claim
without I-Claim
worsening I-Claim
toxicity I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

In B-Claim
this I-Claim
randomized I-Claim
trial I-Claim
, I-Claim
no I-Claim
long-term I-Claim
QOL I-Claim
advantage I-Claim
for I-Claim
either I-Claim
treatment I-Claim
was I-Claim
apparent I-Claim
with B-Claim
the I-Claim
exception I-Claim
of I-Claim
poorer I-Claim
sexual I-Claim
function I-Claim
reported I-Claim
by I-Claim
those I-Claim
treated I-Claim
with I-Claim
cryoablation I-Claim
. I-Claim

Combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
NSCLC-mediated I-Claim
MPE I-Claim
. I-Claim

Given B-Claim
the I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
CRA/IFN/TAX I-Claim
on I-Claim
QOL I-Claim
, I-Claim
the I-Claim
study I-Claim
of I-Claim
other I-Claim
novel I-Claim
agents I-Claim
that I-Claim
target I-Claim
Bcl-2 I-Claim
family I-Claim
proteins I-Claim
is I-Claim
warranted I-Claim
. I-Claim

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

EXE B-Claim
prolongs I-Claim
survival I-Claim
time I-Claim
, I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
, I-Claim
and I-Claim
time I-Claim
to I-Claim
treatment I-Claim
failure I-Claim
compared I-Claim
with I-Claim
MA I-Claim
and I-Claim
offers I-Claim
a I-Claim
well-tolerated I-Claim
treatment I-Claim
option I-Claim
for I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
progressive I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
experienced I-Claim
failure I-Claim
of I-Claim
tamoxifen I-Claim
. I-Claim

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

Depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
FU-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
treatment I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
etoposide I-Claim
can I-Claim
improve I-Claim
both I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

Methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
ACâ†’T I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
QOL I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim

Incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
DCF I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post-radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin/raltitrexed I-Claim
arm I-Claim
. I-Claim

Tamoxifen B-Claim
( I-Claim
TMX I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
HCC I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
HCCs I-Claim
are I-Claim
ER I-Claim
negative I-Claim
. I-Claim

The B-Claim
CCSP I-Claim
as I-Claim
an I-Claim
effective I-Claim
coping I-Claim
intervention I-Claim
has I-Claim
potential I-Claim
as I-Claim
a I-Claim
self-management I-Claim
program I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
CA125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
CA125 I-Claim
in I-Claim
the I-Claim
follow-up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first-line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim

Both B-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
and I-Claim
III-only I-Claim
demonstrated I-Claim
pre-post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web-based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
marimastat I-Claim
after I-Claim
induction I-Claim
therapy I-Claim
for I-Claim
SCLC I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
improved I-Claim
survival I-Claim
and I-Claim
had I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
should I-Claim
be I-Claim
done I-Claim
in I-Claim
this I-Claim
area I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimum I-Claim
training I-Claim
program I-Claim
. I-Claim

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

Patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
CRT I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
CRT I-Claim
. I-Claim

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six-week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self-reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

Alternating B-Claim
chemotherapy I-Claim
with I-Claim
PAV-CyMOC I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

Previous B-Claim
trials I-Claim
have I-Claim
suggested I-Claim
a I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
improvement I-Claim
for I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
erythropoietin I-Claim
, I-Claim
but I-Claim
few I-Claim
used I-Claim
QOL I-Claim
as I-Claim
the I-Claim
primary I-Claim
outcome I-Claim
. I-Claim

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

HRQOL B-Claim
was I-Claim
better I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim

ARSR B-Claim
seem I-Claim
to I-Claim
be I-Claim
a I-Claim
relatively I-Claim
limited I-Claim
problem I-Claim
, I-Claim
probably I-Claim
more I-Claim
influenced I-Claim
by I-Claim
treatment I-Claim
related I-Claim
factors I-Claim
than I-Claim
by I-Claim
choice I-Claim
of I-Claim
skin I-Claim
care I-Claim
products I-Claim
in I-Claim
this I-Claim
patient I-Claim
group I-Claim
. I-Claim

Compared B-Claim
with I-Claim
multiple-fraction I-Claim
radiotherapy I-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
provides I-Claim
equal I-Claim
palliation I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
has I-Claim
lower I-Claim
medical I-Claim
and I-Claim
societal I-Claim
costs I-Claim
, I-Claim
at I-Claim
least I-Claim
in I-Claim
The I-Claim
Netherlands I-Claim
. I-Claim

Erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
Taiwanese I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

Sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

Adding B-Claim
E I-Claim
to I-Claim
G I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1-8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

Data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
GE I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

In B-Claim
the I-Claim
subset I-Claim
analysis I-Claim
, I-Claim
female I-Claim
patients I-Claim
, I-Claim
those I-Claim
that I-Claim
received I-Claim
high I-Claim
dose I-Claim
irradiation I-Claim
, I-Claim
and I-Claim
those I-Claim
that I-Claim
underwent I-Claim
adjuvant I-Claim
chemotherapy I-Claim
could I-Claim
benefit I-Claim
more I-Claim
from I-Claim
psychosocial I-Claim
intervention I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Anemia B-Claim
, I-Claim
highly I-Claim
common I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
is I-Claim
often I-Claim
an I-Claim
underlying I-Claim
cause I-Claim
of I-Claim
cancer-related I-Claim
fatigue I-Claim
and I-Claim
other I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
deficits I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

In B-Claim
recurrent I-Claim
low-grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
PFS I-Claim
, I-Claim
TFS I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
CVP I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
OS I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
single-fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

Vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
QoL I-Claim
. I-Claim

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first-line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co-analgesics I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

rhTSH B-Claim
preserves I-Claim
QoL I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
RRA I-Claim
with I-Claim
similar I-Claim
rates I-Claim
of I-Claim
ablation I-Claim
success I-Claim
compared I-Claim
to I-Claim
hypothyrodism I-Claim
. I-Claim

Acupuncture B-Claim
appears I-Claim
to I-Claim
be I-Claim
equivalent I-Claim
to I-Claim
drug I-Claim
therapy I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first-line I-Claim
chemotherapy I-Claim
. I-Claim

Low-dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
's I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Gefitinib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
superior I-Claim
OS I-Claim
compared I-Claim
with I-Claim
GP I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
for I-Claim
NSLAs I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
HRQOL I-Claim
results I-Claim
, I-Claim
the I-Claim
authors I-Claim
determined I-Claim
that I-Claim
UAE I-Claim
is I-Claim
a I-Claim
good I-Claim
alternative I-Claim
to I-Claim
hysterectomy I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
regimens I-Claim
are I-Claim
generally I-Claim
considered I-Claim
too I-Claim
toxic I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
. I-Claim

It B-Claim
can I-Claim
be I-Claim
concluded I-Claim
that I-Claim
the I-Claim
tailored I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
is I-Claim
effective I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
chronic I-Claim
pain I-Claim
. I-Claim

Cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5-hydroxytryptamine I-Claim
( I-Claim
5-HT I-Claim
) I-Claim
receptor I-Claim
. I-Claim

Most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim

Short-term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
HgB I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
have I-Claim
demonstrated I-Claim
the I-Claim
importance I-Claim
of I-Claim
baseline I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
significant I-Claim
and I-Claim
independent I-Claim
predictor I-Claim
of I-Claim
LRC I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
. I-Claim

Flavonoid-rich B-Claim
fruits I-Claim
and I-Claim
vegetables I-Claim
may I-Claim
provide I-Claim
additional I-Claim
protection I-Claim
against I-Claim
CINV I-Claim
. I-Claim

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single-agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

These B-Claim
data I-Claim
suggest I-Claim
that I-Claim
epoetin I-Claim
alfa I-Claim
may I-Claim
have I-Claim
attenuated I-Claim
the I-Claim
cognitive I-Claim
impairment I-Claim
and I-Claim
fatigue I-Claim
that I-Claim
occurred I-Claim
during I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

Despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
EBRT I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low- I-Claim
and I-Claim
intermediate-risk I-Claim
EC I-Claim
. I-Claim

Intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Recent B-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
administering I-Claim
the I-Claim
aromatase I-Claim
inhibitor I-Claim
exemestane I-Claim
after I-Claim
2-3 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
significantly I-Claim
improves I-Claim
disease-free I-Claim
survival I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
primary I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
comparison I-Claim
with I-Claim
standard I-Claim
5-year I-Claim
tamoxifen I-Claim
treatment I-Claim
. I-Claim

The B-Claim
3-weekly I-Claim
irinotecan I-Claim
schedule I-Claim
also I-Claim
seemed I-Claim
advantageous I-Claim
in I-Claim
terms I-Claim
of I-Claim
grade I-Claim
3/4 I-Claim
diarrhea I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
overall I-Claim
survival I-Claim
and I-Claim
patient I-Claim
convenience I-Claim
, I-Claim
but B-Claim
the I-Claim
study I-Claim
was I-Claim
not I-Claim
designed I-Claim
to I-Claim
detect I-Claim
differences I-Claim
in I-Claim
these I-Claim
parameters I-Claim
. I-Claim

Moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

Subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose-dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
PLD I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
HIV-associated I-Claim
KS I-Claim
treated I-Claim
in I-Claim
the I-Claim
HAART I-Claim
era I-Claim
. I-Claim

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

This B-Claim
investigation I-Claim
supports I-Claim
the I-Claim
clinical I-Claim
relevance I-Claim
of I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scales I-Claim
as I-Claim
indicators I-Claim
of I-Claim
components I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
cancer I-Claim
clinical I-Claim
trials I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

Sunitinib B-Claim
37.5 I-Claim
mg I-Claim
, I-Claim
administered I-Claim
on I-Claim
a I-Claim
continuous I-Claim
once-daily I-Claim
dosing I-Claim
regimen I-Claim
, I-Claim
has I-Claim
a I-Claim
manageable I-Claim
safety I-Claim
profile I-Claim
as I-Claim
second-line I-Claim
mRCC I-Claim
therapy I-Claim
, I-Claim
providing I-Claim
flexible I-Claim
dosing I-Claim
, I-Claim
which I-Claim
can I-Claim
be I-Claim
explored I-Claim
in I-Claim
combination I-Claim
studies I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer-term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient-rated I-Claim
outcomes I-Claim
. I-Claim

Complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
DLQI I-Claim
. I-Claim

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

These B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
HRQoL I-Claim
decrements I-Claim
with I-Claim
VMP I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
HRQoL I-Claim
vs. I-Claim
MP I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short-term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
in I-Claim
overall I-Claim
QOL I-Claim
scores I-Claim
between I-Claim
treatment I-Claim
arms I-Claim
or I-Claim
serially I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
therapy I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
PE I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
PFS I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive-stage I-Claim
SCLC I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

There B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
SNB I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim

Despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
MBAT I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
, I-Claim
sustained I-Claim
benefits I-Claim
across I-Claim
a I-Claim
diverse I-Claim
range I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
particularly I-Claim
those I-Claim
with I-Claim
high I-Claim
stress I-Claim
levels I-Claim
. I-Claim

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

Chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim

Docetaxel-carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel-carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow-up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

Multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

Recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5-fluorouracil I-Claim
( I-Claim
5-FU I-Claim
) I-Claim
with I-Claim
low-dose I-Claim
cisplatin I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim

The B-Claim
previously I-Claim
reported I-Claim
survival I-Claim
advantage I-Claim
supporting I-Claim
the I-Claim
use I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
is I-Claim
maintained I-Claim
when I-Claim
adjusted I-Claim
using I-Claim
quality I-Claim
adjusted I-Claim
survival I-Claim
methodology I-Claim
. I-Claim

Taking B-Claim
a I-Claim
pre-treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mCRC I-Claim
. I-Claim

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

rhTSH-prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

DPPE B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
DOX I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

The B-Claim
LV5FU2-oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression-free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
QoL I-Claim
. I-Claim

The B-Claim
BT I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
HEC I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim

Exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

Subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo-controlled I-Claim
study I-Claim
. I-Claim

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse-free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

DCb B-Claim
and I-Claim
DC I-Claim
were I-Claim
superior I-Claim
to I-Claim
VC I-Claim
in I-Claim
all I-Claim
QoL I-Claim
outcomes I-Claim
assessed I-Claim
except I-Claim
for I-Claim
the I-Claim
difference I-Claim
between I-Claim
DC I-Claim
and I-Claim
VC I-Claim
in I-Claim
LCSS I-Claim
" I-Claim
QoL I-Claim
today I-Claim
" I-Claim
, I-Claim
which I-Claim
was I-Claim
not I-Claim
significant I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
results I-Claim
obtained I-Claim
in I-Claim
the I-Claim
previous I-Claim
SIOP I-Claim
study I-Claim
, I-Claim
treatment I-Claim
in I-Claim
MMT84 I-Claim
was I-Claim
based I-Claim
on I-Claim
response I-Claim
to I-Claim
initial I-Claim
chemotherapy I-Claim
and I-Claim
, I-Claim
despite I-Claim
an I-Claim
overall I-Claim
reduction I-Claim
of I-Claim
the I-Claim
use I-Claim
of I-Claim
local I-Claim
therapy I-Claim
, I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
for I-Claim
patients I-Claim
with I-Claim
non-metastatic I-Claim
disease I-Claim
. I-Claim

Our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine-enriched I-Claim
TPN I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
GI I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

Neoadjuvant B-Claim
docetaxel-cisplatin I-Claim
followed I-Claim
by I-Claim
CRT I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
a I-Claim
manageable I-Claim
toxicity I-Claim
profile I-Claim
that I-Claim
allowed I-Claim
subsequent I-Claim
delivery I-Claim
of I-Claim
full-dose I-Claim
CRT I-Claim
. I-Claim

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well-being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

Leucovorin B-Claim
increases I-Claim
PFS I-Claim
if I-Claim
added I-Claim
to I-Claim
FU24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim

However B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

We B-Claim
recommend I-Claim
implementation I-Claim
alongside I-Claim
evaluation I-Claim
in I-Claim
wider I-Claim
clinical I-Claim
settings I-Claim
and I-Claim
patient I-Claim
populations I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

The B-Claim
study I-Claim
underscores I-Claim
the I-Claim
value I-Claim
of I-Claim
undertaking I-Claim
studies I-Claim
in I-Claim
areas I-Claim
of I-Claim
disease I-Claim
prevalence I-Claim
and I-Claim
the I-Claim
necessity I-Claim
of I-Claim
selecting I-Claim
appropriate I-Claim
outcome I-Claim
measures I-Claim
. I-Claim

The B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost-utility I-Claim
outcomes I-Claim
with I-Claim
epoetin-alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IV I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum-containing I-Claim
chemotherapy I-Claim
. I-Claim

Decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
MBC I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim

Symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
no I-Claim
dose-dependent I-Claim
adverse I-Claim
events I-Claim
. I-Claim

EBRT B-Claim
for I-Claim
endometrial I-Claim
cancer I-Claim
is I-Claim
associated I-Claim
with I-Claim
long-term I-Claim
urinary I-Claim
and I-Claim
bowel I-Claim
symptoms I-Claim
and I-Claim
lower I-Claim
physical I-Claim
and I-Claim
role-physical I-Claim
functioning I-Claim
, I-Claim
even I-Claim
15 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

Integration B-Claim
of I-Claim
the I-Claim
PMP I-Claim
into I-Claim
routine I-Claim
clinical I-Claim
work I-Claim
may I-Claim
help I-Claim
to I-Claim
improve I-Claim
the I-Claim
standard I-Claim
of I-Claim
care I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

In B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
HRQoL I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
HRQoL I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
spherical I-Claim
PVA I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
UAE I-Claim
. I-Claim

The B-Claim
implication I-Claim
is I-Claim
that I-Claim
CBT I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim

HDCT B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression-free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

Two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim

Letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
";" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post-unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease-free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment-related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator-assessed I-Claim
PFS I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim

Despite B-Claim
side I-Claim
effects I-Claim
resulting I-Claim
from I-Claim
administration I-Claim
of I-Claim
tamoxifen I-Claim
, I-Claim
its I-Claim
use I-Claim
as I-Claim
a I-Claim
breast I-Claim
cancer I-Claim
preventive I-Claim
agent I-Claim
is I-Claim
appropriate I-Claim
in I-Claim
many I-Claim
women I-Claim
at I-Claim
increased I-Claim
risk I-Claim
for I-Claim
the I-Claim
disease I-Claim
. I-Claim

The B-Claim
hypofractionated I-Claim
schedule I-Claim
is I-Claim
equivalent I-Claim
in I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
conventional I-Claim
schedule I-Claim
. I-Claim

It B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

Training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient-reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
ARSR I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
Calendula I-Claim
or I-Claim
Essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
, I-Claim
increases I-Claim
survival I-Claim
when I-Claim
combined I-Claim
with I-Claim
irinotecan-based I-Claim
chemotherapy I-Claim
in I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
. I-Claim

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

Cancer B-Claim
patients I-Claim
should I-Claim
be I-Claim
empowered I-Claim
with I-Claim
pain I-Claim
management I-Claim
education I-Claim
to I-Claim
gain I-Claim
knowledge I-Claim
and I-Claim
correct I-Claim
misconceptions I-Claim
in I-Claim
managing I-Claim
their I-Claim
cancer I-Claim
pain I-Claim
. I-Claim

The B-Claim
survival I-Claim
was I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
transthoracic I-Claim
approach I-Claim
. I-Claim

Tamoxifen B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
and I-Claim
safe I-Claim
than I-Claim
RT I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

Although B-Claim
TMZ I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
PCV I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
TMZ I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21-day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5-day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

In B-Claim
the I-Claim
clinical I-Claim
trial I-Claim
, I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
overcame I-Claim
much I-Claim
of I-Claim
the I-Claim
QOL I-Claim
deficit I-Claim
seen I-Claim
in I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
compared I-Claim
with I-Claim
the I-Claim
norm I-Claim
population I-Claim
sample I-Claim
. I-Claim

Abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient-reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
HRQoL I-Claim
deterioration I-Claim
in I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

This B-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
adequately I-Claim
test I-Claim
the I-Claim
ability I-Claim
of I-Claim
beta-hydroxy I-Claim
beta-methylbutyrate I-Claim
, I-Claim
glutamine I-Claim
, I-Claim
and I-Claim
arginine I-Claim
to I-Claim
reverse I-Claim
or I-Claim
prevent I-Claim
lean I-Claim
body I-Claim
mass I-Claim
wasting I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

The B-Claim
-3 I-Claim
and I-Claim
5-year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

Lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient-preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

The B-Claim
present I-Claim
analysis I-Claim
confirms I-Claim
that I-Claim
survival I-Claim
of I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
HRPC I-Claim
is I-Claim
significantly I-Claim
longer I-Claim
after I-Claim
treatment I-Claim
with I-Claim
D3P I-Claim
than I-Claim
with I-Claim
MP I-Claim
. I-Claim

Evidence B-Claim
suggests I-Claim
that I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
( I-Claim
ie I-Claim
, I-Claim
early I-Claim
period I-Claim
after I-Claim
medical I-Claim
treatment I-Claim
completion I-Claim
) I-Claim
presents I-Claim
distinct I-Claim
challenges I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

These B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short-term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

These B-Claim
findings I-Claim
highlight I-Claim
the I-Claim
challenge I-Claim
of I-Claim
maintaining I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
longitudinal I-Claim
research I-Claim
and I-Claim
suggest I-Claim
the I-Claim
need I-Claim
to I-Claim
consider I-Claim
alternative I-Claim
approaches I-Claim
( I-Claim
e.g. I-Claim
, I-Claim
telemedicine I-Claim
) I-Claim
for I-Claim
patients I-Claim
who I-Claim
might I-Claim
benefit I-Claim
from I-Claim
group I-Claim
interventions I-Claim
but I-Claim
are I-Claim
too I-Claim
ill I-Claim
to I-Claim
travel I-Claim
. I-Claim

It B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full-breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

In B-Claim
the I-Claim
watchful-waiting I-Claim
group I-Claim
, I-Claim
side-effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer-related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

This B-Claim
study I-Claim
is I-Claim
the I-Claim
first I-Claim
to I-Claim
show I-Claim
that I-Claim
ORP I-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
as I-Claim
compared I-Claim
with I-Claim
LRP I-Claim
. I-Claim

Darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
EDS I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim

The B-Claim
IMPACT I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim

Extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim

However B-Claim
, I-Claim
patient I-Claim
self-assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

Larger B-Claim
studies I-Claim
should I-Claim
be I-Claim
carried I-Claim
out I-Claim
that I-Claim
also I-Claim
include I-Claim
healthy I-Claim
women I-Claim
who I-Claim
want I-Claim
to I-Claim
avoid I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
. I-Claim

However B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim

There B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
QOL I-Claim
after I-Claim
curative-intent I-Claim
head-neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
";" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Results B-Claim
of I-Claim
previous I-Claim
phase I-Claim
3 I-Claim
trials I-Claim
in I-Claim
inoperable I-Claim
HCC I-Claim
have I-Claim
been I-Claim
conflicting I-Claim
and I-Claim
inconclusive I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
weekly I-Claim
epoetin I-Claim
alfa I-Claim
as I-Claim
an I-Claim
ameliorative I-Claim
agent I-Claim
for I-Claim
cancer-related I-Claim
anemia I-Claim
. I-Claim

The B-Claim
hypothesis I-Claim
of I-Claim
a I-Claim
RR I-Claim
15 I-Claim
% I-Claim
higher I-Claim
than I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA-5-FU I-Claim
treatment I-Claim
can I-Claim
not I-Claim
be I-Claim
ruled I-Claim
out I-Claim
after I-Claim
this I-Claim
interim I-Claim
analysis I-Claim
. I-Claim

Radiotherapy B-Claim
is I-Claim
an I-Claim
effective I-Claim
palliative I-Claim
treatment I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim

Chemotherapy B-Claim
provided I-Claim
on I-Claim
average I-Claim
an I-Claim
additional I-Claim
1.0 I-Claim
quality-adjusted I-Claim
life I-Claim
months I-Claim
within I-Claim
a I-Claim
restricted I-Claim
2-year I-Claim
time I-Claim
period I-Claim
from I-Claim
the I-Claim
time I-Claim
of I-Claim
resection I-Claim
. I-Claim

Imatinib B-Claim
interruption I-Claim
results I-Claim
in I-Claim
rapid I-Claim
progression I-Claim
in I-Claim
most I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
GIST I-Claim
, I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
recommended I-Claim
in I-Claim
routine I-Claim
practice I-Claim
unless I-Claim
patient I-Claim
experience I-Claim
significant I-Claim
toxicity I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

The B-Claim
decrease I-Claim
in I-Claim
IEF I-Claim
and I-Claim
improvements I-Claim
in I-Claim
I-QoL I-Claim
scores I-Claim
were I-Claim
significantly I-Claim
greater I-Claim
in I-Claim
group I-Claim
A I-Claim
for I-Claim
the I-Claim
first I-Claim
16 I-Claim
wk I-Claim
. I-Claim

Treatment B-Claim
, I-Claim
particularly I-Claim
the I-Claim
combination I-Claim
therapy I-Claim
, I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
decrease I-Claim
in I-Claim
QOL I-Claim
. I-Claim

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

Subcutaneous B-Claim
interleukin-2 I-Claim
and/or I-Claim
interferon-alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
can I-Claim
cause I-Claim
discomfort I-Claim
, I-Claim
disrupted I-Claim
sleep I-Claim
, I-Claim
anxiety I-Claim
, I-Claim
and I-Claim
decreased I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

Carboplatin/vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive-stage I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

Bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim

The B-Claim
number I-Claim
and I-Claim
severity I-Claim
of I-Claim
side-effects I-Claim
changes I-Claim
over I-Claim
time I-Claim
at I-Claim
a I-Claim
higher I-Claim
rate I-Claim
than I-Claim
is I-Claim
caused I-Claim
by I-Claim
normal I-Claim
ageing I-Claim
and I-Claim
a I-Claim
loss I-Claim
of I-Claim
sexual I-Claim
ability I-Claim
is I-Claim
a I-Claim
persistent I-Claim
psychological I-Claim
problem I-Claim
for I-Claim
both I-Claim
interventions I-Claim
. I-Claim

We B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
QOL I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow-up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim

Supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim

The B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
EuroQol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
European I-Claim
Organisation I-Claim
for I-Claim
Research I-Claim
in I-Claim
the I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
scales I-Claim
. I-Claim

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

In B-Claim
view I-Claim
of I-Claim
the I-Claim
benefits I-Claim
regarding I-Claim
arm I-Claim
functioning I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
data I-Claim
from I-Claim
this I-Claim
randomised I-Claim
study I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
SNB I-Claim
in I-Claim
patients I-Claim
with I-Claim
clinically I-Claim
node I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

For B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim

Scapula-oriented B-Claim
exercise I-Claim
had I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
pain I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
aspects I-Claim
of I-Claim
strength I-Claim
. I-Claim

Both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

Small B-Claim
effects I-Claim
were I-Claim
seen I-Claim
in I-Claim
some I-Claim
domains I-Claim
consistent I-Claim
with I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
experiencing I-Claim
changes I-Claim
in I-Claim
QOL I-Claim
compatible I-Claim
with I-Claim
a I-Claim
reduction I-Claim
in I-Claim
estrogen I-Claim
synthesis I-Claim
. I-Claim

Gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
RP I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

The B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
CRF I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue-related I-Claim
distress I-Claim
. I-Claim

In B-Claim
V325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
DCF I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor-progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
CF I-Claim
. I-Claim

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p=0.011 I-Premise
, I-Premise
CI=0.063-0.437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p=0.003 I-Premise
, I-Premise
CI=0.146-0.620 I-Premise
) I-Premise
. I-Premise

The B-Premise
rates I-Premise
of I-Premise
attrition I-Premise
at I-Premise
these I-Premise
time I-Premise
points I-Premise
were I-Premise
28.1 I-Premise
% I-Premise
, I-Premise
17.7 I-Premise
% I-Premise
, I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
43.1 I-Premise
% I-Premise
of I-Premise
the I-Premise
participants I-Premise
( I-Premise
66 I-Premise
of I-Premise
153 I-Premise
) I-Premise
completed I-Premise
the I-Premise
entire I-Premise
study I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
12.1 I-Premise
months I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.85-1.15 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
] I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.9 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.6 I-Premise
to I-Premise
1.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

The B-Premise
experimental-to-PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1.15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.86 I-Premise
to I-Premise
1.82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49.6 I-Premise
to I-Premise
61.2 I-Premise
vs. I-Premise
50.1 I-Premise
to I-Premise
51.5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.7349 I-Premise
) I-Premise
. I-Premise

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P=0.11 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3-4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

For B-Premise
19 I-Premise
'per I-Premise
protocol I-Premise
' I-Premise
patients I-Premise
, I-Premise
2/10 I-Premise
in I-Premise
the I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
arm I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
one I-Premise
also I-Premise
had I-Premise
local I-Premise
failure I-Premise
) I-Premise
and I-Premise
3/9 I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
no I-Premise
local I-Premise
failures I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
";" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
was I-Premise
321 I-Premise
days I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
was I-Premise
not I-Premise
reached I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
363 I-Premise
days I-Premise
for I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8/4 I-Premise
mg I-Premise
( I-Premise
P I-Premise
=.491 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
. I-Premise

Mean B-Premise
( I-Premise
s.d I-Premise
. I-Premise
) I-Premise
pain I-Premise
scores I-Premise
on I-Premise
the I-Premise
day I-Premise
of I-Premise
discharge I-Premise
were I-Premise
1Â·9 I-Premise
( I-Premise
3Â·1 I-Premise
) I-Premise
in I-Premise
the I-Premise
epidural I-Premise
group I-Premise
and I-Premise
0Â·7 I-Premise
( I-Premise
0Â·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
WIC I-Premise
group I-Premise
. I-Premise

Dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
Ï‡1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
Ï‡1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

Hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

Sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4.8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
";" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3.3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

No B-Premise
difference I-Premise
in I-Premise
the I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
( I-Premise
70 I-Premise
% I-Premise
vs. I-Premise
66 I-Premise
% I-Premise
) I-Premise
or I-Premise
median I-Premise
survival I-Premise
time I-Premise
( I-Premise
19.4 I-Premise
vs. I-Premise
17.4 I-Premise
months I-Premise
) I-Premise
between I-Premise
the I-Premise
surgery I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise

The B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
RY I-Premise
group I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
TMX120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
P I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.39 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.07-1.81 I-Premise
) I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
2-month I-Premise
follow-up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
IMCP I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
TM I-Premise
group I-Premise
. I-Premise

The B-Premise
intervention I-Premise
also I-Premise
improved I-Premise
all I-Premise
other I-Premise
fatigue I-Premise
aspects I-Premise
measured I-Premise
by I-Premise
MFI I-Premise
, I-Premise
including I-Premise
Physical I-Premise
Fatigue I-Premise
and I-Premise
Mental I-Premise
Fatigue I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-2.36 I-Premise
and I-Premise
-1.94 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
and I-Premise
depression I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-1.83 I-Premise
and I-Premise
-2.13 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
Physical I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.30 I-Premise
";" I-Premise
Functional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.57 I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
Emotional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
";" I-Premise
and I-Premise
Social I-Premise
Functioning I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Months I-Premise
over I-Premise
24 I-Premise
months I-Premise
( I-Premise
QALM-24 I-Premise
) I-Premise
was I-Premise
9.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
8.7 I-Premise
, I-Premise
11.2 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.6 I-Premise
, I-Premise
10.5 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
2-year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

This B-Premise
difference I-Premise
, I-Premise
however I-Premise
, I-Premise
was I-Premise
not I-Premise
observed I-Premise
when I-Premise
the I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
patients I-Premise
compiled I-Premise
questionnaires I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
â‰¤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
paclitaxel I-Premise
and I-Premise
PLD I-Premise
arms I-Premise
revealed I-Premise
comparable I-Premise
response I-Premise
rates I-Premise
( I-Premise
56 I-Premise
% I-Premise
vs I-Premise
46 I-Premise
% I-Premise
";" I-Premise
P=.49 I-Premise
) I-Premise
, I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
17.5 I-Premise
months I-Premise
vs I-Premise
12.2 I-Premise
months I-Premise
";" I-Premise
P=.66 I-Premise
) I-Premise
, I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
( I-Premise
79 I-Premise
% I-Premise
vs I-Premise
78 I-Premise
% I-Premise
";" I-Premise
P=.75 I-Premise
) I-Premise
, I-Premise
but B-Premise
somewhat I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
5 I-Premise
toxicity I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
84 I-Premise
% I-Premise
vs I-Premise
66 I-Premise
% I-Premise
";" I-Premise
P=.077 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel-containing I-Premise
regimen I-Premise
had I-Premise
better I-Premise
QoL I-Premise
than I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
LCSS I-Premise
global I-Premise
item I-Premise
" I-Premise
QoL I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.064 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P=0.016 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
";" I-Premise
EQ-5D I-Premise
global I-Premise
item I-Premise
" I-Premise
health I-Premise
state I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.016 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
docetaxel-carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel-carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
Cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
was I-Premise
0.70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.51 I-Premise
to I-Premise
0.95 I-Premise
) I-Premise
";" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Scores B-Premise
were I-Premise
stable I-Premise
over I-Premise
time I-Premise
and I-Premise
considerably I-Premise
lower I-Premise
than I-Premise
the I-Premise
general I-Premise
population I-Premise
norms I-Premise
. I-Premise

Intention-to-treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow-up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation-only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
0.7-6.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.011 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
intervention I-Premise
by I-Premise
subgroup I-Premise
interactions I-Premise
( I-Premise
P I-Premise
> I-Premise
.10 I-Premise
) I-Premise
. I-Premise

Distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

No B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise

Dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
RT I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

Resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
NTx I-Premise
and I-Premise
Crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
CVP I-Premise
( I-Premise
P I-Premise
=.72 I-Premise
) I-Premise
. I-Premise

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF-8 I-Premise
. I-Premise

Overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CMF I-Premise
. I-Premise

Three-month B-Premise
survival I-Premise
rates I-Premise
for I-Premise
the I-Premise
P I-Premise
, I-Premise
TMX60 I-Premise
, I-Premise
and I-Premise
TMX120 I-Premise
groups I-Premise
were I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
, I-Premise
and I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
trend I-Premise
difference I-Premise
in I-Premise
survival I-Premise
across I-Premise
the I-Premise
3 I-Premise
treatment I-Premise
regimens I-Premise
( I-Premise
P I-Premise
=.011 I-Premise
) I-Premise
. I-Premise

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

18 B-Premise
months I-Premise
post-surgery I-Premise
approximately I-Premise
twice I-Premise
as I-Premise
many I-Premise
patients I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
SNB I-Premise
group I-Premise
reported I-Premise
substantial I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
14 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
or I-Premise
numbness I-Premise
( I-Premise
19 I-Premise
% I-Premise
versus I-Premise
8.7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
the I-Premise
ORR I-Premise
, I-Premise
DCR I-Premise
, I-Premise
and I-Premise
mPFS I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
exhibited I-Premise
no I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
consistent I-Premise
influence I-Premise
on I-Premise
QOL I-Premise
was I-Premise
detected I-Premise
. I-Premise

The B-Premise
dysuria I-Premise
resolved I-Premise
faster I-Premise
in I-Premise
patients I-Premise
implanted I-Premise
with I-Premise
103Pd I-Premise
but B-Premise
was I-Premise
unaffected I-Premise
by I-Premise
the I-Premise
use I-Premise
of I-Premise
supplemental I-Premise
radiotherapy I-Premise
and/or I-Premise
androgen I-Premise
deprivation I-Premise
therapy I-Premise
. I-Premise

In B-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia-related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
area I-Premise
under I-Premise
the I-Premise
mucositis I-Premise
curve I-Premise
( I-Premise
13.2 I-Premise
vs I-Premise
16.6 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

There B-Premise
is I-Premise
no I-Premise
irreversible I-Premise
toxicity I-Premise
with I-Premise
MMC I-Premise
at I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

The B-Premise
mean I-Premise
quality-adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1.8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine/docetaxel I-Premise
group I-Premise
. I-Premise

Although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
UC I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12-months I-Premise
post-surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Capecitabine B-Premise
treatment I-Premise
was I-Premise
associated I-Premise
with I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
constipation I-Premise
and I-Premise
with I-Premise
better I-Premise
appetite I-Premise
than I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
â‰¤ I-Premise
.004 I-Premise
) I-Premise
, I-Premise
but I-Premise
worse I-Premise
hand-foot I-Premise
syndrome I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Additionally B-Premise
, I-Premise
patients I-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
required I-Premise
significantly I-Premise
fewer I-Premise
changes I-Premise
in I-Premise
therapy I-Premise
, I-Premise
had I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
when I-Premise
a I-Premise
change I-Premise
was I-Premise
initiated I-Premise
, I-Premise
and I-Premise
reported I-Premise
greater I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
than I-Premise
the I-Premise
comparator I-Premise
group I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
DOX I-Premise
in I-Premise
OS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.48 I-Premise
to I-Premise
0.91 I-Premise
";" I-Premise
P I-Premise
=.021 I-Premise
) I-Premise
. I-Premise

Only B-Premise
the I-Premise
FACT-G I-Premise
social/family I-Premise
well-being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
EQ-5D I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19.5 I-Premise
% I-Premise
for I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
.22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

GE/G B-Premise
Grade I-Premise
3-4 I-Premise
toxicities I-Premise
included I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
18.3 I-Premise
% I-Premise
/28.2 I-Premise
% I-Premise
) I-Premise
";" I-Premise
thrombocytopenia I-Premise
( I-Premise
14.6 I-Premise
% I-Premise
/25.6 I-Premise
% I-Premise
) I-Premise
";" I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
11.0 I-Premise
% I-Premise
/7.7 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

On B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
QOL I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

When B-Premise
participants I-Premise
in I-Premise
the I-Premise
sham I-Premise
acupuncture I-Premise
group I-Premise
were I-Premise
crossed I-Premise
over I-Premise
to I-Premise
TRUE I-Premise
acupuncture I-Premise
, I-Premise
a I-Premise
further I-Premise
reduction I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
was I-Premise
seen I-Premise
. I-Premise

Hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g/dL I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
SOC I-Premise
: I-Premise
52.0 I-Premise
% I-Premise
v I-Premise
5.1 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
v I-Premise
6.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined-treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p=0.0002 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Difference B-Premise
between I-Premise
groups I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
for I-Premise
BMD I-Premise
at I-Premise
femur I-Premise
was I-Premise
significant I-Premise
. I-Premise

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane-alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Complete B-Premise
and I-Premise
partial I-Premise
response I-Premise
rates I-Premise
to I-Premise
induction I-Premise
PE I-Premise
were I-Premise
3 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

After B-Premise
a I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19/54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+/- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
T3 I-Premise
and I-Premise
T4 I-Premise
assessments I-Premise
. I-Premise

Considering B-Premise
the I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
GM-CSF I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash/eczema I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
IG I-Premise
. I-Premise

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10.5 I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.0067 I-Premise
) I-Premise
. I-Premise

Three B-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
died I-Premise
of I-Premise
treatment-related I-Premise
toxicity I-Premise
compared I-Premise
with I-Premise
none I-Premise
of I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
CVP I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
HRQoL I-Premise
between I-Premise
nurse-led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow-up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
-1.93-4.64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow-up I-Premise
with I-Premise
or I-Premise
without I-Premise
EGP I-Premise
( I-Premise
p I-Premise
= I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
for I-Premise
difference I-Premise
: I-Premise
-3.59-3.00 I-Premise
) I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+15Â·2 I-Premise
, I-Premise
1Â·3 I-Premise
to I-Premise
29Â·1 I-Premise
, I-Premise
P=0.033 I-Premise
) I-Premise
. I-Premise

Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.3 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.053 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
had I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
levels I-Premise
of I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Endocrine I-Premise
Symptoms I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.31-0.52 I-Premise
) I-Premise
and I-Premise
urinary I-Premise
symptoms I-Premise
( I-Premise
Bristol I-Premise
Female I-Premise
Lower I-Premise
Urinary I-Premise
Tract I-Premise
Symptoms I-Premise
Questionnaire I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.29-0.33 I-Premise
) I-Premise
, I-Premise
and I-Premise
they I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
36-Item I-Premise
Short I-Premise
Form I-Premise
Health I-Premise
Survey I-Premise
physical I-Premise
functioning I-Premise
subscale I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.37-0.46 I-Premise
) I-Premise
. I-Premise

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
substantial I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
immediate I-Premise
post-treatment I-Premise
( I-Premise
3-months I-Premise
) I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
eight I-Premise
components I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
scores I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

The B-Premise
15-year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5.8 I-Premise
% I-Premise
for I-Premise
EBRT I-Premise
versus I-Premise
15.5 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.14 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5.6 I-Premise
, I-Premise
6.0 I-Premise
, I-Premise
and I-Premise
6.7 I-Premise
months I-Premise
";" I-Premise
ORRs I-Premise
( I-Premise
Response I-Premise
Evaluation I-Premise
Criteria I-Premise
in I-Premise
Solid I-Premise
Tumors I-Premise
) I-Premise
were I-Premise
2.7 I-Premise
% I-Premise
, I-Premise
7.6 I-Premise
% I-Premise
and I-Premise
3.9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise

Treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
28 I-Premise
, I-Premise
21 I-Premise
, I-Premise
22 I-Premise
and I-Premise
10 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
10-point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
TDD I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
was I-Premise
11.7 I-Premise
months I-Premise
versus I-Premise
8.4 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.1017 I-Premise
) I-Premise
. I-Premise

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

Thirty-two B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
19 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
experienced I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
adverse I-Premise
events I-Premise
( I-Premise
graded I-Premise
using I-Premise
the I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
Common I-Premise
Toxicity I-Premise
Criteria I-Premise
[ I-Premise
version I-Premise
2.0 I-Premise
] I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
intake I-Premise
per I-Premise
kilogram I-Premise
of I-Premise
body I-Premise
weight I-Premise
for I-Premise
the I-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
ranged I-Premise
from I-Premise
28 I-Premise
to I-Premise
31 I-Premise
kcal/kg/day I-Premise
compared I-Premise
with I-Premise
25 I-Premise
to I-Premise
29 I-Premise
kcal/kg/day I-Premise
for I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
P=0.022 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
non-hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

Seventy-one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
â‰¥11.0 I-Premise
g/dL I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FOIS I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
( I-Premise
immediately I-Premise
after I-Premise
CRT I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1-6 I-Premise
] I-Premise
( I-Premise
P I-Premise
= I-Premise
.88 I-Premise
) I-Premise
. I-Premise

The B-Premise
ORRs I-Premise
were I-Premise
48.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38.5 I-Premise
% I-Premise
-59.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58.7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47.9 I-Premise
% I-Premise
-68.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise

Four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
NIP I-Premise
arm I-Premise
. I-Premise

The B-Premise
acceptance I-Premise
of I-Premise
K-tape I-Premise
was I-Premise
better I-Premise
than I-Premise
the I-Premise
bandage I-Premise
, I-Premise
and I-Premise
benefits I-Premise
included I-Premise
longer I-Premise
wearing I-Premise
time I-Premise
, I-Premise
less I-Premise
difficulty I-Premise
in I-Premise
usage I-Premise
, I-Premise
and I-Premise
increased I-Premise
comfort I-Premise
and I-Premise
convenience I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
GJJ I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
outcome I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
at I-Premise
both I-Premise
8 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
( I-Premise
except I-Premise
as I-Premise
indicated I-Premise
) I-Premise
for I-Premise
POMS I-Premise
total I-Premise
mood I-Premise
disturbance I-Premise
( I-Premise
and I-Premise
its I-Premise
subscales I-Premise
of I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
anger I-Premise
[ I-Premise
12 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
vigor I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
confusion I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
, I-Premise
FACT-ES I-Premise
, I-Premise
( I-Premise
and I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
subscales I-Premise
of I-Premise
physical I-Premise
, I-Premise
social I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
functional I-Premise
well-being I-Premise
) I-Premise
, I-Premise
and I-Premise
WHO-5 I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.24 I-Premise
) I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
Spitzer I-Premise
's I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1Â·67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2Â·43 I-Premise
to I-Premise
-0Â·91 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
-1Â·76 I-Premise
, I-Premise
-2Â·54 I-Premise
to I-Premise
-0Â·99 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
31.9 I-Premise
months I-Premise
and I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
15.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
< I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
death I-Premise
was I-Premise
observed I-Premise
. I-Premise

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

A B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
IMRT I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

Multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
P I-Premise
values I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

No B-Premise
interactions I-Premise
were I-Premise
found I-Premise
between I-Premise
other I-Premise
domains I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
functioning I-Premise
, I-Premise
psychological I-Premise
distress I-Premise
and I-Premise
CBT I-Premise
. I-Premise

However B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
QoL I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
. I-Premise

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

No B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer-specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
EDU I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
. I-Premise

Several B-Premise
aspects I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
rated I-Premise
to I-Premise
be I-Premise
better I-Premise
in I-Premise
group I-Premise
B I-Premise
than I-Premise
in I-Premise
group I-Premise
A I-Premise
, I-Premise
although B-Premise
not I-Premise
all I-Premise
differences I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Interaction B-Premise
effects I-Premise
for I-Premise
mental I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
scores I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low-dose I-Premise
radioiodine I-Premise
versus I-Premise
88.9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

CE B-Premise
at I-Premise
the I-Premise
oral I-Premise
dose I-Premise
administered I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
these I-Premise
patients I-Premise
with I-Premise
CACS I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.76 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

Other B-Premise
symptoms I-Premise
including I-Premise
sore I-Premise
mouth I-Premise
and I-Premise
hair I-Premise
loss I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GE I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
0.007 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
had I-Premise
died I-Premise
";" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short-term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long-term I-Premise
group I-Premise
. I-Premise

A B-Premise
path I-Premise
model I-Premise
revealed I-Premise
that I-Premise
intervention I-Premise
participation I-Premise
directly I-Premise
improved I-Premise
health I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
P I-Premise
=.008 I-Premise
) I-Premise
";" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
QoL I-Premise
were I-Premise
detected I-Premise
. I-Premise

Median B-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
complete I-Premise
and I-Premise
partial I-Premise
combined I-Premise
) I-Premise
in I-Premise
the I-Premise
group I-Premise
treated I-Premise
with I-Premise
the I-Premise
combination I-Premise
was I-Premise
33 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
9 I-Premise
to I-Premise
50 I-Premise
months I-Premise
) I-Premise
, I-Premise
versus I-Premise
22 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
5 I-Premise
to I-Premise
38 I-Premise
months I-Premise
) I-Premise
for I-Premise
the I-Premise
second I-Premise
group I-Premise
( I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
. I-Premise

Results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
MBAT I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post-intervention I-Premise
";" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post-intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise

We B-Premise
found I-Premise
significant I-Premise
improvements I-Premise
over I-Premise
time I-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
with I-Premise
significant I-Premise
group I-Premise
differences I-Premise
at I-Premise
month I-Premise
1 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.26 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
and I-Premise
month I-Premise
2 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.35 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
OMWQ-HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12.199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6,1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
FACT-HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
LLLT I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
";" I-Premise
median B-Premise
survival I-Premise
increased I-Premise
from I-Premise
21 I-Premise
to I-Premise
28 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
vinorelbine-treated I-Premise
group I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first-and I-Premise
second-line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second-line I-Premise
therapy I-Premise
. I-Premise

Patients B-Premise
with I-Premise
UM I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

The B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin-alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise

Operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
recovery I-Premise
of I-Premise
food I-Premise
intake I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

HRQOL B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
ccHRT I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise

Although B-Premise
other I-Premise
group I-Premise
Ã— I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation-plus-referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.5 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.0 I-Premise
to I-Premise
4.0 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
= I-Premise
.244 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

Maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise

No B-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
evident I-Premise
with I-Premise
respect I-Premise
to I-Premise
quality I-Premise
of I-Premise
life I-Premise
according I-Premise
to I-Premise
the I-Premise
EORTC I-Premise
QLQ-protocol I-Premise
. I-Premise

After B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
followup I-Premise
of I-Premise
26 I-Premise
months I-Premise
we I-Premise
observed I-Premise
12 I-Premise
biochemical I-Premise
relapses I-Premise
. I-Premise

A B-Premise
convergence I-Premise
of I-Premise
biobehavioral I-Premise
effects I-Premise
and I-Premise
health I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
. I-Premise

Euthyroid B-Premise
patients I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
one I-Premise
third I-Premise
lower I-Premise
radiation I-Premise
dose I-Premise
to I-Premise
the I-Premise
blood I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Lower B-Premise
scores I-Premise
were I-Premise
associated I-Premise
with I-Premise
the I-Premise
combination I-Premise
therapy I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
adverse I-Premise
effects I-Premise
associated I-Premise
with I-Premise
r-HuEPO I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Risk B-Premise
for I-Premise
distress I-Premise
accounted I-Premise
for I-Premise
very I-Premise
few I-Premise
moderation I-Premise
effects I-Premise
. I-Premise

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

Clinically B-Premise
meaningful I-Premise
improvements I-Premise
in I-Premise
SF-36 I-Premise
, I-Premise
pain I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
were I-Premise
also I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
of I-Premise
abatacept I-Premise
treatment I-Premise
. I-Premise

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
TC I-Premise
, I-Premise
49 I-Premise
% I-Premise
";" I-Premise
TCF I-Premise
, I-Premise
57 I-Premise
% I-Premise
";" I-Premise
ECF I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise

Overall B-Premise
, I-Premise
the I-Premise
antiandrogen I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
compared I-Premise
with I-Premise
castration I-Premise
";" I-Premise
with B-Premise
bicalutamide I-Premise
, I-Premise
hot I-Premise
flushes I-Premise
occurred I-Premise
less I-Premise
often I-Premise
and I-Premise
breast I-Premise
tenderness I-Premise
and I-Premise
gynecomastia I-Premise
more I-Premise
often I-Premise
. I-Premise

Cross-sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
QOL I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
25 I-Premise
patients I-Premise
in I-Premise
whom I-Premise
3-month I-Premise
MR I-Premise
imaging I-Premise
follow-up I-Premise
was I-Premise
completed I-Premise
, I-Premise
those I-Premise
treated I-Premise
with I-Premise
TAGM I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
complete I-Premise
infarction I-Premise
of I-Premise
all I-Premise
leiomyomas I-Premise
( I-Premise
six I-Premise
patients I-Premise
vs I-Premise
one I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
at I-Premise
least I-Premise
90 I-Premise
% I-Premise
tumor I-Premise
infarction I-Premise
( I-Premise
eight I-Premise
patients I-Premise
vs I-Premise
four I-Premise
patients I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
mean I-Premise
percent I-Premise
of I-Premise
residual I-Premise
perfused I-Premise
fibroid I-Premise
tumor I-Premise
tissue I-Premise
( I-Premise
9.6 I-Premise
% I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
compared I-Premise
with I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PVA I-Premise
. I-Premise

QOL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
except B-Premise
for I-Premise
the I-Premise
functional I-Premise
activity I-Premise
score I-Premise
of I-Premise
the I-Premise
Rotterdam I-Premise
Symptom I-Premise
Checklist I-Premise
, I-Premise
where I-Premise
QOL I-Premise
data I-Premise
statistically I-Premise
significantly I-Premise
favored I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.043 I-Premise
) I-Premise
. I-Premise

At B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibited I-Premise
significant I-Premise
clinical I-Premise
improvement I-Premise
in I-Premise
OPS I-Premise
, I-Premise
blindly I-Premise
assessed I-Premise
by I-Premise
a I-Premise
physician I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
67 I-Premise
% I-Premise
vs I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P=.046 I-Premise
) I-Premise
. I-Premise

Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
-1.2 I-Premise
g/L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-2.0 I-Premise
to I-Premise
-0.4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
g/L I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.3 I-Premise
to I-Premise
+0.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.006 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.8 I-Premise
to I-Premise
4.6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.6 I-Premise
to I-Premise
11.1 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
4.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.5 I-Premise
to I-Premise
6.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9.5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
6.9 I-Premise
to I-Premise
12.2 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-cisplatin I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
and I-Premise
6.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.5 I-Premise
to I-Premise
8.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.3 I-Premise
to I-Premise
13.3 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Six-month B-Premise
survival I-Premise
rates I-Premise
were I-Premise
41 I-Premise
% I-Premise
for I-Premise
octreotide I-Premise
patients I-Premise
and I-Premise
42 I-Premise
% I-Premise
for I-Premise
control I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3.61 I-Premise
weeks I-Premise
on I-Premise
BCoG I-Premise
and I-Premise
3.96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
P I-Premise
=.61 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2.53 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1.35-4.97 I-Premise
) I-Premise
";" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

Time B-Premise
to I-Premise
response I-Premise
and I-Premise
ORR I-Premise
favor I-Premise
TCF I-Premise
over I-Premise
TC I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
v I-Premise
22.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
patients I-Premise
reported I-Premise
that I-Premise
dignity I-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
than I-Premise
the I-Premise
other I-Premise
two I-Premise
interventions I-Premise
to I-Premise
have I-Premise
been I-Premise
helpful I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=35Â·50 I-Premise
, I-Premise
df=2 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
, I-Premise
improve I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=14Â·52 I-Premise
";" I-Premise
p=0Â·001 I-Premise
) I-Premise
, I-Premise
increase I-Premise
sense I-Premise
of I-Premise
dignity I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=12Â·66 I-Premise
";" I-Premise
p=0Â·002 I-Premise
) I-Premise
, I-Premise
change I-Premise
how I-Premise
their I-Premise
family I-Premise
saw I-Premise
and I-Premise
appreciated I-Premise
them I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33Â·81 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
be I-Premise
helpful I-Premise
to I-Premise
their I-Premise
family I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=33Â·86 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
. I-Premise

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
. I-Premise

Acupuncture B-Premise
had I-Premise
the I-Premise
additional I-Premise
benefit I-Premise
of I-Premise
increased I-Premise
sex I-Premise
drive I-Premise
in I-Premise
some I-Premise
women I-Premise
, I-Premise
and I-Premise
most I-Premise
reported I-Premise
an I-Premise
improvement I-Premise
in I-Premise
their I-Premise
energy I-Premise
, I-Premise
clarity I-Premise
of I-Premise
thought I-Premise
, I-Premise
and I-Premise
sense I-Premise
of I-Premise
well-being I-Premise
. I-Premise

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

55.6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
â‰¥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p=0.085 I-Premise
) I-Premise
. I-Premise

Unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane-based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but B-Premise
substantive I-Premise
differences I-Premise
in I-Premise
many I-Premise
symptom I-Premise
scores I-Premise
favored I-Premise
docetaxel I-Premise
. I-Premise

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

Drain B-Premise
usage I-Premise
, I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
resumption I-Premise
of I-Premise
normal I-Premise
day-to-day I-Premise
activities I-Premise
after I-Premise
surgery I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
axillary I-Premise
operative I-Premise
time I-Premise
was I-Premise
reduced I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
CRs I-Premise
, I-Premise
1 I-Premise
PR I-Premise
, I-Premise
and I-Premise
15 I-Premise
SDs I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
BMI I-Premise
significantly I-Premise
deteriorated I-Premise
compared I-Premise
with I-Premise
preoperative I-Premise
BMI I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise

Energy B-Premise
intake I-Premise
after I-Premise
RT I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

For B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel-platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise

The B-Premise
ICUR I-Premise
for I-Premise
epoetin-alfa I-Premise
treatment I-Premise
was I-Premise
pounds I-Premise
8,851 I-Premise
per I-Premise
QALY I-Premise
, I-Premise
with I-Premise
a I-Premise
99 I-Premise
% I-Premise
probability I-Premise
of I-Premise
a I-Premise
positive I-Premise
net I-Premise
benefit I-Premise
in I-Premise
QALYs I-Premise
( I-Premise
net I-Premise
benefit I-Premise
= I-Premise
0.4805 I-Premise
years I-Premise
of I-Premise
perfect I-Premise
life I-Premise
) I-Premise
and I-Premise
a I-Premise
94 I-Premise
% I-Premise
probability I-Premise
of I-Premise
being I-Premise
acceptable I-Premise
using I-Premise
a I-Premise
threshold I-Premise
ICUR I-Premise
of I-Premise
pounds I-Premise
30,000/QALY I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

Median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9.3 I-Premise
months I-Premise
and I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.90 I-Premise
) I-Premise
. I-Premise

HDCT B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
AT I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise

Regardless B-Premise
of I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
participants I-Premise
reported I-Premise
high I-Premise
levels I-Premise
of I-Premise
QOL I-Premise
with I-Premise
few I-Premise
exceptions I-Premise
. I-Premise

Placebo-treated B-Premise
patients I-Premise
had I-Premise
a I-Premise
mean I-Premise
increase I-Premise
in I-Premise
HgB I-Premise
of I-Premise
0.9 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-3.8 I-Premise
to I-Premise
+5.3 I-Premise
) I-Premise
compared I-Premise
with I-Premise
2.8 I-Premise
g/dL I-Premise
( I-Premise
range I-Premise
, I-Premise
-2.2 I-Premise
to I-Premise
+7.5 I-Premise
) I-Premise
for I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
";" I-Premise
P I-Premise
=.06 I-Premise
) I-Premise
. I-Premise

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
TOF I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs. I-Premise
17 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
TOF I-Premise
group I-Premise
vs. I-Premise
3 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.017 I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

Patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
AET I-Premise
compared I-Premise
with I-Premise
RET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.9-41 I-Premise
";" I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0.38 I-Premise
to I-Premise
0.99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
and I-Premise
from I-Premise
-0.34 I-Premise
to I-Premise
-0.57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-Î± I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

One B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise

Grade B-Premise
2-3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
PE I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
among I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Dry B-Premise
mouth I-Premise
and I-Premise
sticky I-Premise
saliva I-Premise
were I-Premise
problems I-Premise
in I-Premise
both I-Premise
groups I-Premise
2 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
. I-Premise

Compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
HD/LD I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.03 I-Premise
) I-Premise
and I-Premise
the I-Premise
EFP I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

CRF B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
Fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3.04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0.44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.17-0.72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
score I-Premise
by I-Premise
5.40 I-Premise
( I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
Toi I-Premise
score I-Premise
by I-Premise
5.22 I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
Anaemia-ANS I-Premise
by I-Premise
3.76 I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
PMP I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
PRN I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

They B-Premise
deteriorated I-Premise
during I-Premise
follow-up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
ccHRT I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

Forty-six B-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
were I-Premise
in I-Premise
disease I-Premise
remission I-Premise
12 I-Premise
months I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2-year I-Premise
OS I-Premise
rates I-Premise
were I-Premise
65.7 I-Premise
% I-Premise
for I-Premise
CIS I-Premise
and I-Premise
66.2 I-Premise
% I-Premise
for I-Premise
TPZ/CIS I-Premise
( I-Premise
TPZ/CIS I-Premise
-- I-Premise
CIS I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-5.9 I-Premise
% I-Premise
to I-Premise
6.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Capecitabine/docetaxel B-Premise
increased I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
by I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
docetaxel I-Premise
alone I-Premise
( I-Premise
14.5 I-Premise
vs. I-Premise
11.5 I-Premise
months I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
P I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
P I-Premise
= I-Premise
.048 I-Premise
) I-Premise
. I-Premise

OS B-Premise
, I-Premise
PFS I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
RR I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise

Median B-Premise
TTP I-Premise
was I-Premise
4.5 I-Premise
and I-Premise
4.6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

Seventy-eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
GP I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end-of-treatment I-Premise
assessment I-Premise
vs. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Mean B-Premise
total I-Premise
costs I-Premise
of I-Premise
GJJ I-Premise
were I-Premise
higher I-Premise
compared I-Premise
with I-Premise
stent I-Premise
placement I-Premise
( I-Premise
$ I-Premise
16,535 I-Premise
vs I-Premise
$ I-Premise
11,720 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.049 I-Premise
[ I-Premise
comparing I-Premise
medians I-Premise
] I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
.014 I-Premise
) I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
self-efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

CPT-11 B-Premise
+ I-Premise
LFA-5-FU I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
CPT-11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5-FU I-Premise
. I-Premise

The B-Premise
costs I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Occurrence B-Premise
of I-Premise
grade I-Premise
3 I-Premise
and I-Premise
4 I-Premise
diarrhea I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
FU24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
arms I-Premise
";" I-Premise
however B-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
in I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arms I-Premise
) I-Premise
and I-Premise
hematologic I-Premise
toxicity I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
bolus I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
. I-Premise

In B-Premise
all I-Premise
study I-Premise
groups I-Premise
, I-Premise
serum I-Premise
TSH I-Premise
levels I-Premise
showed I-Premise
very I-Premise
good I-Premise
stimulation I-Premise
( I-Premise
mean I-Premise
, I-Premise
82.24 I-Premise
+/- I-Premise
18.21 I-Premise
mU/L I-Premise
) I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.5213 I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

In B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

The B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
C3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow-up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.35 I-Premise
[ I-Premise
0.95-1.91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.09 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.27 I-Premise
[ I-Premise
0.87-1.84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.20 I-Premise
) I-Premise
. I-Premise

Visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68.9 I-Premise
vs. I-Premise
64.4 I-Premise
, I-Premise
P=0.029 I-Premise
) I-Premise
. I-Premise

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

Patients B-Premise
with I-Premise
complete I-Premise
or I-Premise
partial I-Premise
response I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
improvement I-Premise
in I-Premise
the I-Premise
QOL I-Premise
response I-Premise
than I-Premise
patients I-Premise
with I-Premise
stable I-Premise
or I-Premise
progressive I-Premise
disease I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

When B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.68 I-Premise
) I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
) I-Premise
. I-Premise

The B-Premise
incremental I-Premise
cost-effectiveness I-Premise
ratio I-Premise
of I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
GOOSS I-Premise
) I-Premise
> I-Premise
or=2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise

Liver B-Premise
and I-Premise
kidney I-Premise
function I-Premise
and I-Premise
blood I-Premise
tests I-Premise
of I-Premise
the I-Premise
treatment I-Premise
group I-Premise
were I-Premise
within I-Premise
the I-Premise
normal I-Premise
range I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

In B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
SPCG-4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow-up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
";" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
absolute I-Premise
OS I-Premise
rates I-Premise
were I-Premise
10 I-Premise
% I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
15 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
monotherapy I-Premise
arm I-Premise
. I-Premise

Toxicity B-Premise
of I-Premise
HDC I-Premise
has I-Premise
a I-Premise
strong I-Premise
negative I-Premise
impact I-Premise
on I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
phase I-Premise
. I-Premise

The B-Premise
arms I-Premise
were I-Premise
comparable I-Premise
with I-Premise
respect I-Premise
to I-Premise
toxicity I-Premise
except I-Premise
for I-Premise
leucopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
. I-Premise

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

At B-Premise
24-month I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
were I-Premise
significantly I-Premise
more I-Premise
satisfied I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

The B-Premise
change I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
[ I-Premise
ancova I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24.5 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

The B-Premise
score I-Premise
on I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
of I-Premise
transhiatal I-Premise
patients I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
transthoracic I-Premise
patients I-Premise
in I-Premise
the I-Premise
third I-Premise
, I-Premise
sixth I-Premise
and I-Premise
twelfth I-Premise
month I-Premise
. I-Premise

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
anemia I-Premise
developed I-Premise
in I-Premise
22 I-Premise
% I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
topotecan I-Premise
. I-Premise

The B-Premise
weekly I-Premise
VNR/CDDP I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non-statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
schedule I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
loco-regional I-Premise
or I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p=0.022 I-Premise
) I-Premise
. I-Premise

Twenty-four B-Premise
of I-Premise
26 I-Premise
patients I-Premise
with I-Premise
documented I-Premise
progression I-Premise
in I-Premise
the I-Premise
INT I-Premise
arm I-Premise
responded I-Premise
to I-Premise
imatinib I-Premise
reintroduction I-Premise
. I-Premise

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

No B-Premise
acute I-Premise
Grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

The B-Premise
RR I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.3492 I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
( I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
developed I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
and I-Premise
died I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
overall I-Premise
survival I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
( I-Premise
median I-Premise
, I-Premise
16.2 I-Premise
v I-Premise
14.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
. I-Premise

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

Significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
IMCP I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
-6.56 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
symptom-related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
-0.47 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
PFS I-Premise
or I-Premise
OS I-Premise
between I-Premise
IFN1 I-Premise
and I-Premise
IFN5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3.7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3.4 I-Premise
months I-Premise
PFS I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
of I-Premise
25.5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17.5 I-Premise
months I-Premise
OS I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Toxicities B-Premise
were I-Premise
generally I-Premise
mild I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

The B-Premise
CR I-Premise
rate I-Premise
and I-Premise
the I-Premise
3-year I-Premise
CR I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise

Significant B-Premise
KPS-by-gender I-Premise
interactions I-Premise
were I-Premise
noted I-Premise
for I-Premise
FACT-L I-Premise
in I-Premise
the I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
additional I-Premise
concerns-lung I-Premise
subscales I-Premise
( I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
cost I-Premise
per I-Premise
QALY I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13,558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
clinical I-Premise
outcome I-Premise
measures I-Premise
, I-Premise
QOL I-Premise
score I-Premise
improvement I-Premise
was I-Premise
greater I-Premise
for I-Premise
UAE I-Premise
with I-Premise
TAGMs I-Premise
compared I-Premise
with I-Premise
PVA I-Premise
( I-Premise
49.0 I-Premise
vs I-Premise
27.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
but B-Premise
no I-Premise
other I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

PFS B-Premise
was I-Premise
11 I-Premise
months I-Premise
for I-Premise
HDCT I-Premise
and I-Premise
9 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.6 I-Premise
in I-Premise
favor I-Premise
of I-Premise
HDCT I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.5 I-Premise
to I-Premise
0.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
AM I-Premise
, I-Premise
17.3 I-Premise
v I-Premise
no I-Premise
AM I-Premise
, I-Premise
17.9 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
. I-Premise

For B-Premise
willingness-to-pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
on I-Premise
the I-Premise
physical I-Premise
and I-Premise
psychological I-Premise
subscales I-Premise
, I-Premise
the I-Premise
Etoposide I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
other I-Premise
3 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
PSA I-Premise
nadir I-Premise
â‰¤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0.2 I-Premise
to I-Premise
4 I-Premise
ng/ml I-Premise
in I-Premise
CAD I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Dignity B-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
client-centred I-Premise
care I-Premise
in I-Premise
improving I-Premise
spiritual I-Premise
wellbeing I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=10Â·35 I-Premise
";" I-Premise
p=0Â·006 I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
in I-Premise
terms I-Premise
of I-Premise
lessening I-Premise
sadness I-Premise
or I-Premise
depression I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=9Â·38 I-Premise
";" I-Premise
p=0Â·009 I-Premise
) I-Premise
";" I-Premise
significantly B-Premise
more I-Premise
patients I-Premise
who I-Premise
had I-Premise
received I-Premise
dignity I-Premise
therapy I-Premise
reported I-Premise
that I-Premise
the I-Premise
study I-Premise
group I-Premise
had I-Premise
been I-Premise
satisfactory I-Premise
, I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
( I-Premise
Ï‡ I-Premise
( I-Premise
2 I-Premise
) I-Premise
=29Â·58 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0Â·0001 I-Premise
) I-Premise
. I-Premise

Immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
TS I-Premise
. I-Premise

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
vomiting I-Premise
in I-Premise
the I-Premise
GE I-Premise
and I-Premise
GP I-Premise
arms I-Premise
was I-Premise
20.0 I-Premise
and I-Premise
20.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.96 I-Premise
) I-Premise
. I-Premise

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
episode I-Premise
of I-Premise
arm I-Premise
infection I-Premise
or I-Premise
aggravation I-Premise
in I-Premise
limb I-Premise
volume I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
event-rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Ten B-Premise
patients I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
required I-Premise
repeated I-Premise
embolization I-Premise
or I-Premise
hysterectomy I-Premise
for I-Premise
inadequate I-Premise
symptom I-Premise
control I-Premise
. I-Premise

Among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
5.9 I-Premise
months I-Premise
with I-Premise
GC I-Premise
and I-Premise
6.3 I-Premise
months I-Premise
with I-Premise
PE I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
";" I-Premise
p=0.0025 I-Premise
) I-Premise
. I-Premise

At B-Premise
4-month I-Premise
follow-up I-Premise
, I-Premise
intervention I-Premise
patients I-Premise
reported I-Premise
less I-Premise
uncertainty I-Premise
and I-Premise
better I-Premise
communication I-Premise
with I-Premise
spouses I-Premise
than I-Premise
control I-Premise
patients I-Premise
, I-Premise
but B-Premise
they I-Premise
reported I-Premise
no I-Premise
other I-Premise
effects I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

The B-Premise
3-year I-Premise
progression-free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88.2 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.20 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.12 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
7.9 I-Premise
to I-Premise
9.7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.2 I-Premise
to I-Premise
7.1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise

Although B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
across I-Premise
the I-Premise
three I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
the B-Premise
combination I-Premise
treatment I-Premise
was I-Premise
more I-Premise
toxic I-Premise
than I-Premise
the I-Premise
two I-Premise
drugs I-Premise
given I-Premise
singly I-Premise
. I-Premise

Patients B-Premise
with I-Premise
wild-type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
GHS I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
BSC I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3.2 I-Premise
v I-Premise
-7.7 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long-term I-Premise
negative I-Premise
effects I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Two B-Premise
patients I-Premise
, I-Premise
1 I-Premise
in I-Premise
each I-Premise
arm I-Premise
, I-Premise
remained I-Premise
in I-Premise
complete I-Premise
remission I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
last I-Premise
follow-up I-Premise
, I-Premise
at I-Premise
45 I-Premise
and I-Premise
38 I-Premise
months I-Premise
from I-Premise
treatment I-Premise
. I-Premise

Nadir B-Premise
prostate-specific I-Premise
antigen I-Premise
values I-Premise
occurred I-Premise
at I-Premise
a I-Premise
median I-Premise
of I-Premise
18.0 I-Premise
( I-Premise
3.0-54.0 I-Premise
) I-Premise
months I-Premise
after I-Premise
RT I-Premise
. I-Premise

Arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

When B-Premise
wound I-Premise
complication I-Premise
was I-Premise
included I-Premise
in I-Premise
the I-Premise
model I-Premise
, I-Premise
patients I-Premise
with I-Premise
complications I-Premise
had I-Premise
lower I-Premise
MSTS I-Premise
and I-Premise
TESS I-Premise
scores I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
. I-Premise

The B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine-treated I-Premise
patients I-Premise
was I-Premise
0.65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.45-0.93 I-Premise
) I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

The B-Premise
exercise I-Premise
program I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
as I-Premise
evidenced I-Premise
by I-Premise
high I-Premise
attendance I-Premise
( I-Premise
83 I-Premise
% I-Premise
) I-Premise
and I-Premise
compliance I-Premise
rates I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
ability I-Premise
of I-Premise
the I-Premise
participants I-Premise
to I-Premise
exercise I-Premise
at I-Premise
an I-Premise
intensity I-Premise
within I-Premise
the I-Premise
target I-Premise
range I-Premise
for I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
rating I-Premise
of I-Premise
perceived I-Premise
exertion I-Premise
=13.8Â±1.5 I-Premise
) I-Premise
. I-Premise

Intent-to-treat B-Premise
CR I-Premise
rates I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
HDCT I-Premise
and I-Premise
AT I-Premise
were I-Premise
12.5 I-Premise
% I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

In B-Premise
terms I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
, I-Premise
dyspnoic I-Premise
and I-Premise
coughing I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worsened I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.036 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
whereas I-Premise
symptoms I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
progressively I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
. I-Premise

Initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs. I-Premise
euro4820 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
hypertension I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
bevacizumab I-Premise
treatment I-Premise
( I-Premise
16 I-Premise
% I-Premise
v I-Premise
3 I-Premise
% I-Premise
) I-Premise
but B-Premise
was I-Premise
controlled I-Premise
with I-Premise
oral I-Premise
medication I-Premise
and I-Premise
did I-Premise
not I-Premise
cause I-Premise
study I-Premise
drug I-Premise
discontinuation I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

Vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

The B-Premise
3-year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94.1 I-Premise
% I-Premise
and I-Premise
67.7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.078 I-Premise
to I-Premise
0.73 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
. I-Premise

Breast B-Premise
IMRT I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise

Depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
";" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2/group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
. I-Premise

Frequencies B-Premise
of I-Premise
hematologic I-Premise
and I-Premise
nonhematologic I-Premise
toxicities I-Premise
were I-Premise
essentially I-Premise
similar I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
General I-Premise
Fatigue I-Premise
score I-Premise
, I-Premise
between I-Premise
those I-Premise
who I-Premise
received I-Premise
the I-Premise
intervention I-Premise
and I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
was I-Premise
-3.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-3.97 I-Premise
to I-Premise
-2.25 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
group I-Premise
differences I-Premise
in I-Premise
global I-Premise
QoL I-Premise
, I-Premise
pain I-Premise
or I-Premise
fatigue I-Premise
up I-Premise
to I-Premise
26 I-Premise
weeks I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

For B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
QL I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
QoL I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

The B-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0.16 I-Premise
to I-Premise
2.45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0.66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/t/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
PP I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
GP I-Premise
group I-Premise
. I-Premise

Nausea B-Premise
and I-Premise
vomiting I-Premise
frequency I-Premise
, I-Premise
duration I-Premise
, I-Premise
and I-Premise
distress I-Premise
were I-Premise
lower I-Premise
for I-Premise
experimental I-Premise
group I-Premise
members I-Premise
, I-Premise
although B-Premise
a I-Premise
high I-Premise
attrition I-Premise
rate I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
resulted I-Premise
in I-Premise
insufficient I-Premise
power I-Premise
to I-Premise
detect I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
over I-Premise
time I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
26.0 I-Premise
% I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
";" I-Premise
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.088 I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
and I-Premise
hospital I-Premise
stay I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
groups I-Premise
, I-Premise
whereas I-Premise
overall I-Premise
complications I-Premise
were I-Premise
higher I-Premise
on I-Premise
artificial I-Premise
nutrition I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal-related I-Premise
event I-Premise
in I-Premise
patients I-Premise
who I-Premise
had I-Premise
such I-Premise
an I-Premise
event I-Premise
was I-Premise
9Â·2 I-Premise
months I-Premise
( I-Premise
8Â·1-10Â·7 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
10Â·2 I-Premise
months I-Premise
( I-Premise
7Â·3-14Â·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
p=0Â·63 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well-being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5.8 I-Premise
vs I-Premise
5.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.3 I-Premise
) I-Premise
. I-Premise

Analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
( I-Premise
RRs I-Premise
) I-Premise
for I-Premise
PC I-Premise
, I-Premise
VC I-Premise
, I-Premise
GC I-Premise
, I-Premise
and I-Premise
TC I-Premise
were I-Premise
29.1 I-Premise
% I-Premise
, I-Premise
25.9 I-Premise
% I-Premise
, I-Premise
22.3 I-Premise
% I-Premise
, I-Premise
and I-Premise
23.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
in I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
and I-Premise
5.4 I-Premise
months I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31.9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17.7 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
. I-Premise

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
20 I-Premise
wk I-Premise
, I-Premise
4 I-Premise
wk I-Premise
after I-Premise
planned I-Premise
interruption I-Premise
of I-Premise
duloxetine I-Premise
, I-Premise
we I-Premise
observed I-Premise
a I-Premise
U-turn I-Premise
, I-Premise
23 I-Premise
patients I-Premise
were I-Premise
completely I-Premise
dry I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
38 I-Premise
in I-Premise
group I-Premise
B I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
P I-Premise
=.0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.77 I-Premise
) I-Premise
. I-Premise

Mild B-Premise
or I-Premise
moderate I-Premise
nausea I-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
side I-Premise
effect I-Premise
of I-Premise
estramustine I-Premise
. I-Premise

No B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise

The B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease-free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
in I-Premise
69 I-Premise
% I-Premise
( I-Premise
DCF I-Premise
) I-Premise
v I-Premise
59 I-Premise
% I-Premise
( I-Premise
CF I-Premise
) I-Premise
of I-Premise
patients I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

Results B-Premise
from I-Premise
the I-Premise
non-randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

Neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.95 I-Premise
, I-Premise
0.73 I-Premise
to I-Premise
1.24 I-Premise
";" I-Premise
P=0.71 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
short-term I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
improvement I-Premise
rate I-Premise
of I-Premise
clinical I-Premise
syndrome I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
50.0 I-Premise
% I-Premise
, I-Premise
70.0 I-Premise
% I-Premise
and I-Premise
76.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
43.3 I-Premise
% I-Premise
, I-Premise
46.7 I-Premise
% I-Premise
and I-Premise
50.0 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
showing I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
LV5FU2 I-Premise
or I-Premise
ldLV5FU2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
discussed I-Premise
more I-Premise
symptoms I-Premise
over I-Premise
time I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
attention-control I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
and I-Premise
control I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
arms I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

Treatment B-Premise
toxicity I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
and I-Premise
intestinal I-Premise
adhesion I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
study I-Premise
groups I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

Protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

CR B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
16 I-Premise
% I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
29 I-Premise
% I-Premise
in I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
were I-Premise
-1.0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1.5 I-Premise
to I-Premise
-0.5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0.2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.2 I-Premise
to I-Premise
+0.6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
1-year I-Premise
treatment I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

The B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IPSS I-Premise
change I-Premise
of I-Premise
â‰¥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61.0 I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

Mean B-Premise
utility I-Premise
scores I-Premise
in I-Premise
the I-Premise
DTX I-Premise
group I-Premise
were I-Premise
lowest I-Premise
at I-Premise
7 I-Premise
months I-Premise
and I-Premise
tended I-Premise
to I-Premise
remain I-Premise
low I-Premise
for I-Premise
a I-Premise
long I-Premise
time I-Premise
. I-Premise

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Amenorrhea B-Premise
12 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
was I-Premise
significantly I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
: I-Premise
69.8 I-Premise
% I-Premise
for I-Premise
ACâ†’T I-Premise
, I-Premise
57.7 I-Premise
% I-Premise
for I-Premise
TAC I-Premise
, I-Premise
and I-Premise
37.9 I-Premise
% I-Premise
for I-Premise
AT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

AM B-Premise
was I-Premise
associated I-Premise
with I-Premise
higher I-Premise
rates I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
toxicity I-Premise
( I-Premise
P I-Premise
= I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
infection I-Premise
or I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
CCSP I-Premise
was I-Premise
beneficial I-Premise
. I-Premise

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
IIIB I-Premise
subgroup I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13.1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.152 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Self-reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/= I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

The B-Premise
PSA I-Premise
response I-Premise
rates I-Premise
were I-Premise
50 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
measurable I-Premise
disease I-Premise
response I-Premise
rates I-Premise
( I-Premise
CR+PR I-Premise
) I-Premise
14 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
19.4 I-Premise
months I-Premise
and I-Premise
13.9 I-Premise
months I-Premise
on I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
post-hoc I-Premise
as-observed I-Premise
analyses I-Premise
, I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
) I-Premise
achieving I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
low I-Premise
disease I-Premise
activity I-Premise
score I-Premise
( I-Premise
< I-Premise
or I-Premise
= I-Premise
3.2 I-Premise
) I-Premise
and I-Premise
DAS28 I-Premise
( I-Premise
C-reactive I-Premise
protein I-Premise
) I-Premise
-defined I-Premise
remission I-Premise
( I-Premise
< I-Premise
2.6 I-Premise
) I-Premise
increased I-Premise
from I-Premise
18.3 I-Premise
% I-Premise
( I-Premise
13.0 I-Premise
, I-Premise
23.5 I-Premise
) I-Premise
to I-Premise
32.0 I-Premise
% I-Premise
( I-Premise
24.6 I-Premise
, I-Premise
39.4 I-Premise
) I-Premise
and I-Premise
11.1 I-Premise
% I-Premise
( I-Premise
6.8 I-Premise
, I-Premise
15.3 I-Premise
) I-Premise
to I-Premise
20.3 I-Premise
% I-Premise
( I-Premise
13.9 I-Premise
, I-Premise
26.6 I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
was I-Premise
2/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
2.7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1/92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
";" I-Premise
1.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

When B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P=0.0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
P=0.01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
MVC I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
P=0.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
EXE I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
MA I-Premise
( I-Premise
123.4 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
OR I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
";" I-Premise
60.1 I-Premise
v I-Premise
49.1 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20.3 I-Premise
v I-Premise
16.6 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16.3 I-Premise
v I-Premise
15.7 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
=.042 I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
13 I-Premise
months I-Premise
, I-Premise
the I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
with I-Premise
36.2 I-Premise
% I-Premise
1-year I-Premise
survival I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
versus I-Premise
13.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
supportive-care I-Premise
group I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

In B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild-type I-Premise
KRAS I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
PF I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
-0.7 I-Premise
v I-Premise
-7.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-3.4 I-Premise
v I-Premise
-13.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
BSC I-Premise
. I-Premise

High B-Premise
self-assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
";" I-Premise
P I-Premise
= I-Premise
.84 I-Premise
) I-Premise
. I-Premise

Treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
P=.024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in-hospital I-Premise
compared I-Premise
with I-Premise
seven I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
0Â·35 I-Premise
, I-Premise
0Â·16-0Â·78 I-Premise
";" I-Premise
p=0Â·005 I-Premise
) I-Premise
. I-Premise

The B-Premise
patients I-Premise
reported I-Premise
low I-Premise
levels I-Premise
of I-Premise
skin I-Premise
related I-Premise
symptoms I-Premise
and I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
were I-Premise
found I-Premise
. I-Premise

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

Among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
P=.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

After B-Premise
intervention I-Premise
, I-Premise
EG I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
QOL I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.68 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

Survival B-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
alone I-Premise
arm I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.037 I-Premise
) I-Premise
( I-Premise
median I-Premise
survival I-Premise
= I-Premise
6.8 I-Premise
months I-Premise
versus I-Premise
4.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

For B-Premise
6 I-Premise
months I-Premise
post-surgery I-Premise
younger I-Premise
patients I-Premise
reported I-Premise
less I-Premise
favourable I-Premise
QOL I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
greater I-Premise
levels I-Premise
of I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Nine B-Premise
CR I-Premise
and I-Premise
twenty-seven I-Premise
PR I-Premise
were I-Premise
obtained I-Premise
on I-Premise
one I-Premise
hundred I-Premise
eleven I-Premise
evaluable I-Premise
patients I-Premise
treated I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
32 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
: I-Premise
24 I-Premise
% I-Premise
-42 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
two I-Premise
CR I-Premise
and I-Premise
eleven I-Premise
PR I-Premise
were I-Premise
observed I-Premise
among I-Premise
one I-Premise
hundred I-Premise
three I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
control I-Premise
arm I-Premise
( I-Premise
RR I-Premise
= I-Premise
13 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7 I-Premise
% I-Premise
-21 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
survival I-Premise
benefit I-Premise
of I-Premise
D3P I-Premise
compared I-Premise
with I-Premise
MP I-Premise
has I-Premise
persisted I-Premise
with I-Premise
extended I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
. I-Premise

Trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise

In B-Premise
the I-Premise
expanded I-Premise
pattern-mixture I-Premise
model I-Premise
, I-Premise
EVE I-Premise
+ I-Premise
EXE-treated I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
drop I-Premise
out I-Premise
early I-Premise
had I-Premise
stable I-Premise
BRBS I-Premise
and I-Premise
BRAS I-Premise
relative I-Premise
to I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
Patient I-Premise
Health I-Premise
Questionnaire-9 I-Premise
( I-Premise
PHQ-9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
OR I-Premise
] I-Premise
= I-Premise
1.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.16 I-Premise
to I-Premise
3.38 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
( I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1.75 I-Premise
+/- I-Premise
2.15 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
30,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.008 I-Premise
vs. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1.04 I-Premise
+/- I-Premise
1.75 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
20,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
non-significant I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
follow-up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
( I-Premise
33.8 I-Premise
and I-Premise
40.7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
41.4 I-Premise
and I-Premise
57.3 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
of I-Premise
borderline I-Premise
significance I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.055 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

Differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
OR I-Premise
0.12 I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
OR I-Premise
0.52 I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
additional I-Premise
charge I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,748 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
1,194 I-Premise
the I-Premise
result I-Premise
of I-Premise
surgical I-Premise
instruments I-Premise
and I-Premise
$ I-Premise
554 I-Premise
the I-Premise
result I-Premise
of I-Premise
longer I-Premise
operative I-Premise
time I-Premise
) I-Premise
. I-Premise

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
treatment-related I-Premise
AEs I-Premise
were I-Premise
asthenia/fatigue I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hand-foot I-Premise
syndrome I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
MA I-Premise
, I-Premise
there I-Premise
were I-Premise
similar I-Premise
or I-Premise
greater I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
TRSS I-Premise
, I-Premise
and I-Premise
QOL I-Premise
with I-Premise
EXE I-Premise
. I-Premise

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

The B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise

However B-Premise
, I-Premise
after I-Premise
12 I-Premise
months I-Premise
subscale I-Premise
scores I-Premise
for I-Premise
role-physical I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
, I-Premise
and I-Premise
physical I-Premise
function I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
indicating I-Premise
a I-Premise
better I-Premise
condition I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
16.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
10.5 I-Premise
to I-Premise
21.2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
TEE I-Premise
arm I-Premise
and I-Premise
23.4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.9 I-Premise
to I-Premise
30.6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
KA/VE I-Premise
. I-Premise

No B-Premise
study I-Premise
arm I-Premise
effect I-Premise
was I-Premise
observed I-Premise
for I-Premise
function I-Premise
discussions I-Premise
. I-Premise

In B-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
GI I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO-treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
stage I-Premise
IV I-Premise
subgroup I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
was I-Premise
7.6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
8.9 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
P I-Premise
=.246 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
helpful I-Premise
in I-Premise
defining I-Premise
which I-Premise
patients I-Premise
were I-Premise
likely I-Premise
to I-Premise
respond I-Premise
. I-Premise

Rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise

This B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.818 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
VBT I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
RR I-Premise
, I-Premise
RD I-Premise
, I-Premise
or I-Premise
PFS I-Premise
between I-Premise
arms I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
NGT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

The B-Premise
SF-6D I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21Â·2 I-Premise
Â± I-Premise
2Â·5 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
P I-Premise
= I-Premise
0Â·001 I-Premise
) I-Premise
. I-Premise

In B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83.33 I-Premise
vs. I-Premise
50.00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0.55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.27 I-Premise
to I-Premise
0.82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.09 I-Premise
to I-Premise
0.65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.10 I-Premise
to I-Premise
0.64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0.32 I-Premise
, I-Premise
0.05 I-Premise
to I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0.28 I-Premise
, I-Premise
0.02 I-Premise
to I-Premise
0.56 I-Premise
) I-Premise
scores I-Premise
. I-Premise

The B-Premise
FFM/FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Post-treatment B-Premise
symptoms I-Premise
were I-Premise
increased I-Premise
above I-Premise
baseline I-Premise
for I-Premise
all I-Premise
treatments I-Premise
. I-Premise

Mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

Younger B-Premise
patients I-Premise
( I-Premise
< I-Premise
40 I-Premise
years I-Premise
) I-Premise
who I-Premise
received I-Premise
goserelin I-Premise
alone I-Premise
returned I-Premise
to I-Premise
their I-Premise
premenopausal I-Premise
status I-Premise
at I-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
cessation I-Premise
of I-Premise
therapy I-Premise
, I-Premise
while I-Premise
those I-Premise
who I-Premise
received I-Premise
CMF I-Premise
showed I-Premise
marginal I-Premise
changes I-Premise
from I-Premise
their I-Premise
baseline I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
. I-Premise

Subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
LAC I-Premise
in I-Premise
total I-Premise
QOL I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1.17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.95 I-Premise
to I-Premise
1.44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise

With B-Premise
the I-Premise
exceptions I-Premise
of I-Premise
increased I-Premise
granulocytopenia I-Premise
on I-Premise
the I-Premise
low-dose I-Premise
paclitaxel I-Premise
regimen I-Premise
and I-Premise
increased I-Premise
myalgias I-Premise
, I-Premise
neurotoxicity I-Premise
, I-Premise
and I-Premise
, I-Premise
possibly I-Premise
, I-Premise
increased I-Premise
treatment-related I-Premise
cardiac I-Premise
events I-Premise
with I-Premise
high-dose I-Premise
paclitaxel I-Premise
, I-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
arms I-Premise
. I-Premise

No B-Premise
QOL I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10.6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8.0 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Scores B-Premise
on I-Premise
the I-Premise
physical I-Premise
function I-Premise
, I-Premise
role-physical I-Premise
, I-Premise
and I-Premise
general I-Premise
health I-Premise
subscales I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
Canadian I-Premise
normative I-Premise
data I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise

The B-Premise
BPI-SF I-Premise
revealed I-Premise
a I-Premise
decline I-Premise
in I-Premise
pain I-Premise
scores I-Premise
in I-Premise
both I-Premise
arms I-Premise
from I-Premise
the I-Premise
first I-Premise
to I-Premise
fourth I-Premise
assessments I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Post B-Premise
hoc I-Premise
stratification I-Premise
for I-Premise
patients I-Premise
with I-Premise
ADPKD I-Premise
or I-Premise
PCLD I-Premise
revealed I-Premise
similar I-Premise
changes I-Premise
in I-Premise
liver I-Premise
volume I-Premise
, I-Premise
with I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
for I-Premise
both I-Premise
diseases I-Premise
) I-Premise
. I-Premise

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62Â·9-70Â·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64Â·6-71Â·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6Â·6 I-Premise
to I-Premise
3Â·3 I-Premise
";" I-Premise
p=0Â·52 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
seen I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
physical I-Premise
and I-Premise
mental I-Premise
component I-Premise
summary I-Premise
scores I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
, I-Premise
and I-Premise
36 I-Premise
months I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
in-hospital I-Premise
mortality I-Premise
or I-Premise
early I-Premise
complication I-Premise
rates I-Premise
, I-Premise
but B-Premise
late I-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
rigid I-Premise
stenting I-Premise
( I-Premise
risk I-Premise
ratio=2.47 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.88-3.04 I-Premise
) I-Premise
. I-Premise

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
total I-Premise
energy I-Premise
( I-Premise
P=0.029 I-Premise
) I-Premise
and I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
. I-Premise

Of B-Premise
the I-Premise
36 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
that I-Premise
pain I-Premise
interfered I-Premise
with I-Premise
their I-Premise
normal I-Premise
work I-Premise
or I-Premise
activities I-Premise
at I-Premise
baseline I-Premise
, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

The B-Premise
HgB I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+5.1 I-Premise
compared I-Premise
with I-Premise
-2.1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
A I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
A I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2/3 I-Premise
alopecia I-Premise
( I-Premise
A I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
B I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
and I-Premise
survival I-Premise
outcomes I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
randomised I-Premise
and I-Premise
non-randomised I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise

Median B-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
10.0 I-Premise
months I-Premise
and I-Premise
38.4 I-Premise
% I-Premise
for I-Premise
NP I-Premise
, I-Premise
and I-Premise
8.2 I-Premise
months I-Premise
and I-Premise
33.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
v I-Premise
2.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
QOL I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44.5 I-Premise
% I-Premise
vs I-Premise
15.4 I-Premise
% I-Premise
, I-Premise
p=0.02 I-Premise
";" I-Premise
38.5 I-Premise
% I-Premise
vs I-Premise
12.0 I-Premise
% I-Premise
, I-Premise
p=0.03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Global B-Premise
health I-Premise
scores I-Premise
showed I-Premise
continuous I-Premise
improvement I-Premise
in I-Premise
QoL I-Premise
after I-Premise
both I-Premise
treatments I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin-treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
-6.7 I-Premise
Â± I-Premise
1.8 I-Premise
vs I-Premise
-4.0 I-Premise
Â± I-Premise
1.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6.5+/-3.7 I-Premise
( I-Premise
IV I-Premise
arm I-Premise
) I-Premise
vs. I-Premise
7.2+/-4.3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

After B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
QLQ-C30 I-Premise
questionnaire I-Premise
and I-Premise
LC30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
DFI I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise

Increased B-Premise
appetite I-Premise
was I-Premise
reported I-Premise
by I-Premise
73 I-Premise
% I-Premise
, I-Premise
58 I-Premise
% I-Premise
, I-Premise
and I-Premise
69 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
CE I-Premise
, I-Premise
THC I-Premise
, I-Premise
or I-Premise
PL I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Fatigue B-Premise
at I-Premise
T2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self-reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
CBT I-Premise
. I-Premise

Overall B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
was I-Premise
comparable I-Premise
between I-Premise
the I-Premise
ASA404 I-Premise
and I-Premise
placebo I-Premise
arms I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

FACT-B B-Premise
scores I-Premise
increased I-Premise
after I-Premise
treatment I-Premise
began I-Premise
and I-Premise
remained I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25.20 I-Premise
% I-Premise
and I-Premise
17.74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Compliance B-Premise
with I-Premise
QOL I-Premise
was I-Premise
87 I-Premise
% I-Premise
at I-Premise
baseline I-Premise
and I-Premise
more I-Premise
than I-Premise
70 I-Premise
% I-Premise
during I-Premise
treatment I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
-5.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-9.6 I-Premise
% I-Premise
to I-Premise
-1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-1.4 I-Premise
% I-Premise
to I-Premise
+1.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

AET B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Severe B-Premise
toxicities I-Premise
of I-Premise
TOM I-Premise
+ I-Premise
LFA-5-FU I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
DI8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
TOM I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

In B-Premise
the I-Premise
684 I-Premise
patients I-Premise
with I-Premise
data I-Premise
that I-Premise
could I-Premise
be I-Premise
evaluated I-Premise
, I-Premise
ultrasonography I-Premise
of I-Premise
the I-Premise
neck I-Premise
was I-Premise
normal I-Premise
in I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
stimulated I-Premise
thyroglobulin I-Premise
level I-Premise
was I-Premise
1.0 I-Premise
ng I-Premise
per I-Premise
milliliter I-Premise
or I-Premise
less I-Premise
in I-Premise
621 I-Premise
of I-Premise
the I-Premise
652 I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
without I-Premise
detectable I-Premise
thyroglobulin I-Premise
antibodies I-Premise
. I-Premise

With B-Premise
the I-Premise
Spitzer I-Premise
's I-Premise
questionnaires I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
index I-Premise
was I-Premise
observed I-Premise
during I-Premise
treatment I-Premise
with I-Premise
the I-Premise
carboplatin I-Premise
combination I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
cisplatin I-Premise
combination I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine-carboplatin I-Premise
group I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39.9-54.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24.1-37.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.0016 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AE I-Premise
";" I-Premise
78.0 I-Premise
% I-Premise
vs I-Premise
79.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
AE I-Premise
( I-Premise
11.1 I-Premise
% I-Premise
vs I-Premise
9.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
AE I-Premise
( I-Premise
3.8 I-Premise
% I-Premise
vs I-Premise
4.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
AE I-Premise
( I-Premise
2.0 I-Premise
% I-Premise
vs I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct-switch I-Premise
patients I-Premise
. I-Premise

Anxiety B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
quadratic I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
, I-Premise
with I-Premise
trends I-Premise
for I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8.3 I-Premise
, I-Premise
11.0 I-Premise
, I-Premise
and I-Premise
10.4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
C I-Premise
= I-Premise
70.3 I-Premise
( I-Premise
19.6 I-Premise
) I-Premise
";" I-Premise
CP I-Premise
= I-Premise
72.8 I-Premise
( I-Premise
17.4 I-Premise
) I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
treated I-Premise
groups I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
fluoxetine I-Premise
for I-Premise
6 I-Premise
months I-Premise
resulted I-Premise
in I-Premise
an I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
a I-Premise
higher I-Premise
completion I-Premise
of I-Premise
adjuvant I-Premise
treatment I-Premise
( I-Premise
chemotherapy I-Premise
, I-Premise
hormonal I-Premise
therapy I-Premise
, I-Premise
chemotherapy I-Premise
plus I-Premise
hormonal I-Premise
therapy I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non-stent-treated I-Premise
patients I-Premise
( I-Premise
log-rank I-Premise
statistic=4.21 I-Premise
, I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
intakes I-Premise
, I-Premise
whereas I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
returned I-Premise
to I-Premise
or I-Premise
below I-Premise
baseline I-Premise
levels I-Premise
. I-Premise

In B-Premise
a I-Premise
quality-of-life I-Premise
analysis I-Premise
, I-Premise
all I-Premise
significant I-Premise
differences I-Premise
, I-Premise
except I-Premise
on I-Premise
diarrhoea I-Premise
score I-Premise
, I-Premise
were I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
% I-Premise
to I-Premise
23.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
14.1 I-Premise
% I-Premise
to I-Premise
40.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
25.7 I-Premise
% I-Premise
to I-Premise
54.3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Intent-to-treat B-Premise
analysis I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
three I-Premise
arms I-Premise
for I-Premise
appetite I-Premise
, I-Premise
QOL I-Premise
, I-Premise
or I-Premise
cannabinoid-related I-Premise
toxicity I-Premise
. I-Premise

QOL B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow-up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
AM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

Surgery B-Premise
was I-Premise
associated I-Premise
with I-Premise
worsened I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
fatigue I-Premise
symptoms I-Premise
up I-Premise
to I-Premise
6 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
these I-Premise
scales I-Premise
improved I-Premise
at I-Premise
2 I-Premise
years I-Premise
. I-Premise

The B-Premise
combination I-Premise
arm I-Premise
was I-Premise
more I-Premise
effective I-Premise
than I-Premise
arm I-Premise
2 I-Premise
with I-Premise
respect I-Premise
to I-Premise
LBM I-Premise
, I-Premise
REE I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
global I-Premise
QoL I-Premise
. I-Premise

Greater B-Premise
myelosuppression I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue/malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
ES I-Premise
total I-Premise
scores I-Premise
. I-Premise

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
, I-Premise
except B-Premise
for I-Premise
tumor I-Premise
hemorrhage-type I-Premise
events I-Premise
with I-Premise
gefitinib I-Premise
( I-Premise
8.9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
";" I-Premise
11.4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg/day I-Premise
";" I-Premise
1.9 I-Premise
% I-Premise
, I-Premise
methotrexate I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
";" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise

By B-Premise
2 I-Premise
weeks I-Premise
post-treatment I-Premise
, I-Premise
the I-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
whereas I-Premise
hot I-Premise
flashes I-Premise
in I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
remained I-Premise
at I-Premise
low I-Premise
levels I-Premise
. I-Premise

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

Over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
HRQOL I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

For B-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
13.0 I-Premise
% I-Premise
( I-Premise
3/23 I-Premise
) I-Premise
, I-Premise
disease I-Premise
control I-Premise
rate I-Premise
( I-Premise
DCR I-Premise
) I-Premise
was I-Premise
30.4 I-Premise
% I-Premise
( I-Premise
7/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
mPFS I-Premise
) I-Premise
was I-Premise
3.1 I-Premise
months I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
NP I-Premise
and I-Premise
35.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
. I-Premise

Similar B-Premise
trends I-Premise
in I-Premise
survival I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
were I-Premise
seen I-Premise
for I-Premise
men I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
65 I-Premise
years I-Premise
of I-Premise
age I-Premise
, I-Premise
for I-Premise
those I-Premise
with I-Premise
and I-Premise
without I-Premise
pain I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
for I-Premise
those I-Premise
with I-Premise
baseline I-Premise
PSA I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
the I-Premise
median I-Premise
value I-Premise
of I-Premise
115 I-Premise
ng/mL I-Premise
. I-Premise

The B-Premise
estimated I-Premise
4-year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78.1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
71.4 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.10 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
MMP I-Premise
appears I-Premise
to I-Premise
benefit I-Premise
older I-Premise
BCSs I-Premise
by I-Premise
reducing I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
improving I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
10.5 I-Premise
months I-Premise
( I-Premise
placebo I-Premise
) I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
( I-Premise
thalidomide I-Premise
) I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.93 I-Premise
to I-Premise
1.27 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.28 I-Premise
) I-Premise
. I-Premise

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
OS I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
EGFR I-Premise
IHC-positive I-Premise
subgroup I-Premise
( I-Premise
p=0.0233 I-Premise
) I-Premise
. I-Premise

In B-Premise
G1/G2 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
improvement/deterioration I-Premise
of I-Premise
QoL I-Premise
correlated I-Premise
with I-Premise
better I-Premise
or I-Premise
poorer I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

A B-Premise
complete I-Premise
resolution I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
three I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
a I-Premise
difference I-Premise
in I-Premise
the I-Premise
proportion I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
of I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
10-33 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
mean I-Premise
QALYs I-Premise
was I-Premise
: I-Premise
OSC I-Premise
+ I-Premise
WBRT I-Premise
31 I-Premise
days I-Premise
and I-Premise
OSC I-Premise
30 I-Premise
days I-Premise
, I-Premise
difference I-Premise
-1 I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.0 I-Premise
to I-Premise
+13.2 I-Premise
days I-Premise
) I-Premise
. I-Premise

For B-Premise
response I-Premise
, I-Premise
age I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
global I-Premise
QL I-Premise
were I-Premise
significant I-Premise
predictive I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise

Compared B-Premise
with I-Premise
standard I-Premise
TPN I-Premise
, I-Premise
a I-Premise
higher I-Premise
serum I-Premise
prealbumin I-Premise
level I-Premise
and I-Premise
better I-Premise
nitrogen I-Premise
balance I-Premise
were I-Premise
observed I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.039 I-Premise
and I-Premise
0.048 I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
after I-Premise
un-blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0.077 I-Premise
) I-Premise
. I-Premise

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p=0.021 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
IG I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
scores I-Premise
on I-Premise
the I-Premise
FACIT-Fatigue I-Premise
Scale I-Premise
at I-Premise
study I-Premise
completion I-Premise
, I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
scores I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
mental I-Premise
health I-Premise
composite I-Premise
scores I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
. I-Premise

After B-Premise
16 I-Premise
wk I-Premise
, I-Premise
39 I-Premise
patients I-Premise
versus I-Premise
27 I-Premise
were I-Premise
dry I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

QOL B-Premise
scores I-Premise
were I-Premise
increased I-Premise
and I-Premise
complication I-Premise
scores I-Premise
were I-Premise
improved I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
periods I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Mental B-Premise
health I-Premise
increased I-Premise
, I-Premise
although I-Premise
not I-Premise
significantly I-Premise
, I-Premise
for I-Premise
all I-Premise
subjects I-Premise
( I-Premise
P I-Premise
=.019 I-Premise
) I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

The B-Premise
observed I-Premise
mean I-Premise
difference I-Premise
in I-Premise
the I-Premise
average I-Premise
pain I-Premise
score I-Premise
between I-Premise
duloxetine I-Premise
and I-Premise
placebo I-Premise
was I-Premise
0.73 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26-1.20 I-Premise
) I-Premise
. I-Premise

At B-Premise
T3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
CBT I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

In B-Premise
this I-Premise
updated I-Premise
final I-Premise
analysis I-Premise
of I-Premise
all I-Premise
patients I-Premise
randomly I-Premise
assigned I-Premise
with I-Premise
strata I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
plus I-Premise
trastuzumab I-Premise
continued I-Premise
to I-Premise
show I-Premise
superiority I-Premise
to I-Premise
lapatinib I-Premise
monotherapy I-Premise
in I-Premise
PFS I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.58 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.011 I-Premise
) I-Premise
and I-Premise
offered I-Premise
significant I-Premise
OS I-Premise
benefit I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.57 I-Premise
to I-Premise
0.97 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.026 I-Premise
) I-Premise
. I-Premise

Fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
sexual I-Premise
function I-Premise
score I-Premise
was I-Premise
15 I-Premise
points I-Premise
lower I-Premise
at I-Premise
3 I-Premise
years I-Premise
for I-Premise
the I-Premise
cryoablation I-Premise
group I-Premise
and I-Premise
13 I-Premise
% I-Premise
more I-Premise
of I-Premise
the I-Premise
cryoablation I-Premise
men I-Premise
said I-Premise
that I-Premise
sexuality I-Premise
was I-Premise
a I-Premise
moderate I-Premise
or I-Premise
big I-Premise
problem I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

HRQOL B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

Median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O

In O
Lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
IV O
disease O
. O

HDCT O
was O
repeated O
after O
6 O
weeks O
. O

This O
clinical O
trial O
is O
registered O
at O
Current O
Controlled O
Trials O
website O
http O
: O
//www.controlled-trials.com/ISRCTN72466475 O
. O

Patients O
in O
both O
groups O
had O
similar O
demographic O
and O
clinical O
characteristics O
. O

Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

We O
conducted O
a O
randomized O
controlled O
trial O
in O
Edmonton O
, O
Alberta O
, O
Canada O
, O
between O
2005 O
and O
2008 O
that O
stratified O
122 O
lymphoma O
patients O
by O
major O
disease O
type O
and O
current O
treatment O
status O
and O
randomly O
assigned O
them O
to O
usual O
care O
( O
UC O
";" O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

This O
phase O
III O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
LV5FU2 O
, O
with O
progression-free O
survival O
as O
the O
primary O
end O
point O
. O

Patients O
( O
n O
= O
75 O
) O
were O
included O
who O
had O
been O
surgically O
treated O
for O
colorectal O
cancer O
( O
any O
stage O
) O
. O

The O
primary O
outcomes O
-- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
-- O
were O
measured O
with O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Spiritual O
Well-Being O
Scale O
, O
Patient O
Dignity O
Inventory O
, O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
items O
from O
the O
Structured O
Interview O
for O
Symptoms O
and O
Concerns O
, O
Quality O
of O
Life O
Scale O
, O
and O
modified O
Edmonton O
Symptom O
Assessment O
Scale O
. O

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self-assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

Time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O

A O
phase O
II O
trial O
combining O
DPPE O
and O
doxorubicin O
( O
DOX O
) O
in O
metastatic O
breast O
carcinoma O
showed O
increased O
response O
over O
that O
expected O
with O
DOX O
. O

Hot O
flushes O
and O
night O
sweats O
( O
HFNS O
) O
affect O
65-85 O
% O
of O
women O
after O
breast O
cancer O
treatment O
";" O
they O
are O
distressing O
, O
causing O
sleep O
problems O
and O
decreased O
quality O
of O
life O
. O

Many O
patients O
with O
cancer O
experience O
depression O
and O
anxiety O
, O
and O
an O
associated O
decrease O
in O
quality O
of O
life O
( O
QOL O
) O
during O
radiation O
therapy O
( O
RT O
) O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

Response O
rate O
was O
88.4 O
% O
. O

The O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O

Forty-six O
advanced O
non-squamous O
NSCLC O
patients O
who O
failed O
to O
first-line O
therapy O
were O
randomly O
divided O
into O
two O
groups O
with O
23 O
patients O
each O
, O
one O
using O
oral O
Gefitinib O
( O
Gefitinib O
group O
) O
and O
the O
other O
using O
intravenous O
injection O
Pemetrexed O
( O
Pemetrexed O
group O
) O
. O

One O
hundred O
fifty-three O
patients O
were O
randomly O
assigned O
to O
PLD O
( O
n O
= O
76 O
) O
or O
GEM O
( O
n O
= O
77 O
) O
. O

Postoperative O
quality O
of O
life O
( O
QOL O
) O
was O
evaluated O
between O
the O
2 O
methods O
by O
a O
multi-institutional O
prospective O
randomized O
trial O
. O

HRQL O
was O
evaluated O
with O
the O
Short O
Form O
36-Item O
( O
SF-36 O
) O
questionnaire O
";" O
subscales O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
PR25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
OV28 O
and O
CX24 O
modules O
for O
sexual O
symptoms O
";" O
and O
demographic O
questions O
. O

The O
stretch O
group O
received O
instruction O
on O
low-load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

Sensitivity O
analyses O
were O
also O
performed O
for O
selected O
QOL O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O

Patients O
were O
randomly O
assigned O
to O
sequential O
doxorubicin O
( O
A O
) O
and O
cyclophosphamide O
( O
C O
) O
followed O
by O
docetaxel O
( O
T O
";" O
ACâ†’T O
) O
, O
concurrent O
TAC O
, O
or O
AT O
, O
which O
varied O
in O
duration O
( O
24 O
, O
12 O
, O
12 O
weeks O
, O
respectively O
) O
, O
and O
use O
of O
C. O
Endocrine O
therapy O
was O
prescribed O
for O
women O
with O
hormone O
receptor-positive O
tumors O
. O

Patients O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4-week O
cycles O
. O

Using O
a O
single-blinded O
, O
3-armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

The O
median O
follow-up O
was O
22.6 O
months O
. O

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

To O
assess O
the O
effectiveness O
of O
mindfulness-based O
stress O
reduction O
( O
MBSR O
) O
for O
mood O
, O
breast- O
and O
endocrine-specific O
quality O
of O
life O
, O
and O
well-being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
III O
breast O
cancer O
. O

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

Questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
";" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
QOL O
assessments O
. O

A O
cycle O
of O
BEP O
consisted O
of O
etoposide O
500 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
100 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
165 O
mg/m O
( O
2 O
) O
days O
1 O
through O
3 O
, O
cisplatin O
100 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
20 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
50 O
mg/m O
( O
2 O
) O
days O
1 O
and O
2 O
. O

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

Patients O
with O
a O
peripheral O
solitary O
lung O
tumor O
( O
NSCLC O
or O
pulmonary O
metastasis O
) O
â‰¤ O
5 O
cm O
were O
eligible O
. O

In O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
's O
reported O
measures O
of O
OM O
using O
Oral O
Mucositis O
Weekly O
Questionnaire-Head O
and O
Neck O
( O
OMWQ-HN O
) O
and O
QOL O
using O
Functional O
Assessment O
of O
Cancer O
Treatment-Head O
and O
Neck O
( O
FACT-HN O
) O
Questionnaire O
. O

Complications O
, O
drainage O
time O
, O
hospital O
stay O
, O
and O
quality O
of O
life O
( O
Medical O
Outcomes O
Study O
36-item O
short O
form O
and O
World O
Health O
Organization O
quality-of-life O
questionnaires O
) O
were O
also O
analyzed O
. O

It O
is O
equieffective O
as O
oral O
( O
p.o O
. O
) O

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

We O
evaluated O
the O
role O
of O
glutathione-related O
genotypes O
on O
overall O
survival O
, O
time O
to O
progression O
, O
adverse O
events O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
stage O
IIIB/IV O
non-small O
cell O
lung O
cancer O
patients O
who O
were O
stable O
or O
responding O
from O
initial O
treatment O
with O
platinum-based O
chemotherapy O
and O
subsequently O
randomized O
to O
receive O
daily O
oral O
carboxyaminoimidazole O
or O
a O
placebo O
. O

If O
CA125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

A O
total O
of O
217 O
patients O
were O
randomized O
to O
either O
the O
hypofractionated O
( O
108 O
patients O
) O
or O
the O
conventional O
( O
109 O
patients O
) O
dose O
schedule O
, O
with O
planning O
with O
two-dimensional O
( O
2D O
) O
CT O
scan O
planning O
methodology O
in O
the O
majority O
of O
cases O
. O

Most O
of O
these O
effects O
were O
observed O
at O
both O
the O
12-week O
and O
6-month O
follow-ups O
. O

To O
determine O
the O
immediate O
and O
long-term O
effects O
of O
TRUE O
acupuncture O
versus O
sham O
acupuncture O
on O
hot O
flash O
frequency O
in O
women O
with O
breast O
cancer O
. O

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

From O
January O
, O
2001 O
, O
until O
August O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O

Prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ED O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES-D O
) O
";" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS-A O
) O
";" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT-G O
and O
FACT-F O
, O
respectively O
) O
";" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
's O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

Participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O

At O
baseline O
, O
HRQoL O
measures O
were O
comparable O
between O
the O
two O
treatment O
groups O
. O

On O
the O
basis O
of O
previous O
case O
studies O
, O
this O
study O
was O
developed O
to O
evaluate O
the O
effect O
of O
a O
hypnosis O
intervention O
for O
hot O
flashes O
. O

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

The O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed-methods O
approach O
. O

In O
a O
previously O
conducted O
randomized O
trial O
comparing O
LRP O
with O
ORP O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O

Multicenter O
, O
randomized O
trial O
. O

We O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O

Bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O

The O
primary O
outcome O
measure O
was O
survival O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

We O
report O
results O
of O
a O
randomized O
prospective O
study O
that O
compared O
single O
agents O
of O
low O
toxicity O
given O
both O
as O
the O
first-line O
and O
second-line O
chemotherapy O
with O
combination O
chemotherapy O
in O
advanced O
breast O
cancer O
with O
distant O
metastases O
. O

Interviews O
were O
conducted O
to O
explore O
women O
's O
experience O
of O
writing O
. O

However O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

No O
androgen O
deprivation O
was O
allowed O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

HRQOL O
questionnaires O
, O
using O
a O
validated O
instrument O
, O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-H O
& O
amp O
";" O
N O
) O
, O
version O
2 O
, O
were O
completed O
by O
patients O
before O
the O
start O
of O
treatment O
. O

EORTC-QLQ O
and O
ASES-tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week-treatment O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

Exploratory O
analysis O
was O
based O
on O
time O
to O
analgesia O
and O
appearance O
of O
key O
symptoms O
( O
pain O
, O
cough O
and O
dyspnoea O
) O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

Relative O
hazards O
of O
death O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
by O
the O
Cox O
model O
. O

Standard O
guidelines O
for O
cancer O
pain O
treatment O
routinely O
recommend O
training O
patients O
to O
reduce O
barriers O
to O
pain O
relief O
, O
use O
medications O
appropriately O
, O
and O
communicate O
their O
pain-related O
needs O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

Intention-to-treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow-up O
was O
22Â·2 O
months O
( O
IQR O
20Â·2-24Â·8 O
) O
. O

Stage O
IV O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
UK O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

The O
2-year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng/ml O
, O
50 O
to O
< O
500 O
ng/ml O
, O
and O
â‰¥ O
500 O
ng/ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0.03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0.006 O
) O
in O
IAD O
, O
respectively O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
'The O
Body O
Cancer O
Trial O
' O
. O

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O

Follow-up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

To O
determine O
whether O
the O
impact O
of O
" O
laying O
on O
of O
hands O
" O
on O
the O
well-being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self-declared O
" O
healing O
powers O
" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O

Up O
to O
December O
2006 O
, O
eighty-seven O
patients O
of O
stage O
II O
and O
III O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O

Men O
in O
SPCG-4 O
had O
a O
median O
follow-up O
of O
12Â·2 O
years O
( O
range O
7-17 O
) O
and O
a O
median O
age O
of O
77Â·0 O
years O
( O
range O
61-88 O
) O
. O

Four O
hundred O
eighty-six O
patients O
with O
recurrent O
SCCHN O
were O
randomly O
assigned O
to O
oral O
gefitinib O
250 O
mg/day O
, O
gefitinib O
500 O
mg/day O
, O
or O
methotrexate O
40 O
mg/m O
( O
2 O
) O
intravenously O
weekly O
. O

Future O
exercise O
trials O
targeting O
these O
responsive O
subgroups O
are O
needed O
to O
confirm O
these O
findings O
. O

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

Due O
to O
the O
various O
inter-individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Three O
National O
Health O
Service O
oncology O
clinics O
in O
Scotland O
and O
community O
exercise O
facilities O
. O

Participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
CBT O
( O
1:1 O
) O
. O

All O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O

" O
Washout O
" O
patients O
discontinued O
anti-TNF O
therapy O
2 O
months O
or O
longer O
pre-screening O
";" O
" O
direct-switch O
100" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg/kg O
) O
at O
their O
next O
scheduled O
anti-TNF O
therapy O
dose O
. O

Results O
Baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O

The O
potential O
predictive O
value O
of O
plasma O
VEGF-A O
is O
consistent O
with O
findings O
in O
HER2-negative O
LR/MBC O
, O
warranting O
prospective O
evaluation O
. O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

Spiritual O
well-being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin-alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow-up O
for O
12-36 O
months O
post-study O
. O

A O
randomized O
placebo-controlled O
, O
double-blind O
crossover O
study O
was O
designed O
to O
evidence O
the O
effects O
of O
amitriptyline O
in O
patients O
with O
neuropathic O
cancer O
pain O
. O

The O
primary O
outcome O
was O
QOL O
measured O
by O
the O
functional O
living O
index-cancer O
( O
FLI-C O
) O
and O
supplemented O
by O
the O
Kaposi O
's O
sarcoma O
module O
( O
KSM O
) O
. O

We O
have O
compared O
an O
alternating O
regimen O
of O
bolus O
and O
continuous O
infusion O
5-FU O
, O
selectively O
modulated O
for O
the O
schedule O
of O
administration O
, O
with O
modulated O
bolus O
5-FU O
in O
advanced O
colorectal O
cancer O
patients O
. O

438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

Major O
inclusion O
criteria O
were O
a O
history O
of O
systemic O
cancer O
within O
5 O
years O
and O
enhanced O
magnetic O
resonance O
imaging-confirmed O
solitary O
brain O
metastasis O
suitable O
for O
both O
radiosurgery O
and O
surgery O
. O

Quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

Finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O

Breast O
cancer O
patients O
were O
registered O
within O
6 O
weeks O
after O
surgery O
. O

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

Gastrointestinal O
( O
GI O
) O
and O
genitourinary O
( O
GU O
) O
toxicity O
was O
evaluated O
before O
RT O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue-subjective O
, O
objective O
, O
management O
, O
analytic O
( O
LENT-SOMA O
) O
scales O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
sexual O
function O
questionnaire O
. O

Participants O
( O
n O
= O
49 O
) O
ranged O
in O
age O
from O
50 O
to O
90 O
years O
( O
average O
, O
65.6 O
years O
) O
and O
were O
at O
9.8 O
years O
since O
diagnosis O
( O
range O
, O
1-32 O
years O
) O
, O
and O
the O
majority O
were O
white O
, O
unpartnered O
, O
and O
retired O
. O

Quality O
of O
life O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
( O
EORTC-C30 O
) O
questionnaire O
. O

At O
early O
closure O
of O
the O
trial O
, O
56,583 O
had O
been O
screened O
, O
8980 O
entered O
run-in O
, O
and O
5692 O
( O
26 O
% O
of O
target O
of O
22,300 O
) O
started O
treatment O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

Gefitinib O
and O
Pemetrexed O
are O
drugs O
used O
as O
second-line O
therapy O
for O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
, O
although O
studies O
comparing O
the O
two O
drugs O
are O
limited O
. O

The O
study O
was O
carried O
out O
by O
a O
multi-institutional O
cooperative O
group O
in O
chemotherapy-naive O
stage O
IIIB O
to O
IV O
NSCLC O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

Hemoglobin O
responses O
, O
transfusion O
requirements O
, O
and O
prognostic O
factors O
for O
responses O
were O
measured O
. O

Eighty-nine O
chemotherapy-naÃ¯ve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

One O
hundred O
patients O
were O
randomly O
assigned O
to O
undergo O
UAE O
with O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
or O
tris-acryl O
gelatin O
microspheres O
. O

However O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

Patients O
completed O
the O
SWOG O
Quality O
of O
Life O
Questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
";" O
general O
symptom O
status O
";" O
treatment/disease-specific O
symptoms O
";" O
and O
global O
HRQL O
[ O
GHRQL O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O

Oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

Based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O

A O
total O
of O
157 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
who O
had O
received O
no O
prior O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
alone O
( O
78 O
patients O
) O
or O
paclitaxel O
plus O
supportive O
care O
( O
79 O
patients O
) O
. O

bolus O
( O
arm O
C O
) O
. O

We O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O

To O
compare O
the O
effects O
of O
cannabis O
extract O
( O
CE O
) O
, O
delta-9-tetrahydrocannabinol O
( O
THC O
) O
, O
and O
placebo O
( O
PL O
) O
on O
appetite O
and O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
cancer-related O
anorexia-cachexia O
syndrome O
( O
CACS O
) O
. O

Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

A O
total O
of O
104 O
advanced-stage O
gynecological O
cancer O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
either O
megestrol O
acetate O
( O
MA O
) O
plus O
l-carnitine O
, O
celecoxib O
, O
and O
antioxidants O
( O
arm O
1 O
) O
or O
MA O
alone O
( O
arm O
2 O
) O
. O

Toxicity O
was O
graded O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues-subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
LENT-SOMA O
) O
scales O
. O

Randomised O
controlled O
trial O
. O

Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O

We O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new-generation O
platinum-based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
QoL O
) O
and O
survival O
. O

At O
six O
oncology O
clinics O
, O
physicians O
( O
N=22 O
) O
and O
nurses O
( O
N=23 O
) O
enrolled O
patients O
( O
N=93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O

The O
30 O
items O
in O
15 O
subscales O
of O
the O
QLQ-C30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0-100 O
) O
indicate O
better O
HRQOL O
. O

Instruments O
administered O
at O
baseline O
included O
the O
following O
: O
Quality O
of O
Life O
Index-Cancer O
Version O
( O
QOLI-CV O
) O
, O
State-Trait O
Anxiety O
Inventory O
, O
Beck O
Depression O
Inventory O
, O
and O
Coping O
Strategies O
Questionnaire O
. O

There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O

Another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O

Thirty-nine O
patients O
were O
randomly O
assigned O
to O
CONNECT O
and O
36 O
to O
usual O
care O
. O

Analysis O
was O
by O
intent O
to O
treat O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
";" O
secondary O
end O
points O
were O
progression-free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O

Peri- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
";" O
surgeon O
's O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
";" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
";" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
's O
quality-of-life O
self-assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
's O
time O
of O
death O
. O

Compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O

Two O
primary O
end O
points O
were O
examined O
: O
energy/fatigue O
and O
cancer-specific O
distress O
. O

Alterations O
to O
the O
study O
protocol O
will O
be O
necessary O
to O
decrease O
attrition O
. O

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease-free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality-of-life O
outcomes O
between O
patients O
with O
clinically O
node-negative O
invasive O
breast O
cancer O
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

Interventions O
were O
given O
twice O
weekly O
for O
4 O
consecutive O
weeks O
. O

A O
multicenter O
, O
double-blind O
, O
randomized O
clinical O
trial O
was O
performed O
to O
test O
if O
breast O
IMRT O
would O
reduce O
the O
rate O
of O
acute O
skin O
reaction O
( O
notably O
moist O
desquamation O
) O
, O
decrease O
pain O
, O
and O
improve O
quality O
of O
life O
compared O
with O
standard O
radiotherapy O
using O
wedges O
. O

The O
combination O
of O
cisplatin O
with O
Mitomycin O
and O
Vinblastine O
was O
one O
of O
the O
most O
frequently O
used O
in O
the O
palliative O
setting O
at O
the O
time O
of O
design O
of O
our O
study O
. O

A O
median O
number O
of O
4 O
cycles O
( O
range O
, O
1-12 O
) O
were O
administered O
per O
patient O
. O

QoL O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O

The O
2-year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
PSA O
, O
'fast O
' O
and O
'slow O
' O
PSA O
decline O
to O
< O
4 O
ng/ml O
( O
60 O
days O
cut-off O
) O
, O
PSA O
nadir O
, O
performance O
status O
and O
pain O
. O

Chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

bolus O
( O
arm O
B O
) O
";" O
or O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

formulation O
. O

From O
February O
1998 O
to O
June O
1999 O
, O
259 O
chemonaÃ¯ve O
patients O
entered O
the O
study O
and O
were O
randomised O
to O
receive O
either O
vinorelbine-cisplatin O
( O
NP O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
and O
15 O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
or O
vinorelbine-ifosfamide-cisplatin O
( O
NIP O
";" O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
ifosfamide O
3 O
g/m O
( O
2 O
) O
on O
day O
1 O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
with O
both O
regimens O
being O
repeated O
every O
3 O
weeks O
. O

Regression O
analysis O
was O
used O
to O
analyze O
the O
impact O
on O
outcome O
of O
baseline O
factors O
( O
other O
than O
type O
of O
embolic O
agent O
) O
. O

Three O
hundred O
fifty-six O
patients O
( O
178 O
gemcitabine O
plus O
carboplatin O
";" O
178 O
carboplatin O
) O
were O
randomly O
assigned O
. O

Data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
Mann-Whitney O
U O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O

Eligible O
patients O
had O
to O
have O
a O
history O
of O
primary O
breast O
cancer O
without O
evidence O
of O
detectable O
disease O
and O
14 O
or O
more O
weekly O
hot O
flashes O
for O
at O
least O
1 O
month O
. O

We O
based O
the O
program O
on O
the O
CRF O
guidelines O
of O
the O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
TTM O
) O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

Four O
hundred O
seven O
patients O
were O
eligible O
for O
the O
study O
";" O
395 O
patients O
( O
97 O
% O
) O
participated O
in O
the O
health-related O
quality-of-life O
( O
HRQOL O
) O
study O
. O

In O
this O
study O
, O
the O
authors O
tested O
the O
effectiveness O
of O
a O
brief O
behaviorally O
oriented O
intervention O
in O
reducing O
CRF O
and O
improving O
physical O
function O
and O
associated O
distress O
in O
individuals O
who O
were O
receiving O
chemotherapy O
. O

Comparisons O
were O
based O
on O
an O
equivalence O
framework O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual-standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

The O
-1 O
, O
-2 O
, O
and O
3-year O
QOL O
, O
3-year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O

Physical O
symptoms O
, O
symptom-induced O
stress O
, O
and O
self-assessed O
quality O
of O
life O
were O
evaluated O
with O
a O
study-specific O
questionnaire O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

Eligibility O
criteria O
included O
histologically O
proven O
mRCC O
with O
measurable O
disease O
, O
failure O
of O
one O
prior O
cytokine O
regimen O
, O
and O
good O
performance O
status O
. O

Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open-ended O
questions O
. O

They O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
Î¼g/kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O

This O
double-blind O
, O
placebo-controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
Ortho O
Biotech O
, O
Bridgewater O
, O
NJ O
) O
40,000 O
U O
subcutaneous O
weekly O
for O
16 O
weeks O
. O

Median O
age O
was O
72 O
years O
( O
range O
, O
70-82 O
years O
) O
. O

The O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O

In O
the O
MRC O
OV05/EORTC O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
CA125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O

Patients O
were O
randomly O
assigned O
to O
the O
8-week O
MBSR O
program O
or O
standard O
care O
. O

Analyses O
were O
done O
on O
all O
patients O
with O
available O
data O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
intervention O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Twenty-one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

Secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
";" O
quality O
of O
life O
";" O
safety O
";" O
and O
survival O
. O

According O
to O
the O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
-70 O
and O
80-Gy O
arms O
, O
respectively O
( O
p O
= O
.036 O
) O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
, O
where O
available O
, O
the O
EuroQOL O
EQ-5D O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O

After O
documentation O
of O
N2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin-C. O
Mitomycin-C O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O

Repeated O
measurement O
analysis O
was O
performed O
for O
between-group O
analysis O
. O

Adjuvant O
chemotherapy O
for O
early O
stage O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

The O
present O
study O
aimed O
to O
compare O
FUP O
with O
5-FU O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
Mayo O
Clinic O
trials O
. O

Differences O
between O
groups O
from O
baseline O
to O
day O
28 O
were O
analyzed O
using O
one-sided O
, O
two-sample O
t O
tests O
or O
Wilcoxon O
two-sample O
tests O
. O

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

This O
paper O
reports O
the O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
the O
patients O
in O
this O
trial O
. O

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

165 O
of O
441 O
patients O
were O
assigned O
to O
dignity O
therapy O
, O
140 O
standard O
palliative O
care O
, O
and O
136 O
client-centred O
care O
. O

BMD O
of O
48 O
patients O
were O
analyzed O
";" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C. O
The O
serum O
bone O
turnover O
proteins O
bone-specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

They O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O

In O
addition O
, O
predefined O
AEs O
were O
analyzed O
. O

This O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
Individual O
Internet O
Intervention O
( O
III O
) O
embedded O
and O
integrated O
into O
an O
Internet O
Support O
Group O
( O
ISG O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O

All O
statistical O
tests O
were O
two-sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O

Extracellular O
adenosine O
5'-triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

Patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
CA125 O
measurement O
. O

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

Finally O
, O
change O
in O
self-efficacy O
for O
PA O
predicted O
PA O
at O
2-year O
follow-up O
. O

To O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin-based O
chemotherapy O
. O

In O
the O
current O
investigation O
, O
we O
screened O
newly O
diagnosed O
early O
stage O
breast O
cancer O
patients O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
and O
investigated O
whether O
the O
oral O
antidepressant O
fluoxetine O
affected O
depressive O
symptoms O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
quality O
of O
life O
. O

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

Patients O
were O
randomised O
to O
receive O
either O
5-FU/folinic O
acid O
( O
FA O
, O
FUFA O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5-fluorouracil/folinic O
acid O
and O
irinotecan O
( O
FOLFIRI O
) O
stratified O
by O
TS O
( O
low O
versus O
high O
) O
. O

On O
March O
15 O
, O
2005 O
, O
the O
US O
Food O
and O
Drug O
Administration O
approved O
temozolomide O
( O
Temodar O
capsules O
, O
Schering-Plough O
Research O
Institute O
) O
for O
the O
treatment O
of O
adult O
patients O
with O
newly O
diagnosed O
glioblastoma O
multiforme O
concomitantly O
with O
radiotherapy O
and O
then O
as O
maintenance O
treatment O
. O

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single-agent O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

From O
December O
1992 O
to O
May O
1999 O
, O
230 O
patients O
were O
randomised O
. O

Lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
United O
States O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

After O
the O
first O
and O
second O
IAD O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O

Equivalence O
was O
defined O
as O
less O
than O
20 O
% O
difference O
in O
the O
number O
achieving O
an O
improvement O
in O
the O
TSS O
. O

The O
results O
were O
statistically O
significant O
. O

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

They O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
83 O
cases O
) O
and O
the O
control O
group O
( O
84 O
cases O
) O
according O
to O
the O
random O
digit O
table O
. O

Breast O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem-solving O
treatment O
. O

The O
same O
assigned O
treatment O
was O
intended O
to O
continue O
for O
2 O
years O
to O
study O
the O
changes O
in O
the O
bone O
metabolism O
. O

Study O
Type O
-- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O

They O
provide O
key O
information O
for O
discussing O
the O
trial O
with O
patients O
and O
strengthen O
the O
argument O
for O
continuing O
QUARTZ O
to O
definitively O
answer O
this O
important O
clinical O
question O
. O

Three O
hundred O
three O
patients O
were O
randomized O
to O
DOX O
50 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
on O
day O
1 O
and O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
on O
day O
1 O
( O
arm O
2 O
) O
. O

Seventy-two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n=27 O
) O
or O
gastrointestinal O
tumours O
( O
n=42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O

At O
9 O
months O
, O
patients O
underwent O
an O
rhTSH O
stimulation O
test O
, O
diagnostic O
( O
131 O
) O
I O
whole O
body O
scan O
( O
dxWBS O
) O
and O
neck O
ultrasonography O
. O

A O
brief O
training O
in O
the O
SMART O
program O
can O
enhance O
resilience O
and O
quality O
of O
life O
and O
decrease O
stress O
and O
anxiety O
. O

We O
conducted O
a O
two-arm O
, O
wait-list O
control O
, O
randomized O
trial O
of O
a O
complex O
rehabilitation O
intervention O
delivered O
by O
a O
hospice-based O
multidisciplinary O
team O
vs. O
usual O
care O
for O
active O
, O
progressive O
, O
recurrent O
hematological O
and O
breast O
malignancies O
, O
with O
a O
follow-up O
at O
three O
months O
. O

Patients O
were O
randomized O
1:1 O
to O
an O
extended O
dosing O
schedule O
( O
EDS O
: O
darbepoetin O
alfa O
300 O
Î¼g O
Q2W O
if O
chemotherapy O
was O
QW O
, O
Q2W O
, O
or O
Q4W O
or O
darbepoetin O
alfa O
500 O
Î¼g O
Q3W O
if O
chemotherapy O
was O
Q3W O
) O
or O
weekly O
( O
150 O
Î¼g O
QW O
regardless O
of O
chemotherapy O
schedule O
) O
. O

Few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer-term O
follow-up O
. O

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male/female O
= O
45/29 O
, O
oral O
arm O
: O
male/female O
= O
59/33 O
) O
. O

We O
performed O
a O
4-arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low-dose O
intravenous O
bolus O
of O
LV O
( O
20 O
mg/m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5FU O
( O
400 O
mg/m2 O
) O
, O
followed O
by O
a O
22-hour O
continuous O
infusion O
of O
5FU O
( O
600 O
mg/m2 O
) O
on O
day O
1 O
and O
day O
2/2 O
weeks O
( O
ldLV5FU2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high-dose O
5FU O
( O
2.6 O
g/m2/week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
HD-FU O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
Tomudex O
arm O
";" O
3 O
mg/m2/3 O
weeks O
) O
to O
standard O
LV5FU2 O
. O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

An O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O

By O
March O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

Only O
patients O
over O
5 O
years O
of O
age O
with O
parameningeal O
disease O
and O
patients O
over O
12 O
years O
with O
tumours O
at O
any O
site O
were O
given O
systematic O
irradiation O
. O

Our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
. O

PP O
group O
received O
pemetrexed O
500 O
mg/mÂ² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg/mÂ² O
iv O
infusion O
d1 O
, O
whereas O
GP O
group O
received O
gemcitabine O
1,000 O
mg/mÂ² O
iv O
infusion O
d1,8 O
and O
cisplatin O
75 O
mg/mÂ² O
iv O
infusion O
d1 O
. O

The O
co-primary O
endpoints O
of O
SATURN O
were O
progression-free O
survival O
( O
PFS O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
EGFR O
immunohistochemistry O
( O
IHC O
) O
status O
. O

Patients O
were O
evaluated O
on O
five O
occasions O
over O
the O
experimental O
period O
. O

Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1,600 O
mg/d O
of O
megestrol O
acetate O
. O

All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

If O
the O
compounds O
work O
, O
they O
would O
offer O
a O
low-cost O
, O
readily O
available O
adjunctive O
treatment O
for O
the O
management O
of O
CINV O
. O

We O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

Nine O
hundred O
and O
sixty-four O
patients O
were O
recruited O
from O
71 O
centers O
. O

The O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

Many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O

A O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O

For O
patients O
who O
received O
thoracic O
radiotherapy O
, O
the O
median O
time O
to O
start O
was O
15 O
days O
in O
the O
immediate O
treatment O
group O
and O
125 O
days O
in O
the O
delayed O
treatment O
group O
. O

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

This O
study O
investigated O
differences O
between O
the O
symptoms O
associated O
with O
either O
adjuvant O
tamoxifen O
or O
exemestane O
. O

The O
primary O
endpoint O
was O
survival O
. O

For O
this O
three-arm O
randomised O
controlled O
trial O
we O
recruited O
patients O
( O
aged O
â‰¥18 O
years O
) O
from O
clinics O
in O
London O
, O
UK O
, O
with O
new-onset O
gastrointestinal O
symptoms O
persisting O
6 O
months O
after O
pelvic O
radiotherapy O
. O

Patients O
of O
resectable O
esophageal O
cancer O
of O
comparable O
stage O
were O
allocated O
to O
undergo O
the O
transthoracic O
or O
transhiatal O
procedure O
in O
turn O
. O

The O
proposed O
sample O
size O
was O
300 O
patients O
. O

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

Two O
hundred O
and O
ninety-seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

The O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O

This O
phase O
III O
, O
double-blind O
, O
randomized O
, O
multicenter O
study O
evaluated O
the O
efficacy O
, O
pharmacodynamics O
, O
and O
safety O
of O
the O
oral O
aromatase O
inactivator O
exemestane O
( O
EXE O
) O
versus O
megestrol O
acetate O
( O
MA O
) O
in O
postmenopausal O
women O
with O
progressive O
advanced O
breast O
cancer O
who O
experienced O
failure O
of O
tamoxifen O
. O

Perceived O
preparedness O
for O
re-entry O
was O
analyzed O
as O
a O
moderator O
of O
effects O
. O

Patients O
with O
incompletely O
resected O
tumour O
received O
six O
to O
10 O
courses O
of O
IVA O
according O
to O
stage O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

Ninety-four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O

Two O
years O
after O
completing O
radiotherapy O
, O
a O
questionnaire O
that O
assessed O
bladder O
, O
rectal O
, O
and O
sexual O
function O
was O
sent O
to O
301 O
patients O
in O
the O
study O
. O

All O
patients O
received O
four O
cycles O
of O
cisplatin O
and O
etoposide O
every O
3 O
weeks O
( O
step O
1 O
";" O
PE O
) O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

The O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O

Thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O

After O
stratification O
according O
to O
performance O
status O
( O
PS O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
Phase O
II O
trials O
with O
5-FU/6S-LV O
and O
EEP-L O
, O
respectively O
. O

This O
analysis O
evaluates O
the O
effectiveness O
of O
the O
Improving O
Mood-Promoting O
Access O
to O
Collaborative O
Treatment O
( O
IMPACT O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
ICD-9 O
cancer O
diagnosis O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

The O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O

The O
inflammation-related O
cytokines O
including O
interleukin-6 O
, O
interleukin-10 O
, O
and O
tumor O
necrosis O
factor-Î± O
were O
also O
determined O
. O

Decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0.39 O
( O
P O
â‰¥ O
.348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2.54 O
( O
P O
â‰¤ O
.0056 O
) O
. O

There O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy-induced O
peripheral O
neuropathy O
. O

This O
difference O
( O
7.4 O
) O
was O
clinically O
relevant O
. O

Improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
";" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O

The O
primary O
end-point O
was O
acute O
grade O
â‰¥ O
2 O
toxicity O
. O

An O
intent-to-treat O
analysis O
was O
used O
to O
determine O
the O
mean O
duration O
of O
HQL O
improvement O
and O
differences O
in O
improvement O
duration O
between O
groups O
of O
patients O
. O

Quality-of-life O
data O
were O
prospectively O
collected O
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

Using O
hierarchical O
cluster O
analysis O
, O
3 O
mutually O
exclusive O
symptom O
groupings O
were O
identified O
in O
the O
cohort O
. O

Low O
testosterone O
after O
ADT O
and O
incomplete O
testosterone O
recovery O
may O
explain O
similar O
QOL O
. O

Patients O
with O
untreated O
stage O
IC-IV O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
AUC O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
Arm O
A O
) O
or O
with O
dose O
escalations O
in O
cycles O
2-6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
Arm O
B O
) O
. O

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well-being O
. O

Couples O
were O
randomized O
to O
attend O
four O
sessions O
of O
counseling O
together O
or O
to O
have O
the O
man O
attend O
alone O
. O

In O
particular O
, O
this O
study O
focused O
on O
the O
possible O
interaction O
between O
gender-specific O
baseline O
health-related O
QOL O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
in O
a O
prospective O
randomized O
lung O
cancer O
trial O
. O

Older O
breast O
cancer O
survivors O
( O
BCSs O
) O
are O
at O
risk O
for O
late O
and O
long-term O
treatment O
effects O
on O
quality O
of O
life O
( O
QOL O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O

Comparison O
of O
Faslodex O
in O
Recurrent O
or O
Metastatic O
Breast O
Cancer O
( O
CONFIRM O
) O
is O
a O
double-blind O
, O
parallel-group O
, O
multicenter O
, O
phase O
III O
study O
. O

This O
, O
performance O
status O
, O
Hospital O
Anxiety O
and O
Depression O
( O
HAD O
) O
score O
and O
Spitzer O
's O
quality-of-life O
index O
were O
noted O
before O
treatment O
, O
at O
1 O
month O
after O
treatment O
and O
every O
2 O
months O
thereafter O
. O

Clinical O
examination O
and O
CA125 O
measurement O
were O
done O
every O
3 O
months O
. O

Proportions O
of O
patients O
with O
skeletal-related O
events O
, O
time O
to O
the O
first O
skeletal-related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O

Treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low-dose O
and O
high-dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Short-term O
, O
in-hospital O
medication O
use O
and O
pain O
levels O
were O
recorded O
. O

Both O
regimens O
were O
given O
every O
3 O
weeks O
until O
a O
cumulative O
DOX O
dose O
of O
450 O
mg/m O
( O
2 O
) O
. O

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

Nutritional O
intake O
( O
diet O
history O
) O
, O
status O
( O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QoL O
( O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
, O
and O
3 O
months O
after O
radiotherapy O
. O

The O
Steering O
Committee O
closed O
the O
trial O
. O

All O
living O
Swedish O
and O
Finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
SPCG-4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O

In O
the O
ALND O
group O
, O
positive O
non-SLNs O
were O
found O
in O
18 O
patients O
with O
negative O
SLN O
, O
giving O
a O
FALSE O
negative O
rate O
of O
16.7 O
% O
( O
18 O
of O
108 O
) O
. O

Of O
5,187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3,612 O
( O
69.9 O
% O
) O
participated O
in O
the O
QOL O
substudy O
: O
1,799 O
were O
allocated O
to O
placebo O
and O
1,813 O
were O
allocated O
to O
letrozole O
. O

All O
had O
chemotherapy O
. O

Because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
Bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O

The O
primary O
outcome O
, O
Fatigue O
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anaemia O
Questionnaire O
( O
FACT-An- O
) O
( O
FACT-G O
score O
& O
FACT-An O
Anemia O
subscale O
) O
. O

The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

Eligible O
patients O
had O
previously O
untreated O
stage O
IIIB O
or O
IV O
NSCLC O
suitable O
for O
cisplatin-based O
chemotherapy O
. O

230 O
patients O
with O
previously O
untreated O
, O
non-small O
cell O
lung O
cancer O
that O
is O
locally O
too O
advanced O
for O
resection O
or O
radical O
radiotherapy O
with O
curative O
intent O
, O
with O
minimal O
thoracic O
symptoms O
, O
and O
with O
no O
indication O
for O
immediate O
thoracic O
radiotherapy O
. O

Patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
MM O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
MP O
) O
or O
MPT O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
MPT O
arm O
. O

The O
management O
of O
cancer-related O
anorexia/cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

Two O
hundred O
fourteen O
patients O
from O
nineteen O
Italian O
centers O
were O
randomized O
to O
the O
control O
arm O
consisting O
of O
biweekly O
cycles O
of O
MTX O
, O
200 O
mg/m2 O
on O
day O
1 O
, O
followed O
by O
bolus O
5-FU O
600 O
mg/m2 O
on O
day O
2 O
and O
6-S-leucovorin O
rescue O
, O
or O
to O
the O
experimental O
arm O
consisting O
of O
two O
biweekly O
cycles O
of O
the O
same O
regimen O
as O
in O
the O
control O
arm O
alternated O
to O
three O
weeks O
of O
continuous O
infusion O
5-FU O
( O
200 O
mg/m2 O
day O
) O
+ O
weekly O
bolus O
6-S-leucovorin O
, O
20 O
mg/m2 O
. O

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

Patients O
were O
randomized O
in O
a O
2-by-2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon-alfa O
9 O
million O
IU O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin-2 O
9 O
million O
IU O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O

There O
were O
no O
statistically O
significant O
differences O
for O
ED O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

The O
functional O
assessment O
of O
chronic O
illness O
therapy-fatigue O
( O
FACIT-F O
) O
was O
administered O
from O
the O
early O
postoperative O
period O
to O
9 O
months O
. O

Multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O

The O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O

Median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O

Sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium-labeled O
antimony O
sulfide O
colloid O
. O

The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short-term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

After O
initial O
response O
to O
anthracycline- O
or O
taxane-based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high-dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
ST O
) O
. O

The O
CCSP O
components O
included O
educational O
information O
, O
cognitive O
restructuring O
, O
coping O
skills O
enhancement O
, O
and O
relaxation O
with O
guided O
imagery O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

The O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
";" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression-free O
survival O
( O
PFS O
) O
in O
favor O
of O
the O
dose-intensified O
regimen O
. O

Fifty O
four O
patients O
were O
enrolled O
. O

Time O
to O
definitive O
deterioration O
of O
QOL O
parameters O
was O
analyzed O
. O

The O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O

To O
analyze O
the O
predictive O
value O
of O
PSA O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
ADT O
) O
for O
metastatic O
prostate O
cancer O
. O

Mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O

No O
patient O
received O
hormonal O
therapy O
. O

Although O
single- O
and O
multiple-fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
and O
need O
of O
palliative O
radiotherapy O
. O

Most O
patients O
received O
radiotherapy O
in O
the O
adjuvant O
setting O
( O
52 O
of O
the O
83 O
) O
and O
had O
either O
an O
oral O
cavity O
( O
42 O
of O
the O
83 O
) O
or O
an O
oropharyngeal O
( O
16 O
of O
the O
83 O
) O
cancer O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

Survival O
duration O
, O
disease-free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy-fatigue O
( O
FACT-F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

Follow-up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6-month O
follow-up O
. O

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast-conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QOL O
) O
of O
high-risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
PEGASE O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high-dose O
chemotherapy O
( O
HDC O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

The O
median O
follow-up O
was O
61 O
months O
. O

Assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
T0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
T1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
T2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
T3 O
) O
. O

102 O
men O
completed O
the O
study O
. O

A O
follow-up O
phone O
call O
after O
72 O
h O
addressed O
individualized O
treatment O
content O
and O
pain O
communication O
. O

The O
study O
accrued O
344 O
patients O
";" O
330 O
were O
assessable O
for O
efficacy O
and O
305 O
were O
assessable O
for O
QOL O
. O

48 O
patients O
were O
randomised O
( O
supportive O
care O
26 O
, O
chemotherapy O
22 O
) O
, O
being O
eligible O
for O
comparative O
analyses O
. O

The O
primary O
outcome O
assessed O
was O
progression-free O
survival O
( O
PFS O
) O
";" O
secondary O
outcomes O
included O
treatment-free O
survival O
( O
TFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
treatment-related O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
according O
to O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
's O
Quality O
of O
Life O
Questionnaire O
C-30 O
version O
1.0 O
instrument O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

Evaluated O
outcomes O
included O
pain O
intensity O
, O
need O
for O
change O
in O
therapy O
, O
quality O
of O
life O
, O
Karnofsky O
Performance O
Status O
, O
general O
condition O
of O
the O
patient O
, O
and O
adverse O
events O
. O

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

These O
data O
may O
have O
wider O
implications O
particularly O
in O
respect O
of O
the O
management O
of O
chemotherapy-induced O
neutropenia O
. O

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

Twenty-five O
of O
51 O
recruited O
patients O
completed O
therapy O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
( O
median O
age O
, O
75 O
years O
";" O
range O
, O
70-82 O
) O
. O

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

Seven O
hundred O
fifty-two O
patients O
( O
374 O
QW O
patients O
";" O
378 O
EDS O
patients O
) O
received O
â‰¥1 O
dose O
of O
darbepoetin O
alfa O
and O
were O
included O
in O
the O
analysis O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Patients O
were O
randomly O
assigned O
in O
a O
2:1 O
ratio O
to O
undergo O
either O
uterine-artery O
embolization O
or O
surgery O
, O
with O
106 O
patients O
undergoing O
embolization O
and O
51 O
undergoing O
surgery O
( O
43 O
hysterectomies O
and O
8 O
myomectomies O
) O
. O

There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
.05 O
) O
. O

However O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O

The O
median O
follow-up O
time O
was O
27.2 O
months O
for O
all O
patients O
and O
49 O
months O
for O
surviving O
patients O
. O

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

QOL O
was O
assessed O
by O
using O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
ESAS O
) O
and O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Anemia O
questionnaires O
. O

This O
report O
describes O
the O
quality O
of O
life O
( O
QOL O
) O
findings O
of O
a O
randomized O
placebo O
controlled O
study O
of O
erlotinib O
, O
an O
epidermal O
growth O
factor O
receptor O
inhibitor O
, O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

To O
compare O
survival O
in O
patients O
with O
recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
treated O
with O
gefitinib O
250 O
or O
500 O
mg/day O
or O
standard O
methotrexate O
. O

The O
interdisciplinary O
teams O
( O
IDTs O
) O
caring O
for O
these O
dyads O
were O
randomly O
assigned O
to O
either O
experimental O
( O
n O
= O
338 O
) O
or O
control O
( O
n O
= O
371 O
) O
conditions O
. O

In O
addition O
, O
the O
impact O
of O
the O
treatment O
arms O
on O
the O
main O
metabolic O
and O
inflammatory O
parameters O
, O
including O
C-reactive O
protein O
( O
CRP O
) O
, O
interleukin O
( O
IL O
) O
-6 O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
-Î± O
, O
leptin O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
and O
glutathione O
peroxidase O
, O
was O
evaluated O
. O

The O
Intergroup O
conducted O
this O
breast O
cancer O
adjuvant O
trial O
to O
compare O
an O
investigational O
16-week O
regimen O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
5-FU O
";" O
CAF O
) O
. O

All O
studies O
on O
SLN O
biopsy O
in O
breast O
cancer O
report O
a O
variable O
FALSE O
negative O
rate O
, O
whose O
prognostic O
consequences O
are O
still O
unclear O
. O

Response O
was O
evaluated O
4 O
weeks O
after O
the O
last O
cycle O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

Survival O
differences O
were O
analyzed O
by O
Wilcoxon O
and O
log-rank O
tests O
. O

The O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs. O
3 O
intervention O
approaches O
, O
namely O
oral O
Etoposide O
, O
a O
3-drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
QOL O
) O
as O
the O
primary O
measure O
of O
success O
. O

Surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

The O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
";" O
progression-free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

Stimulated O
whole O
( O
SWS O
) O
and O
parotid O
( O
SPS O
) O
saliva O
flow O
were O
measured O
and O
Medical O
Outcomes O
Short O
Form O
36 O
( O
SF-36 O
) O
, O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
core O
quetionnaire O
, O
and O
EORTC O
head-and-neck O
module O
( O
QLQ-H O
& O
amp O
";" O
N35 O
) O
were O
completed O
at O
baseline O
and O
2 O
, O
6 O
, O
and O
12 O
months O
after O
radiotherapy O
. O

Time-to-event O
data O
were O
analyzed O
using O
the O
Kaplan-Meier O
method O
, O
and O
a O
stratified O
log-rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer-related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

Additional O
analyses O
included O
the O
Short O
Form-6 O
Dimensions O
( O
SF-6D O
) O
quality-of-life O
scale O
and O
a O
general O
impression O
( O
GI O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

A O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O

Patient O
HRQoL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
TSP O
) O
, O
time O
to O
deterioration O
( O
TTD O
) O
in O
Trial O
Outcome O
Index O
( O
TOI O
) O
and O
TTD O
. O

One O
hundred O
eighty-five O
patients O
had O
function O
data O
. O

Subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

Ninety-nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

Thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O

Paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg/m O
( O
2 O
) O
and O
250 O
mg/m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O

The O
treatment O
duration O
was O
4 O
months O
. O

The O
feasibility O
of O
measuring O
Bcl-2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl-2 O
targeted O
therapy O
. O

Symptom O
and O
quality O
of O
life O
( O
QOL O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O

Twelve O
patients O
received O
induction O
chemotherapy O
but O
were O
not O
randomized O
to O
RT O
or O
surgery O
thereafter O
. O

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

The O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O

HRQOL O
was O
assessed O
using O
EORTC O
QLQ-C30 O
and O
QLQ-BR23 O
questionnaires O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
treatment O
discontinuation O
because O
of O
disease O
progression O
, O
toxicity O
, O
or O
consent O
withdrawal O
. O

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

The O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O

The O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
QL O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
between O
the O
groups O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health-related O
quality O
of O
life O
( O
HQL O
) O
. O

Three-hundred O
forty-eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
QOL O
. O

SGN-15 O
is O
an O
antibody-drug O
conjugate O
( O
ADC O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
Lewis O
Y O
( O
Le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O

Minimum O
followup O
was O
12 O
months O
. O

Four O
hundred O
seventy-two O
advanced O
cancer O
patients O
with O
between O
2 O
% O
and O
10 O
% O
weight O
loss O
were O
randomized O
to O
a O
mixture O
of O
beta-hydroxyl O
beta-methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
or O
an O
isonitrogenous O
, O
isocaloric O
control O
mixture O
taken O
twice O
a O
day O
for O
8 O
weeks O
. O

One O
hundred O
ninety-five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

Self-report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale-Global O
Fatigue O
";" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Core O
30 O
Questionnaire O
, O
and O
CRF-associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

To O
test O
these O
observations O
with O
a O
large O
, O
randomized O
clinical O
trial O
, O
an O
intervention O
that O
significantly O
impacts O
physical O
activity O
in O
these O
patients O
is O
needed O
. O

Survival O
curves O
were O
calculated O
using O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

To O
determine O
the O
long-term O
outcome O
and O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
patients O
with O
endometrial O
carcinoma O
( O
EC O
) O
treated O
with O
or O
without O
pelvic O
radiotherapy O
in O
the O
Post O
Operative O
Radiation O
Therapy O
in O
Endometrial O
Carcinoma O
1 O
( O
PORTEC-1 O
) O
trial O
. O

Breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
";" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

The O
primary O
endpoint O
was O
volume O
of O
the O
ipsilateral O
limb O
measured O
opto-electronically O
using O
a O
perometer O
and O
expressed O
as O
a O
percentage O
of O
the O
contralateral O
limb O
volume O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

To O
prospectively O
evaluate O
and O
compare O
health-related O
quality-of-life O
( O
QOL O
) O
outcomes O
in O
patients O
with O
head-neck O
squamous O
cell O
carcinoma O
randomized O
to O
either O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
or O
three-dimensional O
conformal O
radiotherapy O
( O
3D-CRT O
) O
and O
assess O
serial O
longitudinal O
change O
in O
QOL O
over O
time O
. O

The O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
LE O
) O
. O

The O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

postprostatectomy O
SUI O
with O
daily O
incontinent O
episodes O
frequency O
( O
IEF O
) O
of O
four O
or O
greater O
. O

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

Consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
IV O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

Of O
168 O
survey O
responders O
, O
60.7 O
% O
had O
BT O
( O
9.5 O
% O
randomly O
assigned O
) O
and O
39.3 O
% O
had O
RP O
( O
9.5 O
% O
randomly O
assigned O
) O
. O

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

Hot O
flash O
frequency O
was O
evaluated O
at O
baseline O
, O
at O
6 O
weeks O
, O
and O
at O
6 O
months O
after O
initiation O
of O
treatment O
. O

Of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O

To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O

At O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
Module O
( O
EORTC-QLQ-30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

All O
volunteers O
were O
given O
dl-alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

The O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0.1 O
% O
" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O

The O
primary O
outcome O
measures O
were O
the O
activity O
score O
and O
profile O
score O
of O
the O
Measure O
Yourself O
Medical O
Outcome O
Profile O
( O
MYMOP O
) O
. O

Using O
a O
two-group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual-care O
group O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

Anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
QoL O
) O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
and O
Hospital O
Anxiety O
and O
Depression O
Scale O
with O
feedback O
to O
oncologists O
) O
, O
attention-control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Exercise O
, O
fatigue O
, O
and O
QOL O
. O

Evidence O
that O
community O
cancer O
services O
improve O
care O
quality O
and/or O
generate O
cost O
savings O
is O
currently O
limited O
. O

This O
study O
was O
initiated O
to O
compare O
up-front O
tandem O
HDCT O
and O
standard O
combination O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
. O

Categorical O
data O
were O
compared O
using O
a O
stratified O
Cochran-Mantel-Haenszel O
test O
. O

Group O
CBT O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho-education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
HFNS O
. O

Data O
were O
analyzed O
using O
repeated O
measure O
ANOVA O
through O
general O
linear O
model O
. O

However O
, O
evidence O
for O
this O
recommendation O
from O
randomized O
clinical O
trials O
is O
lacking O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

Median O
age O
was O
61.4 O
years O
for O
BT O
and O
59.4 O
for O
RP O
( O
P O
= O
.05 O
) O
. O

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

No O
significant O
differences O
were O
noted O
at O
baseline O
between O
the O
two O
treatment O
groups O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

A O
significant O
barrier O
to O
positive O
pain O
management O
is O
patients O
' O
misconceptions O
regarding O
analgesics O
and O
inadequate O
use O
of O
nonpharmacological O
strategies O
as O
pain O
relief O
. O

Patients O
with O
bone O
metastasis-related O
pain O
at O
Numeric O
Rating O
Scale O
â‰¥4 O
were O
enrolled O
to O
this O
randomized O
placebo-controlled O
trial O
. O

The O
change O
in O
the O
Glasgow O
Prognostic O
Score O
( O
GPS O
) O
during O
treatment O
was O
also O
assessed O
. O

No O
significant O
difference O
in O
outcome O
was O
found O
between O
the O
patients O
with O
and O
without O
baseline O
FACT-H O
& O
amp O
";" O
N O
data O
( O
p O
= O
0.58 O
) O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O

The O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
IDTs O
. O

There O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
LLLT O
on O
patient O
's O
subjective O
experience O
of O
OM O
and O
QOL O
. O

We O
evaluated O
safety O
and O
efficacy O
of O
IFNalpha O
and O
isotretinoin O
compared O
with O
IFNalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
IIA O
and O
IIB O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

Body O
image O
and O
QOL O
also O
were O
assessed O
preoperatively O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

We O
evaluated O
QOL O
data O
from O
874 O
pre- O
and O
perimenopausal O
women O
with O
lymph O
node-negative O
breast O
cancer O
who O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
classical O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
( O
CMF O
) O
chemotherapy O
, O
ovarian O
suppression O
with O
goserelin O
for O
24 O
months O
, O
or O
six O
courses O
of O
classical O
CMF O
followed O
by O
18 O
months O
of O
goserelin O
. O

Data O
from O
161 O
patients O
have O
been O
analyzed O
. O

Treatment O
duration O
was O
8 O
weeks O
. O

The O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
VATS O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
";" O
p O
= O
0.027 O
) O
. O

A O
total O
of O
93 O
patients O
were O
enrolled O
onto O
the O
trial O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

A O
multi-method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

Included O
patients O
( O
n O
= O
80 O
) O
received O
supportive O
enteral O
or O
parenteral O
nutrition O
postoperatively O
at O
home O
corresponding O
to O
1000 O
kcal/d O
until O
the O
patients O
did O
not O
wish O
to O
continue O
with O
artificial O
nutrition O
for O
any O
reason O
. O

We O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O

Response O
rate O
( O
RR O
) O
was O
evaluated O
after O
every O
four O
courses O
. O

Approximately O
38 O
% O
of O
patients O
who O
received O
zoledronic O
acid O
at O
4 O
mg O
, O
28 O
% O
who O
received O
zoledronic O
acid O
at O
8/4 O
mg O
, O
and O
31 O
% O
who O
received O
placebo O
completed O
the O
study O
. O

Controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
CRT O
if O
indicated O
. O

Intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

No O
patient O
received O
antiretroviral O
therapy O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

We O
report O
the O
QOL O
results O
of O
JBR.10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

After O
randomization O
, O
L-T4 O
was O
discontinued O
in O
hypothyroid O
( O
hypo O
) O
group O
and O
continued O
in O
rhTSH O
group O
. O

A O
well-tolerated O
and O
effective O
mind-body O
treatment O
for O
hot O
flashes O
would O
be O
of O
great O
value O
. O

Secondary O
end-points O
included O
quality O
of O
life O
( O
QOL O
) O
assessed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-LC13 O
questionnaires O
. O

Gail O
's O
algorithm O
, O
based O
on O
a O
multivariate O
logistic O
regression O
model O
using O
combinations O
of O
risk O
factors O
, O
was O
used O
to O
estimate O
the O
probability O
( O
risk O
) O
of O
occurrence O
of O
breast O
cancer O
over O
time O
. O

The O
investigators O
implemented O
a O
randomized O
controlled O
trial O
and O
enrolled O
a O
sample O
composed O
of O
patients O
with O
ONJ O
, O
where O
the O
predictor O
variable O
was O
HBO O
administered O
at O
2 O
atm O
twice O
a O
day O
for O
40 O
treatments O
as O
an O
adjunct O
to O
conventional O
therapy O
of O
surgery O
and O
antibiotics O
versus O
conventional O
therapy O
alone O
. O

Histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

82 O
postmenopausal O
patients O
with O
histologically O
confirmed O
invasive O
hormone-sensitive O
breast O
cancers O
were O
included O
for O
the O
neoadjuvant O
therapy O
( O
NHT O
) O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

A O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
Emotional O
Distress O
, O
and/or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O

Article O
from O
the O
Special O
issue O
on O
Targeted O
Inhibitors O
. O

Analysis O
was O
performed O
after O
a O
29.2-month O
median O
follow-up O
( O
range O
, O
0 O
months O
to O
54.6 O
months O
) O
. O

Statistical O
tests O
were O
two-sided O
. O

The O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O

Temozolomide O
( O
TMZ O
) O
is O
an O
alkylating O
agent O
licensed O
for O
treatment O
of O
high-grade O
glioma O
( O
HGG O
) O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0-1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

Patients O
were O
mainly O
â‰¥ O
40 O
years O
of O
age O
, O
married O
, O
Caucasian O
, O
and O
diagnosed O
with O
advanced O
breast O
cancer O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

Analysis O
was O
conducted O
after O
intervention O
for O
immediate O
effects O
on O
outcome O
variables O
and O
6 O
weeks O
later O
for O
maintenance O
of O
effects O
. O

Differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O

The O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
KPS O
scores O
, O
QLQ-C30 O
questionnaire O
, O
LC13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
TCM O
efficacy O
, O
the O
6-min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
pilot O
trial O
assessed O
the O
feasibility O
of O
quantifying O
the O
effects O
of O
epoetin O
alfa O
on O
cognitive O
function O
and O
mood O
, O
and O
evaluated O
its O
effects O
on O
fatigue O
and O
QOL O
in O
patients O
with O
breast O
cancer O
treated O
with O
anthracycline-based O
adjuvant O
or O
neoadjuvant O
chemotherapy O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

The O
recommended O
regimens O
were O
17 O
Gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
Gy O
as O
a O
single O
dose O
. O

After O
the O
administration O
of O
the O
131-I O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

Sedentary O
( O
engaging O
in O
< O
60 O
min O
of O
recreational O
activity/week O
) O
breast O
and O
colorectal O
cancer O
survivors O
were O
randomized O
to O
a O
telephone-based O
exercise O
intervention O
or O
usual O
care O
control O
group O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

The O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O

Analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
tests O
, O
Student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

After O
treatment O
arm O
was O
controlled O
for O
, O
MSTS O
change O
scores O
were O
predicted O
by O
a O
lower-extremity O
tumor O
, O
a O
large O
resection O
specimen O
, O
and O
motor O
nerve O
sacrifice O
";" O
TESS O
change O
scores O
were O
predicted O
by O
lower-extremity O
tumor O
and O
prior O
incomplete O
excision O
. O

5 O
significance O
level O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

Supervised O
exercise O
, O
comprising O
high-intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O

Follow-up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

Isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

A O
phase O
III O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i.e. O
, O
lean O
body O
mass O
( O
LBM O
) O
, O
resting O
energy O
expenditure O
( O
REE O
) O
, O
fatigue O
, O
and O
QoL O
. O

Function O
and O
quality O
of O
life O
were O
measured O
by O
the O
Musculoskeletal O
Tumor O
Society O
Rating O
Scale O
( O
MSTS O
) O
, O
the O
Toronto O
Extremity O
Salvage O
Score O
( O
TESS O
) O
, O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
at O
randomization O
, O
6 O
weeks O
, O
and O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
months O
after O
surgery O
. O

One O
thousand O
eighty-eight O
women O
were O
randomly O
allocated O
to O
sentinel-lymph-node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel-lymph-node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

We O
carried O
out O
a O
randomized O
phase O
II O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg/m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
A O
) O
or O
3-weekly O
irinotecan O
at O
a O
dose O
of O
300/240 O
mg/m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
B O
) O
in O
combination O
with O
capecitabine O
1000 O
mg/m O
( O
2 O
) O
twice O
daily O
days O
1-14 O
and O
days O
22-35 O
every O
6 O
weeks O
. O

At O
a O
median O
follow-up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5-year O
disease-free O
survival O
was O
89.9 O
% O
in O
the O
ALND O
arm O
and O
87.6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2.3 O
% O
( O
95 O
% O
confidence O
interval O
: O
-3.1 O
% O
to O
7.6 O
% O
) O
. O

Responses O
were O
assessed O
by O
measuring O
changes O
in O
hemoglobin/hematocrit O
, O
transfusion O
requirement O
, O
and O
quality O
of O
life O
. O

Patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O

Most O
effects O
were O
found O
at O
3 O
months O
only O
. O

Maintenance O
therapy O
can O
delay O
progression O
and O
prolong O
survival O
in O
metastatic O
non-small-cell O
lung O
cancer O
( O
mNSCLC O
) O
. O

Efficacy O
of O
RT O
based O
on O
clinical O
, O
radiologic O
, O
and O
prostate-specific O
antigen O
data O
were O
also O
evaluated O
at O
baseline O
and O
after O
RT O
. O

Based O
on O
this O
safety O
analysis O
, O
the O
next O
step O
of O
study O
recruitment O
was O
continued O
. O

Investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O

The O
majority O
of O
prostate O
carcinoma O
survivors O
experience O
enduring O
sexual O
difficulties O
and O
associated O
distress O
in O
the O
years O
after O
definitive O
treatment O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

These O
measures O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
and O
every O
3 O
months O
until O
death O
or O
study O
completion O
. O

Three O
months O
after O
embolization O
, O
contrast O
material-enhanced O
magnetic O
resonance O
imaging O
examinations O
were O
evaluated O
blindly O
to O
determine O
the O
extent O
of O
leiomyoma O
infarction O
. O

Four O
weeks O
later O
, O
all O
patients O
received O
pamidronate O
120 O
mg O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

A O
clinically O
significant O
decline O
in O
QOL O
was O
defined O
as O
a O
10 O
% O
decrease O
from O
baseline O
to O
week-8 O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

Prespecified O
analyses O
examined O
rates O
of O
amenorrhea O
by O
treatment O
arm O
, O
the O
relationship O
between O
amenorrhea O
and O
QOL O
, O
and O
QOL O
by O
treatment O
arm O
. O

The O
main O
outcome O
measures O
are O
quality O
of O
life O
( O
QOL O
) O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
[ O
EORTC-QLQ-C30 O
] O
and O
Colorectal O
Cancer-Specific O
Module O
[ O
QLQ-CR38 O
] O
) O
, O
sexual O
functioning O
( O
Female O
Sexual O
Functioning O
Index O
) O
, O
and O
psychological O
well-being O
( O
Brief O
Symptom O
Inventory O
Depression/Anxiety O
, O
Impact O
of O
Events O
Scale-Revised O
, O
CR-38 O
Body O
Image O
) O
. O

Sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
when O
given O
at O
50 O
mg/d O
on O
a O
4-weeks-on O
2-weeks-off O
regimen O
. O

We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

23 O
centres O
in O
the O
United O
Kingdom O
, O
Ireland O
, O
and O
South O
Africa O
. O

In O
a O
phase O
III O
clinical O
trial O
organized O
by O
the O
French O
Federation O
of O
Cancer O
Institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
n O
= O
109 O
";" O
etoposide O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
plus O
cisplatin O
at O
100 O
mg/m O
( O
2 O
) O
on O
day O
2 O
) O
or O
PCDE O
( O
n O
= O
117 O
";" O
etoposide O
and O
cisplatin O
given O
as O
in O
EP O
plus O
cyclophosphamide O
at O
400 O
mg/m O
( O
2 O
) O
on O
days O
1-3 O
and O
4'-epidoxorubicin O
at O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O

The O
laser O
group O
received O
LLLT O
( O
Technomed O
Electronics O
Advanced O
Laser O
Therapy O
1000 O
, O
He-Ne O
, O
Î» O
= O
632.8 O
nm O
, O
power O
density O
= O
24 O
mW/cm O
( O
2 O
) O
, O
dosage O
= O
3.0 O
J O
at O
each O
point O
, O
total O
dose/session O
= O
36-40 O
J O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time/point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O

It O
is O
not O
clear O
whether O
the O
administration O
of O
radioiodine O
provides O
any O
benefit O
to O
patients O
with O
low-risk O
thyroid O
cancer O
after O
a O
complete O
surgical O
resection O
. O

Treatment-related O
quality O
of O
life O
was O
assessed O
by O
the O
Breast O
Chemotherapy O
Questionnaire O
( O
BCQ O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O

The O
importance O
of O
parallel O
evaluation O
of O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
has O
been O
recognized O
as O
fundamental O
and O
the O
aim O
was O
to O
assess O
QoL O
and O
quality O
adjusted O
survival O
. O

Regimen O
A O
consisted O
of O
PAV O
( O
cisPlatin O
, O
Adriamycin O
, O
VP O
16-213 O
, O
and O
Regimen O
B O
of O
CyMOC O
( O
Cyclophosphamide O
, O
Methotrexate O
, O
Oncovin O
, O
CCNU O
) O
. O

Monthly O
fatigue O
assessments O
were O
completed O
between O
T2 O
and O
T3 O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

We O
compared O
the O
use O
of O
radiotherapy O
plus O
short-term O
androgen O
suppression O
with O
the O
use O
of O
radiotherapy O
plus O
long-term O
androgen O
suppression O
in O
the O
treatment O
of O
locally O
advanced O
prostate O
cancer O
. O

This O
analysis O
included O
a O
protocol-specified O
time O
to O
definitive O
deterioration O
( O
TDD O
) O
analysis O
at O
a O
5 O
% O
decrease O
in O
HRQOL O
versus O
baseline O
, O
with O
no O
subsequent O
increase O
above O
this O
threshold O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O

The O
study O
group O
joined O
a O
weekly O
session O
of O
ALT O
for O
3 O
months O
in O
addition O
to O
the O
self-management O
therapy O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

After O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O

Patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O

Patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
Cardiff O
Wound O
Impact O
Schedule O
( O
CWIS O
) O
. O

Median O
ECOG O
was O
1 O
, O
and O
median O
number O
of O
prior O
chemotherapy O
regimens O
was O
2 O
. O

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

In O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

Baseline O
scores O
from O
both O
EQ-5D O
scales O
were O
significant O
predictors O
of O
OS O
in O
Cox O
proportional O
hazard O
models O
. O

We O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
a O
pain O
management O
program O
( O
PMP O
) O
on O
pain O
intensity O
, O
use O
of O
PRN O
drugs O
and O
nonpharmacological O
strategies O
as O
pain O
relief O
, O
and O
barriers O
to O
managing O
pain O
in O
cancer O
patients O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

The O
FDA O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Chemotherapy O
regimens O
consisted O
of O
a O
control O
FU O
arm O
( O
5-FU O
500 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
) O
and O
the O
investigational O
FUP O
arm O
( O
continuous O
5-FU O
1000 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O

We O
report O
QOL O
data O
collected O
during O
3 O
years O
after O
random O
assignment O
in O
patients O
without O
disease O
recurrence O
. O

Women O
's O
perceptions O
of O
emotional O
support O
, O
quality O
of O
life O
( O
QOL O
) O
, O
mood O
, O
and O
healthcare O
utilisation O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
3 O
months O
and O
6 O
months O
. O

Nutritional O
intake O
( O
determined O
by O
diet O
history O
) O
and O
status O
( O
determined O
by O
Ottery O
's O
Subjective O
Global O
Assessment O
) O
, O
and O
QOL O
( O
determined O
by O
the O
European O
Organization O
for O
the O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
version O
3.0 O
[ O
EORTC O
QLQ-C30 O
] O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
of O
RT O
, O
and O
at O
3 O
months O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

In O
addition O
, O
the O
long-term O
effectiveness O
was O
investigated O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
QoL O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
NSCLC O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O

After O
demonstrating O
the O
efficacy O
of O
chemotherapy O
combined O
with O
tamoxifen O
for O
postmenopausal O
patients O
with O
lymph O
node-positive O
disease O
, O
the O
International O
Breast O
Cancer O
Study O
Group O
launched O
a O
randomized O
trial O
( O
Trial O
IX O
) O
to O
evaluate O
the O
role O
of O
adjuvant O
chemotherapy O
preceding O
treatment O
with O
tamoxifen O
for O
patients O
with O
lymph O
node-negative O
disease O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

To O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
NSCLC O
, O
the O
Eastern O
Cooperative O
Oncology O
Group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O

A O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
QOL O
. O

Exercise O
has O
been O
found O
to O
effectively O
decrease O
fatigue O
levels O
and O
improve O
physical O
functioning O
in O
cancer O
patients O
. O

Pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
GOO O
. O

Mean O
age O
was O
58 O
Â± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O

Women O
( O
n O
= O
177 O
) O
with O
uterine O
fibroids O
and O
heavy O
menstrual O
bleeding O
who O
were O
scheduled O
to O
undergo O
hysterectomy O
were O
randomly O
assigned O
to O
undergo O
UAE O
( O
n O
= O
88 O
) O
or O
hysterectomy O
( O
n O
= O
89 O
) O
. O

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

Patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
ACP O
) O
, O
four O
cycles O
of O
anthracycline-containing O
regimens O
followed O
by O
docetaxel O
( O
ACD O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
PTX O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
DTX O
) O
. O

From O
December O
1997 O
through O
February O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
EBRT O
( O
median O
dose O
68 O
Gy O
) O
. O

Functional O
Assessment O
of O
Cancer O
Therapy O
core O
questionnaire O
( O
FACT-G O
) O
with O
its O
additional O
breast O
cancer O
subscale O
were O
performed O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
NHT O
. O

MH O
and O
QOL O
were O
assessed O
with O
standardized O
questionnaires O
at O
baseline O
";" O
cycle O
4 O
, O
day O
1 O
";" O
and O
every O
6 O
months O
through O
24 O
months O
. O

Participants O
were O
assessed O
before O
cancer O
treatment O
( O
T1 O
) O
, O
postintervention O
( O
T2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1-year O
follow-up O
( O
T3 O
) O
. O

We O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open-label O
, O
randomized O
phase O
III O
trial O
in O
elderly O
patients O
with O
advanced O
NSCLC O
. O

Chemotherapy-naÃ¯ve O
patients O
age O
70 O
years O
or O
older O
with O
stage O
IIIB/IV O
NSCLC O
and O
performance O
status O
2 O
or O
lower O
were O
eligible O
. O

No O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

The O
final O
sample O
was O
302 O
dyads O
. O

All O
patients O
kept O
a O
daily O
pain O
diary O
. O

Two O
hundred O
eighty-four O
patients O
were O
randomized O
to O
treatment O
with O
IFNalpha2a O
plus O
13-CRA O
or O
treatment O
with O
IFNalpha2a O
alone O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

This O
trial O
was O
conducted O
to O
determine O
whether O
high-dose O
fluorouracil O
( O
FU O
) O
given O
as O
a O
weekly O
24-hour O
infusion O
is O
more O
active O
than O
bolus O
FU O
+ O
leucovorin O
( O
LV O
) O
, O
and O
whether O
high-dose O
infusional O
FU O
can O
be O
modulated O
by O
LV O
. O

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

To O
assess O
the O
long O
term O
risks O
and O
benefits O
of O
hormone O
replacement O
therapy O
( O
combined O
hormone O
therapy O
versus O
placebo O
, O
and O
oestrogen O
alone O
versus O
combined O
hormone O
therapy O
) O
. O

Patients O
were O
randomly O
assigned O
to O
a O
sunitinib O
starting O
dose O
of O
37.5 O
mg/d O
in O
the O
morning O
( O
AM O
) O
or O
evening O
( O
PM O
) O
. O

Locally O
advanced O
breast O
cancer O
patients O
were O
randomly O
assigned O
onto O
a O
study O
comparing O
cyclophosphamide O
( O
C O
";" O
75 O
mg/m O
( O
2 O
) O
orally O
days O
1 O
to O
14 O
) O
, O
epirubicin O
( O
E O
";" O
60 O
mg/m O
( O
2 O
) O
intravenously O
[ O
IV O
] O
days O
1 O
, O
8 O
) O
, O
and O
fluorouracil O
( O
F O
";" O
500 O
mg/m O
( O
2 O
) O
IV O
days O
1 O
, O
8 O
) O
six O
cycles O
every O
28 O
days O
versus O
E O
( O
120 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
C O
( O
830 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
and O
granulocyte O
colony-stimulating O
factor O
( O
filgrastim O
";" O
5 O
micro O
g/kg/d O
subcutaneously O
days O
2 O
to O
13 O
) O
six O
cycles O
every O
14 O
days O
. O

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

Supervised O
exercise O
comprising O
high O
intensity O
cardiovascular O
and O
resistance O
training O
, O
relaxation O
and O
body O
awareness O
training O
, O
massage O
, O
nine O
hours O
weekly O
for O
six O
weeks O
in O
addition O
to O
conventional O
care O
, O
compared O
with O
conventional O
care O
. O

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES-D O
) O
, O
respectively O
. O

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

Survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
PC O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

Patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
double O
HDCT O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral-blood O
stem-cell O
transplantation O
. O

Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

Neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O

Costs O
were O
in O
British O
pounds O
and O
year O
2000 O
values O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

ADT O
is O
also O
used O
in O
patients O
with O
PCa O
as O
neo-adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down-stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

Postoperatively O
, O
body O
mass O
index O
( O
BMI O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
QOL O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O

We O
investigated O
the O
role O
of O
DC/CIK O
( O
dendritic O
cell/cytokine-induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

To O
examine O
the O
effects O
of O
a O
scapula-oriented O
exercise O
on O
upper O
limb O
dysfunction O
in O
breast O
cancer O
survivors O
. O

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Three O
hundred O
and O
sixteen O
patients O
completed O
1,201 O
questionnaires O
. O

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

Survival O
curves O
were O
drawn O
using O
the O
Kaplan-Meier O
method O
and O
analyzed O
by O
the O
Mantel-Haenszel O
test O
. O

Intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
-10 O
to O
20-minute O
sessions O
1 O
week O
apart O
. O

All O
structures O
including O
the O
IUS O
and O
EUS O
were O
contoured O
on O
T2-weighted O
MRI O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
CT. O
Spearman O
's O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
Ï O
) O
was O
used O
for O
statistical O
analyses O
. O

HRQOL O
data O
were O
not O
collected O
after O
disease O
progression O
. O

The O
WBC O
, O
Hb O
, O
and O
PLT O
were O
detected O
in O
all O
patients O
before O
treatment O
, O
6 O
months O
after O
treatment O
, O
and O
1 O
year O
after O
treatment O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5Dâ„¢ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

Patients O
were O
randomized O
to O
either O
an O
experimental O
group O
( O
receiving O
the O
PMP O
) O
or O
a O
control O
group O
( O
routine O
care O
) O
. O

The O
sessions O
included O
education O
on O
prostate O
carcinoma O
and O
sexual O
function O
and O
options O
to O
treat O
ED O
as O
well O
as O
sexual O
communication O
and O
stimulation O
skills O
. O

When O
60 O
cases O
of O
non-small O
cell O
lung O
cancer O
patients O
in O
stage O
IIIb O
and O
IV O
reached O
stable O
disease O
after O
treatment O
with O
4 O
cycles O
of O
a O
two-drug O
regimen O
with O
platinum O
, O
they O
were O
randomly O
divided O
into O
two O
groups O
. O

Those O
in O
the O
intervention O
group O
received O
six O
multidisciplinary O
90-minute O
sessions O
designed O
to O
address O
the O
five O
major O
domains O
of O
QOL O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

This O
study O
addressed O
two O
questions O
: O
the O
dose-response O
relationship O
of O
Taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O

The O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
EuroQol O
classification O
system O
( O
EQ-5D O
) O
questionnaire O
. O

Secondary O
outcomes O
of O
self-reported O
end-of-life O
experiences O
were O
assessed O
in O
a O
survey O
that O
was O
undertaken O
after O
the O
completion O
of O
the O
study O
. O

Functional O
outcome O
and O
health O
status O
of O
extremity O
STS O
patients O
randomized O
in O
a O
phase O
III O
trial O
comparing O
preoperative O
versus O
postoperative O
RT O
is O
described O
. O

Further O
investigation O
and O
data O
collection O
will O
allow O
the O
assessment O
of O
this O
procedure O
beyond O
1 O
year O
after O
operation O
. O

Reliable O
population O
norm O
data O
are O
now O
available O
to O
aid O
in O
the O
interpretation O
of O
clinical O
trial O
results O
where O
the O
FACT-An O
questionnaire O
is O
administered O
. O

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Forty-two O
patients O
with O
esophageal O
cancer O
who O
were O
receiving O
cisplatin-based O
neoadjuvant O
chemotherapy O
were O
assigned O
to O
either O
a O
ghrelin O
group O
( O
n O
= O
21 O
) O
or O
a O
placebo O
group O
( O
n O
= O
21 O
) O
. O

Eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ECOG O
performance O
status O
of O
0 O
to O
2 O
";" O
stable O
brain O
metastases O
were O
allowed O
. O

The O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
B-30 O
trial O
included O
menstrual O
history O
( O
MH O
) O
and O
quality-of-life O
( O
QOL O
) O
studies O
to O
compare O
treatments O
on O
these O
outcomes O
. O

The O
mean O
age O
of O
randomised O
women O
was O
62.8 O
( O
SD O
4.8 O
) O
years O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

All O
subjects O
completed O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Version O
IV O
( O
FACIT O
F O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O

Gemcitabine O
( O
G O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O

Rehabilitation O
department O
at O
a O
university O
hospital O
. O

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer-specific O
50-item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

This O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
TSH O
( O
rhTSH O
) O
to O
prepare O
euthyroid O
patients O
on O
L-thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3.7 O
GBq O
( O
100 O
mCi O
) O
131I O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O

Single-agent O
therapy O
with O
bicalutamide O
, O
a O
nonsteroidal O
antiandrogen O
, O
was O
compared O
with O
castration O
, O
either O
surgical O
or O
medical O
, O
in O
patients O
with O
untreated O
Stage O
D2 O
prostate O
cancer O
. O

Survival O
was O
analyzed O
on O
an O
intent-to-treat O
basis O
. O

Forty-one O
participants O
were O
enrolled O
and O
36 O
completed O
the O
trial O
. O

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

Australian O
private O
radiotherapy O
facility O
. O

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2-4 O
. O

The O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
EORTC O
QLQ-lung O
cancer-specific O
module O
( O
LC13 O
) O
were O
used O
to O
investigate O
airway O
symptom O
relief O
and O
changes O
in O
HRQOL O
. O

Despite O
this O
, O
it O
remains O
an O
understudied O
, O
underreported O
, O
and O
undertreated O
issue O
in O
the O
field O
of O
cancer O
survivorship O
. O

Convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

All O
statistical O
tests O
were O
two-sided O
. O

At O
6-month O
follow-up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self-esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

A O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
EORTC-QLQ-C30 O
) O
functioning O
( O
Health O
Survey O
Short O
Form-36 O
) O
or O
psychological O
distress O
( O
Symptom O
Checklist-90 O
) O
moderated O
the O
effect O
of O
CBT O
on O
fatigue O
. O

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

GE/G O
median O
OS O
was O
5.6/5.1 O
months O
";" O
median O
PFS O
was O
3.4/3.0 O
months O
. O

All O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6-108 O
) O
months O
. O

Both O
treatments O
then O
were O
followed O
by O
carboplatin O
to O
an O
area O
under O
the O
plasma O
concentration-time O
curve O
of O
5 O
. O

Relatively O
small O
patient O
population O
. O

Lymphedema O
is O
an O
adverse O
effect O
of O
breast O
cancer O
surgery O
. O

Endpoints O
were O
overall O
survival O
, O
progression-free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
. O

Caregivers O
and O
patients O
are O
adversely O
affected O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Eighteen O
patients O
underwent O
conventional O
treatment O
( O
surgery O
, O
radiotherapy O
, O
and O
chemotherapy O
) O
and O
received O
adjuvant O
autologous O
dendritic O
cell O
vaccine O
, O
and O
16 O
patients O
( O
control O
group O
) O
underwent O
conventional O
treatment O
only O
. O

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost-effectiveness O
of O
controlled-release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

Associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
Cox O
proportional O
hazards O
model O
. O

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low-frequency O
low-intensity O
electrotherapy O
or O
to O
undergo O
first O
low-frequency O
low-intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

Allocation O
concealment O
was O
by O
use O
of O
opaque O
sealed O
envelopes O
. O

Secondary O
objectives O
were O
overall O
survival O
, O
tumor O
response O
, O
and O
toxicity O
. O

As O
treatment O
for O
mNSCLC O
is O
non-curative O
, O
its O
impact O
on O
patient O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
is O
an O
important O
consideration O
. O

Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

The O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
RP O
) O
plus O
observation O
versus O
RP O
plus O
adjuvant O
radiation O
therapy O
( O
RT O
) O
. O

Progression-free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
HRQOL O
. O

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

Overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
QL O
forms O
were O
received O
. O

Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O

Fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O

From O
July O
2000 O
to O
December O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O

Health-related O
quality O
of O
life O
( O
HRQOL O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
AEs O
) O
were O
compared O
between O
Japanese O
postmenopausal O
patients O
with O
hormone-sensitive O
breast O
cancer O
( O
BC O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open-labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
National O
Surgical O
Adjuvant O
Study O
of O
Breast O
Cancer O
( O
N-SAS O
BC O
) O
4 O
substudy O
of O
the O
Tamoxifen O
Exemestane O
Adjuvant O
Multinational O
( O
TEAM O
) O
trial O
. O

Carry-over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O

Behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum/paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

To O
assess O
the O
effect O
of O
a O
multimodal O
group O
exercise O
intervention O
, O
as O
an O
adjunct O
to O
conventional O
care O
, O
on O
fatigue O
, O
physical O
capacity O
, O
general O
wellbeing O
, O
physical O
activity O
, O
and O
quality O
of O
life O
in O
patients O
with O
cancer O
who O
were O
undergoing O
adjuvant O
chemotherapy O
or O
treatment O
for O
advanced O
disease O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
for O
increasing O
resiliency O
and O
for O
decreasing O
stress O
and O
anxiety O
among O
mentors O
who O
themselves O
were O
previously O
diagnosed O
with O
breast O
cancer O
. O

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

At O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O

The O
combination O
of O
cisplatin O
and O
etoposide O
( O
PE O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor-prognosis O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
. O

During O
the O
first O
week O
of O
study O
, O
patients O
were O
administered O
25 O
mg O
of O
amitriptyline O
or O
equivalent O
drops O
of O
placebo O
at O
night O
for O
3 O
days O
and O
50 O
mg O
for O
the O
following O
4 O
days O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

At O
baseline O
, O
domain O
scores O
were O
similar O
between O
arms O
. O

Promising O
results O
in O
a O
randomized O
phase O
II O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
TPZ O
) O
combined O
with O
cisplatin O
( O
CIS O
) O
and O
radiation O
led O
to O
this O
phase O
III O
trial O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

In O
a O
prospective O
randomised O
single-centre O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
oesophagectomy O
for O
cancer O
. O

All O
P O
values O
are O
two-sided O
. O

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

We O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
PCV O
) O
versus O
TMZ O
in O
chemotherapy-naive O
patients O
with O
recurrent O
HGG O
. O

Bone-cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

In O
this O
randomized O
phase O
III O
trial O
, O
a O
total O
of O
313 O
Korean O
never-smokers O
with O
stage O
IIIB O
or O
IV O
lung O
adenocarcinoma O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
GP O
chemotherapy O
( O
gemcitabine O
1,250 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
";" O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self-report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

CONNECT O
was O
in O
addition O
to O
standard O
clinical O
follow-up O
. O

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT-I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

Quality O
of O
life O
was O
assessed O
using O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
. O

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

This O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O

There O
were O
752 O
patients O
enrolled O
between O
2007 O
and O
2010 O
";" O
92 O
% O
had O
papillary O
cancer O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

To O
determine O
the O
effect O
of O
a O
nursing-led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O

Secondary O
end O
points O
included O
objective O
response O
rate O
, O
clinical O
benefit O
rate O
( O
CBR O
) O
, O
duration O
of O
clinical O
benefit O
( O
DoCB O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

Sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1-year O
study O
period O
. O

Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

However O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
MPE O
remains O
unknown O
. O

Randomized O
controlled O
trial O
. O

Inclusion O
criteria O
were O
an O
age O
of O
18 O
years O
or O
older O
";" O
total O
thyroidectomy O
for O
differentiated O
thyroid O
carcinoma O
";" O
tumor-node-metastasis O
( O
TNM O
) O
stage O
, O
ascertained O
on O
pathological O
examination O
( O
p O
) O
of O
a O
surgical O
specimen O
, O
of O
pT1 O
( O
with O
tumor O
diameter O
â‰¤1 O
cm O
) O
and O
N1 O
or O
Nx O
, O
pT1 O
( O
with O
tumor O
diameter O
> O
1 O
to O
2 O
cm O
) O
and O
any O
N O
stage O
, O
or O
pT2N0 O
";" O
absence O
of O
distant O
metastasis O
";" O
and O
no O
iodine O
contamination O
. O

Quality O
of O
life O
assessments O
were O
performed O
using O
the O
EORTC O
QLQ-C30 O
and O
QLQ-OES24 O
modules O
. O

Among O
all O
participants O
, O
the O
mean O
number O
of O
logins O
over O
8 O
weeks O
was O
20.8 O
Â± O
17.7 O
logins O
for O
the O
III O
+ O
ISG O
compared O
with O
12.5 O
Â± O
12.5 O
in O
III-only O
( O
p O
= O
0.15 O
) O
. O

Planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
CIs O
. O

Assessments O
included O
weight O
, O
symptoms O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
, O
and O
quality O
of O
life O
by O
the O
Functional O
Assessment O
of O
Anorexia/Cachexia O
Therapy O
( O
FAACT O
) O
questionnaire O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
MPE O
. O

Postoperative O
pain O
was O
assessed O
with O
a O
visual O
analog O
scale O
and O
the O
McGill O
Pain O
Questionnaire O
. O

A O
total O
of O
118 O
patients O
( O
59 O
per O
arm O
) O
were O
randomly O
assigned O
to O
receive O
IFN O
at O
a O
dose O
of O
0.5 O
million O
units O
( O
MU O
) O
given O
subcutaneously O
twice O
daily O
( O
IFN1 O
) O
or O
IFN O
at O
a O
dose O
of O
5 O
MU O
given O
subcutaneously O
daily O
( O
IFN5 O
) O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

A O
body O
image O
questionnaire O
was O
used O
to O
evaluate O
body O
image O
and O
cosmesis O
. O

A O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment/observation O
period O
. O

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

Analysis O
of O
the O
primary O
endpoint O
was O
done O
by O
modified O
intention O
to O
treat O
. O

The O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
. O

QOL O
was O
assessed O
over O
a O
1-year O
follow-up O
period O
, O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C-30 O
. O

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

Of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O

Administration O
of O
ESAs O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on-time O
chemotherapy O
delivery O
. O

One O
hundred O
fifty-nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5-FU O
) O
were O
randomly O
allocated O
to O
receive O
: O
CPT-11 O
, O
200 O
mg/m2 O
i.v O
. O

Meta-analysis O
of O
published O
studies O
was O
also O
conducted O
. O

A O
single-item O
linear O
analogue O
self-assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28-item O
adjective O
checklist O
for O
emotional O
well-being O
. O

Fifty-seven O
( O
57 O
) O
women O
met O
inclusion O
criteria O
and O
53 O
were O
randomized O
to O
the O
study O
. O

Ninety-seven O
patients O
being O
offered O
outpatient-based O
cancer O
treatment O
were O
randomised O
to O
treatment O
delivered O
in O
a O
hospital O
day O
unit O
, O
at O
the O
patient O
's O
home O
or O
in O
local O
general O
practice O
( O
GP O
) O
surgeries O
. O

The O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node-negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

We O
investigated O
whether O
dignity O
therapy O
could O
mitigate O
distress O
or O
bolster O
the O
experience O
in O
patients O
nearing O
the O
end O
of O
their O
lives O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

This O
was O
a O
randomized O
, O
parallel-arm O
, O
active-controlled O
, O
open-label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240/80 O
mg O
) O
or O
goserelin O
( O
3.6 O
mg O
) O
for O
12 O
weeks O
. O

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O

Although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O

However O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

We O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O

The O
purpose O
of O
this O
randomized O
study O
was O
to O
prospectively O
compare O
the O
efficacy O
and O
tolerability O
of O
strong O
opioids O
as O
first-line O
agents O
with O
the O
recommendations O
of O
the O
WHO O
in O
terminal O
cancer O
patients O
. O

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

Clinical O
follow-up O
was O
obtained O
in O
35 O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

The O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin-based O
chemotherapy O
. O

An O
intention-to-treat O
analysis O
was O
carried O
out O
. O

We O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O

Randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

Interim O
analysis O
halfway O
through O
the O
trial O
had O
a O
Lan-DeMets O
monitoring O
boundary O
with O
an O
O'Brien-Fleming O
stopping O
rule O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28.5 O
% O
) O
. O

This O
study O
is O
registered O
as O
ISRCTN83176944 O
. O

Survival O
was O
the O
major O
study O
end O
point O
. O

Additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
RR O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

Treatments O
are O
associated O
with O
morbidity O
. O

We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O

QOL O
was O
evaluated O
by O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
PR-25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
OV-28 O
. O

A O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

To O
date O
, O
practice O
guidelines O
for O
the O
prevention O
and O
treatment O
of O
CACS O
are O
lacking O
. O

Final O
planned O
overall O
survival O
( O
OS O
) O
analysis O
from O
EGF104900 O
is O
reported O
here O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Prospective O
, O
randomized O
, O
controlled O
trial O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

Patients O
in O
group O
1 O
in O
whom O
gynecomastia O
or O
breast O
pain O
developed O
were O
subsequently O
randomized O
to O
receive O
tamoxifen O
or O
RT O
soon O
after O
symptoms O
started O
. O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

Tumor O
treatment O
was O
unrestricted O
. O

The O
control O
group O
received O
normal O
care O
. O

Only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O

Fifty-one O
randomly O
assigned O
women O
completed O
the O
study O
. O

Baseline O
FACT-H O
& O
amp O
";" O
N O
data O
were O
available O
for O
1,093 O
patients O
and O
missing O
for O
417 O
patients O
. O

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

All O
patients O
had O
stage O
IV O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

Median O
survival O
time O
was O
19.2 O
months O
( O
95 O
% O
CI O
, O
17.5 O
to O
21.3 O
months O
) O
in O
the O
D3P O
arm O
, O
17.8 O
months O
( O
95 O
% O
CI O
, O
16.2 O
to O
19.2 O
months O
) O
in O
the O
D1P O
arm O
, O
and O
16.3 O
months O
( O
95 O
% O
CI O
, O
14.3 O
to O
17.9 O
months O
) O
in O
the O
MP O
arm O
. O

For O
this O
clinical O
trial O
, O
263 O
patient-spouse O
dyads O
were O
stratified O
by O
research O
site O
, O
phase O
of O
illness O
, O
and O
treatment O
";" O
then O
, O
they O
were O
randomized O
to O
the O
control O
group O
( O
standard O
care O
) O
or O
the O
experimental O
group O
( O
standard O
care O
plus O
a O
5-session O
family O
intervention O
) O
. O

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

QOL O
outcomes O
were O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QOL O
questionnaire O
( O
QLQ-C30 O
) O
and O
Head-Neck O
module O
( O
HN-35 O
) O
at O
baseline O
( O
pre-treatment O
) O
and O
subsequently O
periodically O
on O
follow-up O
. O

To O
assess O
the O
effects O
of O
an O
expressive O
writing O
( O
EW O
) O
intervention O
on O
perceptions O
of O
emotional O
support O
in O
women O
completing O
treatment O
for O
early O
stage O
breast O
cancer O
. O

Forty-eight O
women O
( O
56 O
+/- O
10 O
years O
) O
, O
with O
a O
12.8 O
% O
lymphedema O
relative O
volume O
, O
participated O
in O
the O
study O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment-related O
morbidity O
and O
cosmesis O
. O

Multicentre O
, O
randomised O
, O
placebo O
controlled O
, O
double O
blind O
trial O
. O

Patients O
were O
randomized O
to O
receive O
MVP O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatin O
100 O
mg/m2 O
d1 O
) O
or O
MVC O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatin O
300 O
mg/m2 O
d1 O
) O
every O
3 O
weeks O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

Kaposi O
's O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
Zimbabwe O
. O

The O
mean O
age O
was O
52.3 O
vs. O
59.5 O
, O
respectively O
. O

Three O
main O
quality O
of O
life O
scales O
( O
general O
health O
status O
, O
functional O
, O
and O
symptom O
scales O
) O
were O
assessed O
and O
compared O
between O
two O
treatment O
groups O
. O

The O
original O
analysis O
, O
undertaken O
in O
August O
2003 O
when O
557 O
deaths O
had O
occurred O
, O
showed O
significantly O
better O
survival O
and O
response O
rates O
for O
pain O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
and O
quality O
of O
life O
for O
D3P O
when O
compared O
with O
MP O
. O

The O
primary O
end-point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

Subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6-min O
walk O
test O
( O
6MWT O
) O
, O
modified O
sit O
and O
reach O
test O
, O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
, O
Beck O
Depression O
Index O
( O
BDI O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
QLQ O
BR23 O
. O

Patients O
were O
randomly O
assigned O
to O
paclitaxel O
135 O
mg/m O
( O
2 O
) O
over O
24 O
hours O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
2 O
every O
3 O
weeks O
( O
PC O
, O
reference O
arm O
) O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
VC O
) O
";" O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
day O
1 O
and O
8 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
GC O
) O
";" O
or O
topotecan O
0.75 O
mg/m O
( O
2 O
) O
days O
1 O
, O
2 O
, O
and O
3 O
plus O
Cis O
50 O
mg/m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
TC O
) O
. O

Quality O
of O
life O
was O
measured O
by O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
for O
Palliative O
Care O
( O
score O
range O
, O
0-184 O
) O
. O

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

The O
oral O
pamidronate O
dose O
was O
600 O
mg/d O
( O
high O
dose O
[ O
HD O
] O
) O
during O
the O
earliest O
study O
years O
, O
then O
changed O
to O
300 O
mg/d O
( O
low O
dose O
[ O
LD O
] O
) O
because O
of O
gastrointestinal O
toxicity O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

Primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM-treated O
patients O
versus O
PLD-treated O
patients O
( O
P O
= O
.007 O
) O
. O

The O
primary O
outcome O
was O
QOL O
. O

The O
aim O
of O
this O
multicenter O
, O
double-blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation-induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Sixty-eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15.5 O
years O
( O
range O
2-41 O
) O
after O
axillary/supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51/68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

A O
total O
of O
191 O
women O
were O
enrolled O
, O
stratified O
by O
age O
and O
stress O
level O
, O
and O
randomized O
to O
receive O
either O
an O
8-week O
MBAT O
intervention O
or O
a O
breast O
cancer O
educational O
support O
program O
of O
equal O
time O
and O
duration O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
within O
the O
randomized O
FLOT65+ O
phase O
II O
trial O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

To O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
BEP O
) O
and O
of O
the O
5-day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good-prognosis O
germ O
cell O
cancer O
. O

Two O
university O
hospitals O
in O
Copenhagen O
, O
Denmark O
. O

Seventy-six O
patients O
were O
randomly O
assigned O
to O
each O
study O
arm O
. O

In O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O

To O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
with O
use O
of O
tris-acryl O
gelatin O
microspheres O
( O
TAGM O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
. O

Indecisive O
patients O
were O
randomized O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
â‰¥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
â‰¥ O
5 O
% O
. O

All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0.05 O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

Lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
QoL O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O

Nocturnal O
administration O
of O
branched-chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

Bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uCa O
) O
, O
hydroxyproline O
( O
Hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
NTx O
, O
Crosslaps O
and O
Free O
Dpd O
. O

With O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
LCR O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O

This O
randomized O
controlled O
trial O
assessed O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
among O
25 O
women O
diagnosed O
with O
breast O
cancer O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

Baseline O
LCSS O
scores O
were O
low O
, O
indicating O
low O
symptom O
burden O
for O
patients O
without O
disease O
progression O
after O
completion O
of O
first-line O
treatment O
. O

QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0.001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0.01 O
) O
. O

We O
investigated O
whether O
patient O
preparation O
using O
rhTSH O
was O
comparable O
to O
conventional O
thyroid O
hormone O
withdrawal O
with O
respect O
to O
efficacy O
of O
postsurgical O
remnant O
ablation O
in O
low-risk O
patients O
receiving O
a O
30 O
mCi O
RI O
. O

The O
current O
study O
evaluated O
the O
cost-effectiveness O
of O
the O
capecitabine/docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality-adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

A O
total O
of O
646 O
node-positive O
, O
receptor-negative O
patients O
were O
randomly O
assigned O
to O
receive O
either O
the O
1 O
6-week O
regimen O
or O
six O
cycles O
of O
CAF O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
2-year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
CRT O
) O
. O

From O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O

Adjustments O
were O
made O
for O
the O
baseline O
score O
. O

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

We O
randomly O
assigned O
1077 O
patients O
to O
receive O
docetaxel O
at O
75 O
mg/m2 O
of O
body O
surface O
area O
( O
1-hour O
intravenous O
infusion O
) O
or O
paclitaxel O
at O
175 O
mg/m2 O
( O
3-hour O
intravenous O
infusion O
) O
. O

Here O
, O
we O
report O
a O
6-month O
follow-up O
of O
exercise O
behavior O
and O
patient-rated O
outcomes O
from O
an O
exercise O
trial O
in O
breast O
cancer O
patients O
. O

Study O
patients O
included O
472 O
low-income O
, O
predominantly O
female O
Hispanic O
patients O
with O
cancer O
age O
> O
or= O
18 O
years O
with O
major O
depression O
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ-LC13 O
) O
tools O
. O

Cancer O
related O
fatigue O
( O
CRF O
) O
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O

The O
final O
analysis O
was O
conducted O
as O
planned O
after O
256 O
progression O
events O
( O
median O
follow-up O
, O
20.5 O
months O
) O
. O

The O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post-treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O

In O
our O
randomized O
, O
phase O
3 O
trial O
, O
we O
compared O
two O
thyrotropin-stimulation O
methods O
( O
thyroid O
hormone O
withdrawal O
and O
use O
of O
recombinant O
human O
thyrotropin O
) O
and O
two O
radioiodine O
( O
( O
131 O
) O
I O
) O
doses O
( O
i.e. O
, O
administered O
activities O
) O
( O
1.1 O
GBq O
and O
3.7 O
GBq O
) O
in O
a O
2-by-2 O
design O
. O

In O
phase O
II O
studies O
, O
irinotecan O
is O
active O
in O
metastatic O
colorectal O
cancer O
, O
but O
the O
overall O
benefit O
has O
not O
been O
assessed O
in O
a O
randomised O
clinical O
trial O
. O

Twenty O
men O
with O
established O
bone O
metastases O
secondary O
to O
prostate O
cancer O
were O
randomly O
assigned O
to O
a O
12-week O
resistance O
exercise O
program O
in O
which O
exercise O
prescription O
was O
based O
on O
the O
location O
of O
bone O
lesions O
( O
n=10 O
) O
or O
usual O
care O
( O
n=10 O
) O
. O

The O
differences O
of O
gender O
, O
age O
, O
primary O
GI O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
P O
> O
0.05 O
) O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

The O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide-treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
";" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O

Clinicians O
' O
assessments O
of O
symptom O
improvement O
were O
at O
2 O
, O
6 O
, O
and O
14 O
weeks O
after O
completion O
of O
TRT O
. O

The O
PPT O
group O
had O
four O
appointments O
with O
a O
nurse O
who O
assessed O
nine O
symptoms O
on O
a O
0 O
to O
10 O
numeric O
rating O
scale O
( O
NRS O
) O
. O

The O
primary O
end O
point O
was O
QL O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O

Two O
hundred O
fifteen O
cancer O
patients O
were O
identified O
from O
the O
1,801 O
participants O
in O
the O
parent O
study O
. O

Patients O
were O
eligible O
if O
they O
were O
aged O
> O
OR= O
70 O
years O
, O
had O
stage O
IIIB O
( O
with O
pleural O
effusion O
) O
or O
stage O
IV O
NSCLC O
, O
had O
a O
performance O
status O
of O
0/1 O
, O
had O
not O
previously O
received O
chemotherapy O
, O
and O
had O
normal O
organ O
function O
. O

Demographic O
and O
clinical O
factors O
studied O
were O
age O
, O
performance O
status O
, O
dominant O
site O
of O
disease O
and O
preceding O
disease-free O
interval O
( O
DFI O
) O
. O

Days O
1 O
, O
8 O
, O
and O
15 O
in O
28-day O
cycles O
";" O
G O
arm O
: O
G O
as O
in O
GE O
. O

This O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
CBT O
. O

The O
aim O
of O
this O
study O
is O
to O
explore O
the O
effects O
, O
safety O
, O
and O
quality O
of O
life O
( O
QoL O
) O
of O
Gefitinib O
and O
Pemetrexed O
on O
patients O
with O
advanced O
non-squamous O
NSCLC O
. O

After O
a O
week O
, O
a O
crossover O
took O
place O
for O
the O
second O
week O
, O
with O
the O
other O
treatment O
at O
an O
inverse O
sequence O
. O

To O
determine O
the O
effect O
of O
duloxetine O
, O
60 O
mg O
daily O
, O
on O
average O
pain O
severity O
. O

Lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O

Fifty-five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

This O
may O
cause O
cisplatin-induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O

To O
analyze O
the O
prospectively O
collected O
health-related O
quality-of-life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90-03 O
and O
91-11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and/or O
overall O
survival O
( O
OS O
) O
. O

Secondary O
endpoints O
included O
overall O
survival O
( O
OS O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
QoL O
) O
and O
biomarker O
analyses O
. O

Subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O

Twenty-four O
mentors O
at O
Mayo O
Clinic O
in O
Rochester O
, O
Minnesota O
, O
were O
randomized O
in O
a O
single-blind O
, O
wait-list O
controlled O
clinical O
trial O
to O
either O
the O
SMART O
intervention O
or O
a O
control O
group O
for O
12 O
weeks O
. O

Of O
the O
351 O
patients O
confirmed O
to O
be O
alive O
with O
correct O
address O
, O
246 O
( O
70 O
% O
) O
returned O
the O
questionnaire O
. O

QOL O
was O
assessed O
using O
FACT-Cx O
, O
consisting O
of O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT-G O
) O
plus O
a O
cervix O
cancer-specific O
subscale O
, O
the O
Brief O
Pain O
Inventory-Short O
Form O
( O
BPI-SF O
) O
, O
and O
a O
neurotoxicity O
subscale O
. O

Pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression-free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo-controlled O
study O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

Transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O

Other O
measurements O
included O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
quality-of-life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O

Hence O
, O
we O
did O
this O
study O
to O
evaluate O
the O
effects O
of O
LLLT O
on O
a O
patient O
's O
reported O
measures O
of O
OM O
and O
QOL O
in O
head O
and O
neck O
cancer O
( O
HNC O
) O
patients O
receiving O
CRT O
. O

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index-Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA/B O
non-small-cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69.6 O
Gy O
at O
1.2 O
Gy O
bid O
) O
. O

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

Tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor-related O
signs O
and O
symptoms O
( O
TRSS O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

The O
standard O
doublet O
, O
vinorelbine-cisplatin O
, O
was O
compared O
with O
a O
triplet O
of O
vinorelbine-ifosfamide-cisplatin O
, O
in O
terms O
of O
survival O
, O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3-month O
follow-up O
( O
T2 O
) O
. O

Uterine O
and O
quality-of-life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

There O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O

Five O
participants O
( O
exercise=2 O
";" O
usual O
care=3 O
) O
did O
not O
complete O
the O
intervention O
, O
three O
of O
which O
were O
due O
to O
advancing O
disease O
( O
exercise=2 O
";" O
usual O
care=1 O
) O
. O

In O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96.1 O
% O
) O
. O

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

End O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
and O
response O
duration O
( O
RD O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
OS O
) O
. O

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

Patients O
randomly O
received O
docetaxel O
60 O
mg/m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg/m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core-30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN-20 O
) O
. O

Eighteen O
patients O
were O
randomized O
to O
GJJ O
and O
21 O
to O
stent O
placement O
. O

The O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
Week O
13 O
. O

The O
training O
group O
followed O
an O
8-week O
exercise O
program O
consisting O
of O
3 O
weekly O
sessions O
of O
90-min O
duration O
, O
supervised O
by O
an O
experienced O
investigator O
and O
divided O
into O
resistance O
exercises O
and O
aerobic O
training O
. O

Patients O
with O
stable O
or O
responding O
disease O
were O
then O
randomized O
to O
observation O
or O
four O
cycles O
of O
topotecan O
( O
1.5 O
mg/m O
( O
2 O
) O
/d O
for O
5 O
days O
, O
every O
3 O
weeks O
";" O
step O
2 O
) O
. O

QOL O
outcomes O
were O
analyzed O
at O
a O
median O
follow-up O
of O
2 O
years O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O

Patients O
with O
cancer O
( O
n O
= O
178 O
) O
who O
agreed O
to O
participate O
in O
the O
study O
were O
randomized O
to O
the O
intervention O
arm O
( O
n O
= O
89 O
) O
or O
the O
control O
arm O
( O
n O
= O
89 O
) O
. O

Eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
NCI O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy-induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O

Participants O
drank O
4 O
oz O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
clinical O
specialist O
( O
supervised O
by O
a O
psychiatrist O
) O
who O
offered O
education O
, O
structured O
psychotherapy O
, O
and O
maintenance/relapse O
prevention O
support O
. O

The O
primary O
endpoint O
was O
investigator-assessed O
overall O
response O
rate O
( O
ORR O
) O
";" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

Each O
patient O
was O
examined O
just O
before O
and O
after O
each O
treatment O
. O

Sixty-four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti-aromatase O
therapy O
( O
exemestane O
) O
and O
COX-2 O
inhibitors O
neoadjuvantly O
. O

A O
total O
of O
103 O
patients O
with O
gastric O
cancer O
were O
prospectively O
randomly O
divided O
into O
groups O
for O
RY O
( O
n O
= O
51 O
) O
or O
INT O
reconstruction O
( O
n O
= O
52 O
) O
after O
total O
gastrectomy O
. O

In O
addition O
, O
we O
also O
evaluated O
the O
impact O
of O
rhTSH O
( O
rhTSH O
vs. O
conventional O
thyroid O
hormone O
withdrawal O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RI O
ablation O
. O

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

If O
inoperable O
, O
optimal O
supportive O
care O
( O
OSC O
) O
, O
including O
steroids O
, O
and O
whole O
brain O
radiotherapy O
( O
WBRT O
) O
are O
generally O
considered O
to O
be O
standard O
care O
, O
although O
there O
is O
no O
randomised O
evidence O
demonstrating O
that O
the O
addition O
of O
WBRT O
to O
OSC O
improves O
survival O
or O
quality O
of O
life O
. O

The O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

A O
randomised O
controlled O
trial O
of O
radiotherapy O
alone O
versus O
radiotherapy O
with O
concomitant O
and O
adjuvant O
temozolomide O
for O
patients O
with O
glioblastoma O
showed O
that O
survival O
was O
higher O
for O
patients O
assigned O
combination O
treatment O
compared O
with O
those O
assigned O
standard O
radiotherapy O
alone O
. O

Ninety-one O
patients O
were O
randomized O
, O
47 O
to O
fludarabine O
and O
44 O
to O
CVP O
. O

To O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer-related O
fatigue O
. O

Overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

Five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

This O
randomized O
, O
multicenter O
, O
phase O
III O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
AT O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
as O
first-line O
chemotherapy O
( O
CT O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first-line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

The O
primary O
end-point O
of O
the O
study O
was O
the O
incidence O
of O
Radiation O
Therapy O
Oncology O
Group O
grade O
3 O
mucositis O
. O

The O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

The O
follow-up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5-fluorouracil O
( O
5-FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

Dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90-99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O

Few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon-alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin-2 O
. O

The O
two O
principal O
aims O
were O
: O
( O
1 O
) O
to O
improve O
the O
survival O
of O
children O
with O
rhabdomyosarcoma O
";" O
and O
( O
2 O
) O
to O
reduce O
the O
late O
effects O
from O
therapy O
by O
restricting O
the O
indications O
for O
surgery O
and/or O
radiotherapy O
after O
good O
response O
to O
initial O
chemotherapy O
. O

Patients O
were O
randomly O
assigned O
( O
2:1 O
) O
to O
GE O
or O
G O
treatment O
";" O
GE O
arm O
: O
E O
500 O
mg O
p.o O
. O

Several O
guidelines O
on O
the O
treatment O
of O
cancer-related O
fatigue O
recommend O
optimizing O
treatment O
of O
accompanying O
symptoms O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long-acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long-term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O

Patients O
with O
histologically-proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg/m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg/m2 O
. O

For O
cost-effectiveness O
, O
the O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

Pittsburgh O
Sleep O
Quality O
Index O
( O
PSQI O
) O
, O
Daily O
Diary O
, O
Wrist O
Actigraph O
, O
and O
Piper O
Fatigue O
Scale O
measures O
and O
Repeated O
Linear O
Mixed O
Model O
analysis O
following O
the O
Intent O
to O
Treat O
paradigm O
were O
used O
. O

Randomisation O
was O
stratified O
by O
centre O
. O

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

Secondary O
end O
points O
were O
depressive O
symptoms O
and O
post-traumatic O
growth O
. O

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long-term O
results O
. O

Both O
cross-sectional O
single-time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention-to-treat O
analysis O
using O
Wilcoxon O
rank-sum O
tests O
. O

Therefore O
, O
we O
performed O
a O
randomized O
, O
phase O
III O
non-inferiority O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
( O
PT O
) O
with O
paclitaxel O
plus O
carboplatin O
( O
TC O
) O
in O
patients O
with O
advanced O
ovarian O
cancer O
. O

We O
investigated O
the O
baseline O
psychosocial O
status O
of O
women O
enrolled O
in O
a O
randomized O
trial O
testing O
two O
psychosocial O
interventions O
for O
women O
at O
the O
end O
of O
primary O
treatment O
. O

Primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
ORR O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O

An O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O

Patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O

To O
compare O
dose-volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
IUS/EUS O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Multicentre O
randomised O
controlled O
trial O
. O

Aqua O
lymphatic O
therapy O
( O
ALT O
) O
is O
a O
novel O
treatment O
for O
limb O
volume O
reduction O
. O

Patients O
with O
advanced O
solid O
tumor O
cancers O
( O
n O
= O
153 O
) O
were O
randomized O
to O
eight O
sessions O
of O
either O
the O
MCGP O
or O
SGP O
. O

This O
analysis O
investigated O
the O
treatment O
effects O
on O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

To O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well-being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1,169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O

Secondary O
outcomes O
were O
other O
domains O
of O
the O
SCNS O
, O
psychological O
status O
, O
continuity O
of O
care O
, O
quality O
of O
life O
, O
and O
resource O
use O
. O

Consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

Patients O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
received O
concomitant O
temozolomide O
( O
75 O
mg/m2 O
) O
once O
daily O
for O
the O
duration O
of O
radiation O
therapy O
( O
42-49 O
days O
) O
. O

Before O
CTX O
, O
research O
nurses O
coached O
intervention O
participants O
to O
develop O
a O
BT O
plan O
including O
stimulus O
control O
, O
modified O
sleep O
restriction O
, O
relaxation O
therapy O
, O
and O
sleep O
hygiene O
. O

Outcomes O
included O
quality O
of O
life O
( O
QoL O
) O
, O
function O
( O
fitness O
and O
upper O
body O
) O
and O
treatment-related O
side O
effects O
( O
fatigue O
, O
lymphoedema O
, O
body O
mass O
index O
, O
menopausal O
symptoms O
, O
anxiety O
, O
depression O
and O
pain O
) O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

We O
therefore O
studied O
the O
effects O
of O
a O
high-fat O
diet O
, O
particularly O
on O
body O
composition O
. O

Endpoints O
were O
quality O
of O
life O
( O
QoL O
) O
, O
aerobic O
fitness O
, O
muscular O
strength O
, O
lean O
body O
mass O
, O
and O
body O
fat O
. O

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

Patients O
in O
control O
group O
( O
31 O
cases O
) O
received O
conventional O
chemotherapy O
, O
whereas O
patients O
in O
the O
combined O
treatment O
group O
( O
41 O
cases O
) O
were O
given O
verapamil O
intraperitoneally O
in O
addition O
to O
chemotherapy O
drugs O
. O

Everolimus O
( O
EVE O
) O
+exemestane O
( O
EXE O
";" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression-free O
survival O
versus O
placebo O
( O
PBO O
) O
+ O
EXE O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health-related O
quality-of-life O
( O
HRQOL O
) O
in O
patients O
with O
hormone-receptor-positive O
( O
HR O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
who O
recurred O
or O
progressed O
on/after O
nonsteroidal O
aromatase O
inhibitor O
( O
NSAI O
) O
therapy O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

A O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O

We O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
QL O
) O
with O
similar O
disease-free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
. O

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

For O
NSCLC O
lung O
tumors O
â‰¤ O
3 O
cm O
, O
a O
dose O
of O
48 O
Gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
Gy O
in O
4 O
fractions O
was O
delivered O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

Sexual O
dysfunction O
represents O
a O
complex O
and O
multifactorial O
construct O
that O
can O
affect O
both O
men O
and O
women O
and O
has O
been O
noted O
to O
often O
deteriorate O
significantly O
after O
treatment O
for O
rectal O
and O
anal O
cancer O
. O

Dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short-term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life-threatening O
or O
life-limiting O
illness O
. O

Participants O
with O
recurrent O
platinum-sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine-carboplatin O
or O
carboplatin O
every O
21 O
days O
. O

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

Outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O

Using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
, O
HRQOL O
was O
assessed O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
disease O
progression O
and/or O
treatment O
discontinuation O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
self-efficacy O
for O
symptom O
management O
";" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self-efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O

and O
intravenous O
( O
i.v O
. O
) O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

The O
primary O
end-point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Limited O
data O
exist O
on O
the O
psychosocial O
aspects O
of O
the O
transitional O
period O
between O
the O
end O
of O
primary O
treatment O
and O
survivorship O
. O

Each O
group O
consisted O
of O
40 O
patients O
, O
scheduled O
to O
receive O
treatment O
for O
5 O
min O
, O
three O
times O
a O
week O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

We O
randomized O
122 O
patients O
with O
lymphoma O
to O
usual O
care O
( O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

Study O
objectives O
included O
response O
( O
primary O
) O
, O
survival O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Chemotherapy O
consisted O
of O
intravenous O
( O
i.v O
. O
) O

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

or O
12 O
months O
( O
p.o O
. O
) O
. O

The O
psychiatrist O
prescribed O
antidepressant O
medications O
for O
patients O
preferring O
or O
assessed O
to O
require O
medication O
. O

Sixty-two O
patients O
with O
recurrent O
or O
metastatic O
NSCLC O
expressing O
Le O
( O
y O
) O
, O
one O
or O
two O
prior O
chemotherapy O
regimens O
, O
and O
PS O
< O
or O
2 O
were O
randomized O
2:1 O
to O
receive O
SGN-15 O
200 O
mg/m2/week O
with O
docetaxel O
35 O
mg/m2/week O
( O
Arm O
A O
) O
or O
docetaxel O
35 O
mg/m2/week O
alone O
( O
Arm O
B O
) O
for O
6 O
of O
8 O
weeks O
. O

A O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

Patients O
received O
either O
r-HuEPO O
( O
150 O
U/kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O

One O
hundred O
twenty-eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
20/90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O

carboplatin O
300 O
mg/m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg/m2 O
orally O
on O
days O
1-5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

Each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

One O
hundred O
seventy-four O
patients O
were O
enrolled O
. O

Seventeen O
participants O
met O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
criteria O
for O
depressive O
symptoms O
( O
HADS O
â‰¥ O
8 O
) O
. O

Because O
neither O
clinical O
nor O
HRQOL O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
survival O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

Primary O
objective O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
objectives O
assessed O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
relationships O
between O
biomarker O
expression O
and O
clinical O
outcomes O
. O

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

During O
2000-2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5-fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

Eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
VNR O
25mg/m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
CDDP O
100mg/m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
VNR O
30 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
CDDP O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O

Those O
in O
the O
treatment O
group O
additionally O
took O
FJD O
, O
50 O
-100 O
mL O
each O
time O
, O
twice O
daily O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast-enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

Data O
were O
analysed O
up O
to O
6 O
months O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

Patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O

All O
patients O
were O
treated O
according O
to O
standard O
local O
practice O
. O

Patients O
randomized O
to O
oral O
nutrition O
only O
served O
as O
control O
subjects O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

Of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
LAC O
and O
219 O
underwent O
open O
colectomy O
. O

Change O
in O
peak O
cardiovascular O
fitness O
mediated O
the O
change O
in O
patient-rated O
physical O
functioning O
. O

Pain O
severity O
was O
assessed O
using O
the O
Brief O
Pain O
Inventory-Short O
Form O
" O
average O
pain O
" O
item O
with O
0 O
representing O
no O
pain O
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg/m2 O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

Exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O

The O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue-related O
thoughts O
and O
behavior O
. O

Dysuria O
was O
evaluated O
on O
a O
0-10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

Patients B-Premise
on I-Premise
Arm I-Premise
B I-Premise
reported I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
QOL I-Premise
between I-Premise
baseline I-Premise
and I-Premise
week I-Premise
9/10 I-Premise
( I-Premise
.71 I-Premise
s.d I-Premise
. I-Premise
) O
, I-Premise
and I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
level I-Premise
of I-Premise
QOL I-Premise
than I-Premise
Arm I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Triglycerides B-Premise
and I-Premise
high-density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and O
low-density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1-year I-Premise
study I-Premise
period I-Premise
. I-Premise

Consistent O
with O
the O
2-year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient-reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
tamoxifen I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18.5 I-Premise
% I-Premise
vs. I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34.0 I-Premise
% I-Premise
vs. I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17.3 I-Premise
% I-Premise
vs. I-Premise
8.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O

However O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8.9 I-Premise
months I-Premise
v I-Premise
9.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
this I-Claim
trial I-Claim
made I-Claim
its I-Claim
results I-Claim
inconclusive I-Claim
, I-Claim
but O
several O
observations O
are O
notable O
. O

Systematic B-Claim
assessment I-Claim
is I-Claim
vital I-Claim
to I-Claim
palliative I-Claim
care I-Claim
, O
but O
documentation O
confirming O
completion O
of O
systematic O
assessment O
in O
hospice O
settings O
is O
often O
inadequate O
or O
absent O
. O

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
MBAT I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

Patients B-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
do I-Claim
not I-Claim
have I-Claim
curative I-Claim
treatment I-Claim
options I-Claim
";" I-Claim
therefore O
, O
treatments O
should O
prolong O
survival O
and O
improve O
quality O
of O
life O
( O
QoL O
) O
. O

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
several I-Premise
HQL I-Premise
domains I-Premise
, I-Premise
and O
only B-Premise
physical I-Premise
functioning I-Premise
and I-Premise
pain I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
mitoxantrone-plus-prednisone I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone-alone I-Premise
group I-Premise
. I-Premise

In O
a O
retrospective O
analysis O
, O
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
pamidronate I-Premise
90 I-Premise
mg I-Premise
group I-Premise
developed I-Premise
osteonecrosis I-Premise
of I-Premise
the I-Premise
jaw I-Premise
compared I-Premise
with I-Premise
two I-Premise
patients I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
. I-Premise

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3-drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Premise
5-year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short-term I-Premise
and I-Premise
long-term I-Premise
suppression I-Premise
was I-Premise
19.0 I-Premise
% I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
the O
observed O
hazard O
ratio O
was O
1.42 O
( O
upper O
95.71 O
% O
confidence O
limit O
, O
1.79 O
";" O
P=0.65 O
for O
noninferiority O
) O
. O

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

Parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition-related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim

Although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim

Although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow-up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
INT I-Claim
and I-Claim
RY I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long-term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O

There B-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
community I-Premise
treatment I-Premise
compromised I-Premise
patient I-Premise
safety I-Premise
and O
no B-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
terms I-Premise
of I-Premise
overall I-Premise
costs I-Premise
or I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Year I-Premise
. I-Premise

Complete O
remission O
rates O
before O
random O
assignment O
were O
11 O
% O
for O
those O
receiving O
HDCT O
and O
12 O
% O
for O
those O
receiving O
ST. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
48 I-Premise
months I-Premise
, I-Premise
79 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
and I-Premise
77 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
ST I-Premise
arm I-Premise
";" I-Premise
seven B-Premise
patients I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
died I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
toxicity I-Premise
. I-Premise

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

Furthermore O
, O
no B-Premise
differences I-Premise
between I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
and I-Premise
their I-Premise
corresponding I-Premise
control I-Premise
groups I-Premise
were I-Premise
found I-Premise
in I-Premise
role I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
feelings I-Premise
of I-Premise
control I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
p-values I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

The O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50-59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
";" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5-year I-Premise
risk I-Premise
. I-Premise

Zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
given I-Claim
as I-Claim
a I-Claim
15-minute I-Claim
infusion I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
but O
the B-Claim
8-mg I-Claim
dose I-Claim
was I-Claim
associated I-Claim
with I-Claim
renal I-Claim
function I-Claim
deterioration I-Claim
. I-Claim

However O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
Student I-Premise
t-test I-Premise
) I-Premise
. I-Premise

DC-treated B-Premise
patients I-Premise
experienced I-Premise
improved I-Premise
pain I-Premise
relief I-Premise
compared I-Premise
with I-Premise
VC I-Premise
( I-Premise
P=0.033 I-Premise
) I-Premise
, I-Premise
whereas O
pain B-Premise
relief I-Premise
with I-Premise
DCb I-Premise
and I-Premise
VC I-Premise
was I-Premise
similar I-Premise
. I-Premise

The O
RRs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
CI O
) O
: O
21 O
% O
-48 O
% O
) O
in O
arm O
A O
, O
including O
3 O
complete O
responses O
( O
CRs O
) O
and O
15 O
partial O
responses O
( O
PRs O
) O
, O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
in O
arm O
B O
, O
including O
2 O
CRs O
and O
11 O
PRs O
, O
and O
24 O
% O
( O
95 O
% O
CI O
: O
14 O
% O
-38 O
% O
) O
, O
with O
2 O
CRs O
and O
11 O
PRs O
, O
in O
arm O
C. O
After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18-108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
OM I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise

Taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Specifically O
, O
AET B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non-Hodgkin I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post-diagnosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.007 I-Premise
) I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5-year I-Premise
period I-Premise
. I-Premise

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

Although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin-alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0.126 I-Premise
] I-Premise
) I-Premise
. I-Premise

Recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
February I-Premise
2006 I-Premise
( I-Premise
n=150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.04-2.45 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.04 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.62 I-Premise
[ I-Premise
1.06-2.41 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.02 I-Premise
) I-Premise
. I-Premise

For B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
";" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O

Both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

The B-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
OPS-DNA I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
DNA I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
P=.045 I-Premise
) I-Premise
. I-Premise

The B-Premise
PFS I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
6.2 I-Premise
vs. I-Premise
4.3 I-Premise
months I-Premise
, I-Premise
odds I-Premise
ratio I-Premise
0.66 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
, I-Premise
while O
the B-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
14.8 I-Premise
months I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
vs. I-Premise
14.1 I-Premise
months I-Premise
in I-Premise
control I-Premise
arm I-Premise
) I-Premise
";" I-Premise
quality B-Claim
of I-Claim
life I-Claim
was I-Claim
similar I-Claim
as I-Claim
well I-Claim
. I-Claim

Moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient-rated I-Premise
outcomes I-Premise
. I-Premise

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

Changes O
in O
QOL O
during O
chemotherapy O
were O
relatively O
modest O
";" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
QOL I-Premise
. I-Premise

Moreover O
, O
compared B-Premise
with I-Premise
participants I-Premise
reporting I-Premise
no I-Premise
regular I-Premise
exercise I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
, I-Premise
those I-Premise
reporting I-Premise
regular I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
also I-Premise
reported I-Premise
better I-Premise
patient-rated I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
9.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.2-17.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
. I-Premise

However O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

As O
a O
result O
of O
these O
observations O
, O
paclitaxel B-Claim
( I-Claim
135 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
) I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
has I-Claim
replaced I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
as I-Claim
the I-Claim
reference I-Claim
regimen I-Claim
in I-Claim
our I-Claim
recently I-Claim
completed I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

Low-frequency B-Premise
low-intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19.77 I-Premise
mL I-Premise
, I-Premise
P I-Premise
= I-Premise
0.36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13.1 I-Premise
, I-Premise
16.2 I-Premise
and I-Premise
6.4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
FACT-B+4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5.4 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.015 I-Premise
) I-Premise
. I-Premise

Although O
capecitabine B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
QoL I-Claim
during I-Claim
treatment I-Claim
, O
QoL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A. I-Premise
SGN-15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well-tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

Body B-Premise
weight I-Premise
and I-Premise
whole I-Premise
body I-Premise
fat I-Premise
declined I-Premise
similarly I-Premise
over I-Premise
time I-Premise
in I-Premise
all I-Premise
groups I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
, I-Premise
whereas O
lean B-Premise
body I-Premise
mass I-Premise
was I-Premise
unchanged I-Premise
during I-Premise
follow-up I-Premise
compared I-Premise
to I-Premise
preoperative I-Premise
values I-Premise
. I-Premise

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Furthermore O
, O
the B-Premise
most I-Premise
common I-Premise
toxicities I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n=9 I-Premise
, I-Premise
39.13 I-Premise
% I-Premise
) I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
, I-Premise
whereas I-Premise
those I-Premise
in I-Premise
the I-Premise
in I-Premise
Gefitinib I-Premise
group I-Premise
were I-Premise
skin I-Premise
rash I-Premise
( I-Premise
n=8 I-Premise
, I-Premise
34.78 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
n=4 I-Premise
, I-Premise
17.39 I-Premise
% I-Premise
) I-Premise
. I-Premise

In O
addition O
, O
at B-Premise
6 I-Premise
months I-Premise
follow-up I-Premise
, I-Premise
participants I-Premise
attending I-Premise
five I-Premise
or I-Premise
more I-Premise
sessions I-Premise
trended I-Premise
toward I-Premise
retaining I-Premise
treatment I-Premise
effects I-Premise
better I-Premise
in I-Premise
the I-Premise
MBAT I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

